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Abstract 
 
BACKGROUND  
Computed Tomography Coronary Angiography (CTCA) is a technique for imaging 
coronary arteries with increasing indications in clinical cardiology. 
AIMS 
1.Develop a heart rate (HR) lowering regime for CTCA and to measure its association 
with image quality. 
2.Examine the diagnostic accuracy of 64 slice CTCA (CTCA64) in patients with known 
coronary artery disease (CAD). 
3.Examine the diagnostic accuracy of CTCA64 for assessment of stent restenosis  
4.Demonstrate utility of CTCA as an endpoint in assessment of novel diagnostic 
biomarkers of CAD. 
METHODS  
I developed a HR reducing strategy using metoprolol and assessed its effectiveness for 
improving CTCA64 image quality. 
The diagnostic value of CTCA in patients with suspected angina was evaluated by 
comparison with invasive coronary angiography. 
The diagnostic value of CTCA for quantifying stent restenosis was evaluated by 
comparison with intravascular ultrasound. 
The utility of CTCA for evaluating the diagnostic value of B-type natriuretic peptide 
(BNP) and high sensitivity cardiac troponin I (hs-TnI) was evaluated by blood sampling 
in patients with suspected angina who subsequently underwent CTCA.  
RESULTS  
1. In 121 patients undergoing CTCA, 75 required rate control. This was achieved (rate 
≤60 bpm) in 83% using a systematic regimen of oral and IV metoprolol (n=71) or 
verapamil (n=4). I demonstrated a significant relation between HR reduction and 
graded image quality (p<0.001). 
2. 80 patients underwent CTCA64 and invasive coronary angiography. 724 coronary 
arterial segments were available for analysis. The sensitivity and specificity of CTCA for 
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significant luminal stenosis was 83.3% (95% CI 67.1-92.5%) and 96.7% (95% CI 95.1-
97.9%), respectively, but the positive predictive value was only 63.5% (95% CI 50.4-
75.3%). 
3. 80 patients with 125 stented segments underwent CTCA64 and invasive coronary 
angiography. Additional intravascular ultrasound (IVUS) examination of stented 
segments was performed in 48 patients. Using IVUS as the gold-standard for stent 
restenosis, CTCA and invasive coronary angiography had comparable diagnostic 
specificities for binary stent restenosis: 82.7% (95% confidence intervals 69.7-91.84%) 
and 78.9% (95% confidence intervals 65.3-88.9%), respectively. Sensitivities were 
lower, particularly the sensitivity of CTCA which was only 11.8% (95% confidence 
intervals 1.5-36.4%) compared with 58.8% (95% confidence intervals 32.9-81.6%) for 
invasive coronary angiography.   
4. In 93 patients with suspected angina CTCA64 provided a useful endpoint for 
assessing the diagnostic value of novel circulating biomarkers. BNP levels were higher 
in the 13 patients shown to have significant (≥50% stenosis) coronary artery disease 
compared with patients who had unobstructed coronary arteries (18.08pg/ml (IQR 22) 
vs 9.14pg/ml (IQR 12.62), p=0.024) and increased significantly with exercise, 
particularly in the group with anatomic coronary artery disease (2.73 ± 5.69 pg/ml vs 
1.27±3.29 pg/ml, p=0.16). Conversely I found no association between hs-TnI and the 
presence of CAD. 
CONCLUSION  
Image quality of CTCA64 is enhanced by heart rate reduction below 60 bpm which can 
be achieved safely by a regimen of oral and intravenous metoprolol. Although CTCA64 
is a useful non-invasive method for diagnosis of coronary artery disease, it has a low 
positive predictive value for identifying severe (≥50%) luminal stenosis which limits its 
clinical value. Its value for assessment of stent restenosis is even more limited but it 
finds useful application as an endpoint for diagnostic evaluation of novel biomarkers, 
allowing confirmation of an association between circulating BNP levels and stable 
coronary artery disease.  
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Glossary of key terms and acronyms 
ACS Acute coronary syndrome: encompasses both unstable angina and 
Myocardial infarction 
AF Atrial fibrillation - an irregular heart rhythm 
Agatston An American cardiologist whose name has been given to the score 
for measuring the degree of calcification within the coronary arteries 
visible on CT he developed 
Angioplasty See PTCA 
ANP Atrial Natriuretic Peptide 
ApoB Apolipoprotein B 
β-blocker see Beta blocker 
Beta blocker A term for beta-adrenoreceptor antagonists - a class of drugs block 
the action of endogenous catecholamines on β-adrenergic receptors, 
part of the sympathetic nervous system. 
BNP B type Natriuretic Peptide 
bpm Beats per minute 
CABG Coronary artery bypass graft: involves opening the patients chest 
under general anaesthetic and bypassing the narrowed arteries with 
vessels from elsewhere in the same patient (e.g. leg veins, internal 
mammary artery) 
CAD Coronary Artery Disease 
CAX Invasive coronary angiography 
CD-36 Cluster of Differentiation 36 - a membrane protein 
CHD Coronary heart disease: a spectrum of clinical disorders including 
stable and unstable angina and acute MI 
CMR Cardiac MRI 
contrast Intravenous contrast agent - usually iodine based used to improve 
visibility of structures in CT imaging 
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CrCL Creatinine Clearance - a measure of renal function 
CT Computed Tomography 
CTCA Computed Tomography Coronary Angiography 
CTCA64 CTCA utilising a scanner with 64 detectors 
cTnI Cardiac Troponin I 
cTnT Cardiac Troponin T 
diastasis The middle stage of diastole during the cardiac cycle when the heart 
is least mobile 
diastole The part of the cardiac cycle during which ventricular relaxation 
occurs 
DSE Dobutamine Stress Echo 
EBCT Electron Beam CT 
ECG Electrocardiogram.  A non-invasive investigation to test heart 
function measuring electrical currents of the heart 
ETT Exercise Tolerance Test (Exercise electrocardiography) -Non-invasive 
investigation to test heart function measuring electrical currents of 
the heart while exercising on a treadmill 
FDA United States of America Food and Drug Administration 
FRISC A study investigating the management of acute coronary syndromes  
entitled 'Fragmin and Fast Revascularization During Instability in 
Coronary Artery Disease' 
GUSTO-IV  A study investigating the role of abciximab in acute coronary 
syndromes 
HbA1C Glycated hemoglobin - a form of hemoglobin that is measured 
primarily to identify the average plasma glucose concentration over 
prolonged periods of time. 
HR Heart Rate 
hs-TnI Cardiac Troponin I measured using a high sensitvity assay 
HU Hounsfield Units 
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If Channel Cardiac pacemaker channel 
iv Intravenous 
IVUS Intravascular Ultrasound 
kernel A term for a reconstruction algorithm used to convert raw CT data 
into images 
LDL Low Density Lipoprotein 
LV Left Ventricle or Left Ventricular 
mass concentration The mass of a constituent substance divided by the volume of 
the mixture 
MDCT Multidetector CT 
MHRA Medicines and Healthcare products Regulatory Agency 
MI Myocardial Infarction 
MIP Maximum Intensity Projection 
MPR Multiplanar Reformat 
MRI Magnetic Resonance Imaging 
mRNA messenger RNA - molecule of RNA that encodes a 'blueprint' for a 
protein 
MSCT Multi Slice CT (also termed MDCT) 
NICE National Institute for Health and Clinical Excellence 
NT-proBNP  The inactive N-terminal fragment of the prohormone proBNP which 
is formed when proBNP is cleaved. 
PCI Percutaneous Coronary Intervention (see PTCA) 
PTCA Percutaneous transluminal coronary angioplasty: a local anaesthetic 
procedure in which a balloon is inserted and inflated to dilate the 
narrowed coronary artery. Re-stenosis (re-narrowing) of this artery is 
a problem, hence stents are increasingly deployed. Percutaneous 
coronary intervention (PCI) is the generic term for PTCA with or 
without stent 
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RACPC Rapid Access Chest Pain Clinic 
restenosis Development of narrowing within a previously treated (stented) 
coronary artery 
r-wave Part of the electrocardiographic trace corresponding to the electrical 
onset of systole 
scintillator A material which exhibits luminescence when excited by ionizing 
radiation 
SMC Smooth Muscle Cell 
SPC Summary of Product Characteristics 
ST Refers to the part of the electrocardiogram that characteristically 
changes during acute myocardial infarction 
Stent A metal tube inserted across the narrowed coronary artery to hold it 
open, can be drug-eluting (coated with drugs inhibiting intimal 
proliferation) 
systole The part of the cardiac cycle during which ventricular contraction 
occurs 
TLR-2 Toll-like receptor 2 - a membrane protein also termed CD282 (cluster 
of differentiation 282) 
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Aims 
 
 
1. Develop a heart rate lowering regime for CTCA and to measure association with 
image quality.  (Chapter 3) 
 
2. Examine the diagnostic accuracy of 64 slice CTCA in patients with known coronary 
artery disease.  (Chapter 4) 
 
3. Examine the diagnostic accuracy of 64 slice CTCA for quantifying stent restenosis.  
(Chapter 5) 
 
4. Demonstrate utility of CTCA as an endpoint in assessment of novel biomarkers.  
(Chapter 6) 
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1. INTRODUCTION 
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In this thesis the technique of computed tomography (CT) and its role in the 
assessment of coronary disease and the utility of the biomarkers cardiac Troponin I 
(cTnI) and B-type natriuretic peptide in the setting of stable chest pain will be 
explored. 
The technology of CT coronary angiography (CTCA) will be examined and the 
importance of heart rate control when acquiring images of the heart will be explored 
and a regime to lower patients’ heart rates at the time of performing a CTCA scan will 
be investigated.  The existing evidence on the diagnostic accuracy of CTCA in the 
context of native vessels and coronary arteries that have previously had stents placed 
will be reviewed and the application of 64 slice CTCA to a cohort with previously 
treated coronary disease will be explored with comparison of accuracy with published 
data.  
The utility of CTCA as an endpoint in suspected CAD will be demonstrated with a cross-
sectional assessment of the application of calcium scoring, CTCA, BNP and cTnI in 
addition to exercise testing and clinical assessment in the setting of patients 
presenting with stable angina symptoms. 
This chapter first outlines the background to the atherosclerotic disease process that 
leads to coronary artery disease, its prevalence and impact on health.  Having outlined 
the importance of coronary artery disease, the current methods for assessing and 
treating coronary artery disease will be explored before examining the technology and 
technique of CTCA and exploring the current evidence supporting the use of CTCA. 
Finally an overview of the use of biomarkers in the setting of stable angina will be 
explored and current evidence outlined. 
  
Assessment of coronary artery disease by CT  Will Roberts 
 
22 
1.1 Atherosclerosis 
Coronary artery disease is predominantly caused by the process of atherosclerosis 
within the coronary arteries.  The word atherosclerosis is based on the Greek words 
athere which can be translated as gruel and skleros meaning hard.  The word itself is a 
simple description of the complex process of accumulation of lipid and thickening of 
the arterial intima. 
Our understanding of the process of atherosclerosis is based on observations from 
epidemiology studies which have identified factors contributing to atherosclerosis. 
Inspection in vivo and in post-mortem studies of coronary and other arterial samples 
has enabled the development of a model of atherosclerosis, elements of which have 
been further defined by animal models.  There is a vast amount of research and 
evidence on the subject of the pathogenesis of atherosclerosis and huge detail has 
emerged of the processes involved.  Although an in-depth analysis is beyond the scope 
of this thesis a summary of the models published by Libby1, Weber2 and Falk3 is 
described below. 
As can be seen in Figure 1 the normal coronary arteries have three layers; from lumen 
outwards the tunica intima, tunica media and the adventitia.  The inner most surface 
of the tunica intima is a single layer of endothelial cells that is in contact with the blood 
flowing in the lumen.  It has been suggested that these endothelial cells respond to a 
trigger or insult such as hypertension, abnormal inflammatory mediators or lipids. This 
process is illustrated as a passive loss of endothelial barrier in response to injury 
whereby plasma molecules and lipoprotein particles enter the subintimal space. These 
lipoproteins are oxidised by enzymes likely to include myeloperoxidase, 15-
lipoxygenase, and nitric oxide synthase (NOS) to become proinflammatory, 
chemotactic and cytotoxic.  The enzyme Lp-PLA2 (lipoprotein-associated 
phospholipase A2) enters the intima bound to low density lipoprotein (LDL) and is also 
secreted by inflammatory cells, it hydrolyses oxidised lipoproteins to form bioactive 
lipid mediators that are thought to be chemotactic and also cytotoxic to macrophages. 
The endothelium responds by upregulating expression of adhesion molecules including 
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vascular cell adhesion molecule-1 (VCAM-1) on the lumen surface and secreting 
chemokines.1 
Leukocytes (mostly monocytes) in the circulating blood then bind to these adhesion 
molecules and changes occur in the extracellular matrix and basement membrane with 
retention of low density lipoprotein (LDL).4  This further stimulates leukocyte binding 
and, with chemokines such as Monocyte chemotactic protein-1 (MCP-1) encourage the 
monocytes to migrate into the intima and differentiate into macrophages as illustrated 
in Figure 1(2).  These macrophages then absorb lipoprotein molecules that have 
accumulated and become foam cells, heavily laden with lipid.  The foam cells 
internalise the lipoproteins by means of scavenger receptors SR-A and CD36. One can 
say that the key step now in the formation and growth of pathological plaque is the 
result of failure of the macrophages to remove the lipid from the vessel wall at this 
point by what has been coined reverse cholesterol transport.  Unfortunately in 
atherosclerosis this mechanism fails as the scavenger receptors are not down-
regulated by the accumulation of cholesterol within the cells and the foam cells remain 
in the intima and continue to accumulate lipid until they die either by apoptosis or 
necrosis, possibly with the involvement of Lp-PLA2.  These foam cells and the debris of 
the dead cells forms a lipid rich core to the atherosclerotic plaque. The foam cells also 
extend the inflammatory process by the release of chemical mediators and contribute 
to the creation of a pro-thrombotic state by releasing pro-coagulant tissue factors.1  
The inflammatory process of atherosclerosis is complex and many pathways, immune 
cells and receptors are involved.  The adhesion molecules on the activated endothelial 
cells also bind a smaller number of T cells. T helper 1 cells can be activated by antigen 
presenting cells and secrete interferon-g which magnifies and sustains the 
inflammatory response in the media.  Inflammation can also be initiated via Toll-like 
receptor 2 (TLR2) signalling by lipoproteins bearing apolipoprotein C-III (Apo-CIII) or 
apolipoprotein B (Apo-B).1  Working to decrease the inflammatory process regulatory T 
cells produce anti- inflammatory cytokines interleukin-10 (IL-10) and transforming 
growth factor-β (TGF-β) and a small number of B cells around atherosclerotic arteries 
may produce antibodies to attenuate the inflammatory process.1   
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Figure 1 An overview of the atherosclerotic process.  (1) Layers of normal 
arterial wall with lipoprotein entering through endothelium into intima.  (2) 
Binding of monocytes, migration and differentiation and formation of 
foam cells.  (3) Migration of SMC and formation of lipid core of plaque.  (4) 
Rupture of plaque leading to thrombus formation. Adapted from Libby 
2011.1 
 
The third stage in atheroma development as seen in Figure 1(3) is the migration of 
smooth muscle cells from the tunica media to the intima where they proliferate and 
form a fibrous cap of collagen and elastin over the plaque. Some of the foam cells 
within the plaque die and the cellular debris accumulates to create a lipid rich core of 
the plaque.1 
Some plaques, typically those with a thin cap with few smooth muscle cells5, 6 and an 
active inflammatory process7 may go on to rupture.8  As can be seen in Figure 1(4), 
plaque rupture exposes a large quantity of thrombogenic material to the arterial 
lumen and can result in acute thrombosis and acute myocardial infarction. It will be 
demonstrated that this is a major cause of mortality and morbidity.9 
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Other plaques take a more indolent course with smooth muscle cells and fibroblasts 
creating a thicker, fibrous cap over the plaque reducing the chance of rupture.  These 
lesions appear more stable, either exerting no significant physical effect or gradually 
encroaching on the arterial lumen until restriction of blood flow leads to symptoms 
such as angina pectoris.  Over time the atherosclerotic process can lead to an increase 
in vessel size termed positive remodelling, whereby, despite increased atheromatous 
plaque, the vessel lumen can be maintained by increase in the overall size of the 
vessel.10 
Calcification occurs in atherosclerotic lesions but the mechanism and significance are 
not fully understood.11  The first evidence of calcification is seen in the second decade 
of life and calcification increases with ageing.12  In a study of autopsy specimens early 
and small areas of calcification were found within the cytoplasm of cells and within the 
extracellular material in and near the lipid core of plaques.  This is thought to originate 
from dead cells such as fibroblasts and smooth muscle cells13 but it may also be due to 
osteogenic differentiation of senescent vascular smooth muscle cells.14  The 
significance of this calcification is not fully understood, nor is it’s relationship to plaque 
rupture which remains contentious.15, 16  Calcification within the coronary arteries can 
be viewed as an indicator of the overall burden of atherosclerotic plaque within an 
individual and has been used as an indicator of cardiovascular risk.17-19 
 
1.2 Morbidity and mortality in coronary artery 
disease 
It has been shown that the development of coronary artery disease is a gradual 
process and in order to gain more understanding of the impact of coronary artery 
disease it is best to look at the consequence of the process and the morbidity and 
mortality caused by it.  Coronary artery disease leads to many disease states and the 
major ones are outlined below. 
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Table 1 Morbidity and mortality in coronary artery disease 
Coronary artery disease causes death by: 
 Cardiac failure 
 Cardiac arrhythmias 
 Mechanical failure such as ventricular rupture or valvar incompetence. 
Coronary artery disease causes morbidity by: 
 Cardiac failure and limitation of functional capacity 
 Myocardial Ischaemia leading to angina pectoris 
 Recurrent arrhythmias 
 
Coronary artery disease is a major cause of morbidity and mortality worldwide.  The 
World Health Organisation (WHO) estimates that 7.2million people died in 2004 from 
coronary artery disease,20 this represents approximately 4% of all deaths globally.  As 
traditional causes of death such as malnutrition and infectious disease decline and risk 
factors for coronary artery disease rise worldwide the WHO estimates that this will 
continue to increase with heart disease and stroke predicted to remain the single 
leading causes of death worldwide.  In Europe coronary artery disease is the biggest 
cause of death, responsible for 22% of all deaths.21 
It is harder to quantify morbidity from coronary artery disease than mortality but in 
the 2006 Health Survey for England 3.4 million adults reported suffering from angina 
or a heart attack.22  This is likely to be an underestimate for prevalence of angina and 
myocardial infarction and does not include those living with symptoms of heart failure 
as a result of coronary artery disease.  The Heart of England study screened patients 
using a combination of clinical examination and echocardiography data and suggests 
that there are over 700,000 people over the age of 45 in the United Kingdom (UK) with 
‘definite heart failure’23 with coronary artery disease being the cause in approximately 
70% of patients.24, 25  
In recent years in the UK there has been greater success in treating patients with 
myocardial infarctions and a reduction in the mortality rate, however the corollary to 
this is that there is an increasing burden of chronic heart failure.  
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It can be concluded that coronary artery disease will continue to have a considerable 
impact on mortality and morbidity worldwide for many years to come. 
Coronary artery disease can remain asymptomatic or manifest itself to the medical 
profession in a variety of ways from angina to sudden death.  The disease can present 
for the first time in a previously asymptomatic individual with an acute myocardial 
infarct or with gradual development of angina, or with heart failure symptoms.  
Approximately 50% of patients presenting with acute myocardial infarction have no 
previous symptoms.26  In a large proportion of these patients acute myocardial 
infarction leads to death or heart failure in spite of contemporary treatment strategies 
including primary percutaneous revascularisation and thrombolysis. The challenge 
therefore is to try to identify these patients at an earlier stage where the disease 
process can be modified and the long term sequelae prevented. 
 
 
 
1.3 Treatments for coronary artery disease 
The medical approach to coronary artery disease has many facets. Public health 
interventions are aimed at reducing the development of coronary artery disease in the 
general population and there have been measures to address some of the risk factors 
that lead to atherosclerosis in relation to smoking cessation, exercise and diet.  The 
identification and treatment of groups likely to develop significant atherosclerosis and 
suffer with its consequence is another key aspect; hypertension, diabetes, 
hyperlipidaemias are all addressed by medical and non-medical means. 
In individuals who present with symptoms related to coronary artery disease there is a 
wide range of presentations and treatment strategies.  The main presentations are; 
acute coronary syndromes, stable angina, heart failure and arrhythmias. 
In patients who present with acute coronary syndromes the mainstay of treatment is 
revascularisation and secondary prevention. Each patient is risk stratified depending 
on their individual case and consideration given to the likely risks and benefits of 
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revascularisation versus medical secondary prevention alone.  Acute coronary 
syndromes are largely split into three further groups although various terms and 
classifications are used; ST elevation myocardial infarction, Non-ST elevation 
myocardial infarction and unstable angina. ST elevation refers to the characteristic 
changes seen on electrocardiogram (ECG) that suggest ongoing infarction of 
myocardial cells. 
In acute ST elevation myocardial infarction, there is abrupt occlusion of a coronary 
artery by thrombus and prompt re-opening of the occluded artery is required to 
prevent extensive myocardial infarction and the subsequent heart failure and 
arrhythmic consequences.  In contemporary practice this is accomplished by means of 
either the administration of thrombolytic drugs or by immediate percutaneous 
coronary intervention (PCI) widely called ‘Primary PCI.’  In primary PCI catheters are 
manipulated within the arterial system and placed at the ostium of the affected 
coronary artery, through these catheters various devices can be deployed to aspirate 
thrombus and dilate the coronary arteries in an attempt to restore flow down the 
artery.  In the current era primary PCI usually results in the placement of a coronary 
stent, a mesh metal tube designed to scaffold the coronary artery.   Patients treated 
with thrombolytics are also usually then assessed by means of coronary angiography 
and undergo revascularisation. 
Patients with other acute coronary syndromes are risk stratified depending on their 
presentation, ECG findings, and biomarkers such as troponins which are released from 
the heart during infarction.  A large number of these patients considered at high risk 
then go on to have further assessment usually by means of coronary angiography and 
then will undergo revascularisation by either PCI with the placement of coronary 
stents or by coronary artery bypass grafting (CABG). CABG is a significant operation 
that involves the placing of conduits such as redirected internal mammary arteries and 
reversed saphenous veins to provide an alternate supply of blood to the distal 
coronary arterial tree, bypassing proximal occlusions or stenoses. 
Patients with stable angina symptoms are treated with a range of medical therapies 
such as beta-blockers, nitrates, calcium channel blockers and other medications 
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designed to improve myocardial blood flow or reduce myocardial oxygen demand.  
These are prescribed in conjunction with medications and interventions such as 
smoking cessation designed to reduce the further development of atheroma and 
reduce the risk of subsequent myocardial infarction.   This can be an effective strategy 
in a large number of patients but many are refractory to medications and require 
revascularisation to improve their symptoms.  As in acute coronary syndromes, 
revascularisation can be either PCI or CABG. 
The treatment of heart failure patients requires a combination of medical therapies, 
devices such as cardiac resynchronisation pacemakers, exercise training and even 
cardiac transplantation.  This requires provision of an extensive service with staff from 
many disciplines and places a significant burden on the health care system.   
Patients with arrhythmias as a result of coronary artery disease often have heart 
failure and there is significant overlap in their therapy with the use of devices such as 
pacemakers and implantable cardiac defibrillators and the use of anti-arrhythmic 
medications. 
Thus it can be seen that the treatment of patients with coronary artery disease results 
in the prescription of medications for disease modification and symptom control and a 
large number of patients undergo the placement of cardiac stents, bypass surgery or 
implantation of cardiac devices. 
 
 
1.4 In-stent restenosis 
Coronary artery stenoses are often treated by means of percutaneous dilatation using 
small balloons within the coronary arteries to dilate the artery at the point of stenosis.  
In contemporary practice this technique is usually augmented by the placement of 
stents within the coronary arteries to overcome elastic recoil.  These are metal alloy 
stents with a mesh structure that can be introduced into the coronary arteries 
mounted on a balloon and dilated to achieve apposition to the vessel wall.  These 
stents can be coated in a drug eluting polymer to try to reduce the extent of restenosis 
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within the stent.  Restenosis after coronary stenting, defined by ≥50% luminal loss, 
occurs in about 10- 20% of cases in the first 12 months and usually presents with 
recurrent chest pain.27  The assessment of patients with existing coronary stents is a 
growing area with over 30% of diagnostic procedures performed in this setting and 
with the increasing use of coronary stents, this number is likely to increase. 
 
1.4.a The development of in-stent restenosis 
Initially coronary interventions were performed using balloons to dilate lesions within 
the coronary arteries.  There was a high level of restenosis in patients undergoing 
these procedures.  Intravascular ultrasound (IVUS) and histopathological examination 
found that 75% of the restenosis was due to elastic recoil or negative remodelling and 
25% due to the development of new plaque within the treated area (neo intimal 
proliferation).28, 29  After the use of stent implantation the mechanical factors were 
virtually eliminated leaving neo-intimal proliferation as the main cause of restenosis.30, 
31  Neo-Intimal proliferation is caused by arterial injury which leads to platelet 
activation and inflammation via the action of mediators such as growth factors and 
cytokines.  This leads to proliferation and migration of vascular smooth muscle cells 
and the synthesis and secretion of extracellular matrix and cytokines by the vascular 
smooth muscle cells that together form the neo-intima.32 
 
1.4.b Assessment of suspected in-stent restenosis 
There are several different ways a patient returning with stable chest pain after 
coronary stenting can be assessed.  The central division in assessment strategy after 
clinical assessment is that between either anatomical assessment or assessment of 
ischaemia.  Currently invasive coronary angiography is the only technique widely 
employed for the anatomical assessment of these patients.  Ischaemia can be assessed 
by means of stress echo, nuclear imaging, perfusion MRI or less commonly now 
exercise ECG.  The assessment strategy used is defined by the pre-test probability for 
ischaemia based largely on the history with an anatomical strategy with invasive 
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coronary angiography (CAX) employed in patients thought likely to have significant 
coronary stenoses.  A number of patients with atypical chest pain are likely to be 
assessed first by an ischaemia test but it is not uncommon for a combination of 
anatomical and ischaemia measures to be used. 
 
1.4.b.i Invasive coronary angiography 
Invasive angiography is a procedure by which x-ray contrast medium is injected 
directly into the coronary arteries and two dimensional images are obtained from 
various angles in an attempt to fully visualise the coronary anatomy.  In order to inject 
contrast media directly into the coronary arteries the operator needs to gain access to 
the arterial circulation usually by puncturing the radial or femoral artery and 
introducing a sheath that allows passage of further devices into the arterial system.  
The operator then introduces small specially shaped tubes (catheters) 2-3mm 
diameter, into the arterial circulation and by the means of careful manipulation and 
the use of x-ray guidance, positions the catheter at the ostium of each of the coronary 
arteries in turn.  The procedure is resource intensive and requires skilled operators 
with the support of a catheter laboratory team. 
The procedure of invasive coronary angiography is a widely performed procedure, 
both for the assessment of native coronary artery disease and for the assessment of 
patients with prior coronary artery bypass grafts and previous stenting.  However the 
procedure does have some risk associated with it.  Although the majority of data come 
from an earlier era it is thought that the true risk of a diagnostic coronary angiogram is 
between 1 and 2%.33, 34  These complications include bleeding, usually related to the 
site used to access the arterial system, stroke, myocardial infarction and death, 
common to other contrast reliant x-ray techniques such as CTCA there is also a small 
chance of anaphylactoid contrast reaction or contrast induced nephropathy, which; 
although usually transient, can result in permanent renal failure. 
Invasive coronary angiography only allows visualisation of coronary anteries by the 
contrast injected filling the arterial lumen and blocking the passage of x-rays.  Thus 
invasive coronary angiography only provides information about the coronary artery 
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lumen and has sometimes been called lumenography.  It is possible to gain some 
additional information through visualisation of dense calcification in the coronary 
arterial tree or visualisation of the outline of coronary stents, although calcification is 
not always apparent via angiography and it can be hard to visualise some stent types. 
Invasive angiography also only provides a planar, two dimensional view of the 
coronary artery, and whilst images can be obtained from a range of angles there can 
be problems with overlapping arteries and the technique cannot fully delineate the 
three dimensional nature of coronary plaque.  Coronary arterial plaque is often 
eccentric and this can lead to misleading appearances on coronary angiography that 
generally leads to underestimation of lesion severity.  It has long been recognised that 
there are limitations to the accuracy of the technique of coronary angiography, 
specifically related to underestimation of disease severity when compared to post-
mortem studies and intra-operative flow studies.35-38  Coronary angiography has also 
been shown to have a high interobserver and intraobserver variability.39, 40 
 
1.4.b.ii Intravascular ultrasound (IVUS) 
Invasive coronary angiography is generally considered the clinical standard for 
assessment of coronary artery disease and in-stent restenosis, as described above it is 
becoming increasingly recognised that this technique has weaknesses and in fact when 
stents are assessed by intravascular ultrasound (IVUS) or optical coherence 
tomography (OCT), there can be significant discrepancy between the angiographic 
findings and the IVUS or OCT findings.41 
IVUS and OCT techniques provide tomographic images from a probe within the 
coronary artery, providing a much higher spatial resolution image than invasive 
angiography, and overcoming the problem of overlapping vessels.  In IVUS the probe is 
a miniaturised ultrasound probe that takes a tomographic image of the coronary artery 
and in OCT a similar cross-sectional image is obtained by the use of near-infrared light. 
IVUS uses high frequency sound waves reflected off the coronary arterial wall from 
within the lumen.  The technique has a spatial resolution of 100-200µm and a tissue 
penetrance sufficient to image the full depth of a coronary artery wall.  OCT has a 
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much higher spatial resolution of 10-20µm but has a lower penetrance of 1-3mm in 
tissue.42  OCT also is sensitive to scatter from red blood cells and requires a blood free 
field within the lumen so the vessel must be flushed to fill it with contrast during image 
acquisition.  IVUS is the most widely available of these two techniques in clinical 
practice and is the modality that will be investigated later in this thesis. 
IVUS was first proved in the 1980s and 1990s at a time when it was apparent that 
there was significant intra-observer and interobserver variation with coronary 
angiography and discrepancy between coronary angiograms and post-mortem 
examination and the realisation that the angiographic severity of stenoses was a poor 
predictor of physiological severity.37, 38, 40, 43  Technology has greatly improved since the 
early years of IVUS by increasing the transducer frequency and power which improves 
image quality and miniaturising the probes allowing smaller vessels and more severe 
stenoses to be assessed. 
IVUS is more invasive than diagnostic coronary angiography due to the need to pass 
guide wires into the lumen of the coronary artery being assessed and the passage of a 
probe into the artery itself. They thus have a slightly higher procedural risk than 
diagnostic angiography alone.  In the multicentre survey by Haussman44 of 2207 
procedures it was identified that IVUS was predominantly associated with coronary 
spasm with 2.9% of patients suffering transient spasm and more serious complications 
such as acute vessel occlusions, dissections, and/or embolism in 0.4 % of the patients 
although they could not all be directly attributed to the IVUS procedure and may have 
occurred with diagnostic angiography alone.  In Batkoff’s study of 718 IVUS studies the 
complication rate including both spasm and major complications was 1.1% but these 
all occurred in patients undergoing coronary angioplasty.45  In the abstract presented 
by Gorge,46 spasm occurred in 3% of all patients and there was a 0.14% complication 
rate consisting of coronary artery dissection, thrombosis, ventricular fibrillation and 
severe spasm.  
IVUS reveals more about the three dimensional nature of plaque than invasive 
coronary angiography and has been used to track changes in coronary arterial plaque 
in response to medical therapies.47   
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In-stent restenosis is often seen as very short segments of stenosis (<1mm)48 which 
can be missed by conventional angiography.  The IVUS probe within the vessel is more 
likely to detect the area of greatest narrowing.  Angiography only allows a 
measurement in variations of luminal diameter of stented and adjacent non stented 
areas and provides only an indirect measure of in-stent neointimal hyperplasia and 
cannot account for positive remodelling.49  Stent struts are well visualised by IVUS and 
the relationship of tissue to the stent can be accurately established, this is not possible 
with conventional angiography as it can be very difficult to visualise stents and even 
harder to tell the relationship of tissue to the stent.  IVUS is now widely used as the 
gold standard for assessing in stent restenosis and hyperplasia, particularly when 
comparing different coronary stents and also provides other important information 
such as adequacy of stent deployment, apposition to vessel wall and accurate sizing 
which are important in reducing in-stent thrombosis. 
 
 
1.5 CT coronary angiography 
 
Invasive coronary angiography is currently the clinical standard for assessing coronary 
artery stenoses. It has excellent spatial and temporal resolution and allows for 
percutaneous intervention at the same sitting. However as described earlier, invasive 
angiography can be associated with serious complications and may reveal non-
obstructive disease that does not lead to an intervention.  Invasive coronary 
angiography without adjunctive techniques cannot image the vessel wall and assess 
plaque characteristics. There has, therefore, been great interest in developing non-
invasive methods of performing coronary angiography and assessing plaque 
morphology. 
Coronary arteries are difficult to image because they are small and move not only with 
the cardiac cycle but also with respiration. Non-invasive imaging of these structures 
needs a technique that produces high spatial and temporal resolution and that also 
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compares well with the current gold standard.  Technological advances (both 
hardware and software) in computed tomography (CT) imaging over the last few years 
have made it an appealing technique for providing non-invasive images of coronary 
arteries. 
In the following section the process of cardiac CT will be summarised and some of the 
unanswered questions will be highlighted. 
 
1.5.a History 
In 1895, William Röntgen (a German physicist) produced and detected electromagnetic 
radiation in a wavelength range today known as X-rays or Röntgen Rays. Whilst 
investigating materials that could stop these rays he passed his hand in front of the X-
ray source and produced the first X-ray image.  He was awarded the Nobel Prize for 
Physics in 1901 in recognition of “the extra-ordinary services he has rendered by the 
discovery of the remarkable rays subsequently named after him”.50  Clinical CT itself 
was invented by Godfrey Hounsfield in 1972. He also received the Nobel Prize (for 
medicine) in 1979 along with Allan Cormack and in his acceptance speech stated that 
“…. a further promising field may be the detection of the coronary arteries….”51 
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Figure 2 Timeline of the development of cardiac CT 
 
Initial CT scanners were limited to tomographic sections of the brain that took several 
minutes to acquire. Slip ring technology replaced the cables of older scanners and 
permitted fast spiral scanning whereby the X-ray source and detector continuously 
rotate around the patient whilst the patient table moves through the scanner. The 
scan speed was further improved by changing the shape of the radiation beam (to a 
fan shape) and increasing the number and quality of X-ray detectors in what are called 
multi-detector (or multi-slice) CT scanners (Figure 3).  Developed in 1991, the Elscint 
CT Twin was the first multi-slice (MSCT) scanner and had two parallel banks of x-ray 
detectors to acquire two slices per gantry rotation.  Quickly the technology developed 
with scanners with 4 slices, then 16 slices, and current scanners having 64 slices with 
320 slice scanners available. 
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Figure 3 Comparison of single slice and multi slice CT scanners 
 
Recently the first dual-source MSCT was launched.52  This has two pairs of X-ray 
sources and multi-slice detectors mounted at 90 degrees to each other (Figure 4). 
 
 
 
Figure 4 Diagram illustrating concept of a dual source CT scanner.53 
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This produces faster scanning and achieves a temporal resolution of 75ms. The effect 
of multiple slices, faster rotation times and dual-source technology on spatial and 
temporal resolution is shown in Table 1.  The data in the table only consider the 
temporal resolution available from CT scanners using single sector reconstructions.  
Several manufacturers use multi sector reconstructions to obtain faster theoretical 
temporal resolutions and this will be discussed further in the technology section.  
There are limited independent data on the true spatial resolutions obtained during 
cardiac scans. 
 
Table 2 Comparison of temporal and spatial resolution of different 
coronary imaging modalities 
 Spatial 
Resolution 
(mm) 
Temporal 
Resolution 
(ms) 
Invasive Angiography 0.2 5-20 
Electron Beam CT54 >0.6 33-100 
16-Slice CT 0.5 200 
64-Slice CT 55 0.4 165 
Dual-Source   2 x 64-Slice CT 52 0.4 75 
Magnetic Resonance Angiography 54 0.7 20 
 
 
Electron-beam CT (EBCT) was launched in 1990. It provided very high temporal 
resolution due to the electronic sweeping of the electron beam which can be 
completed much faster than the mechanical rotation of multi-slice CT.  EBCT has been 
extensively used in calcium scoring of coronary arteries17 but suffers from poor spatial 
resolution.  Multi slice CT can now perform accurate calcium scoring56 and is more 
widely available than EBCT which will not be addressed further here. 
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1.5.b CT Technology 
CT scanners have an X-ray source (tube) and sensors mounted on opposite sides of a 
gantry that continuously rotates around the patient.  Scans are then taken as the 
patient moves through the gantry. Computer systems can process these data to 
generate three-dimensional volumetric information, which is in turn viewable from 
multiple different perspectives on attached CT workstation monitors.  
 
1.5.b.i Spatial resolution and coverage 
The image obtained on the monitor is made up of a series of 3D pixels (or voxels) the 
size of which depends on the scanners spatial resolution.  The voxel itself displays a 
shade of grey (from black to white) depending on the average attenuation of the tissue 
within the voxel. Bone and (importantly for cardiac scanning) calcium have high 
attenuation values (Hounsfield Units) and are displayed as white. Air has a low 
attenuation value and is displayed as black. Unfortunately, if a voxel within a coronary 
artery contains calcium and a tissue with a low attenuation signal (eg a fatty plaque), 
the whole of the voxel will be displayed as white and the useful information is lost. 
This accounts for ‘partial volume’ effects seen in CT. The smaller the voxel size, 
therefore, the less partial volume effects will be seen and the spatial resolution will be 
better.  Voxel size is dependent on the resolution of the X-ray sensors, not the number 
of slices.   
To increase the speed at which an area of interest such as the heart can be scanned 
(thereby reducing the length of breath-hold), more recent scanners have an array of x-
ray detectors covering a larger area and collecting data from multiple ‘slices’ per 
rotation of the scanner.  The size of the array is dependent on the size and number of 
individual detectors.  Increasing the size of detectors would result in a worse spatial 
resolution, thus if spatial resolution is to be maintained, larger arrays require more 
detectors.  The time it takes to scan an area of interest is dependent on the area 
covered by the detector array, the rotation speed and the speed at which the patient 
passes through the scanner (termed the ‘pitch’).  Figure 5 illustrates several available 
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arrays, fixed arrays have evenly spaced detectors and adaptive arrays have a 
combination of detectors of varying sizes that can be used in different configurations. 
 
 
 
Figure 5 Fixed and adaptive arrays, showing variation in detector size 
 
Some scanners use an alternating focal spot technique to increase the number of 
slices.  The x-ray beam from the source rapidly alternates between two points (Figure 
6), resulting in double sampling of the detectors to effectively achieve double the 
number of slices.  The disadvantage is that in this mode the coverage of the array 
tends to be less and thus requires more time to scan the heart than a larger detector, 
the signal to noise ratio is also lower and thus higher radiation doses are required.  
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Figure 6 The alternating focal spot technique to increase spatial 
resolution 
 
1.5.b.ii Temporal resolution 
In order to image the coronary arteries, the heart needs to be as stationary as possible. 
Respiratory motion is excluded by performing the scan during a breath-hold and 
cardiac motion is limited by obtaining images when the heart is at its least mobile 
during diastole.  The temporal resolution of CT scanners is essentially determined by 
the speed of rotation of the gantry around the patient.  As it is possible to accurately 
reconstruct images using data acquired from a 180 degree rotation rather than the full 
360 degree rotation, the temporal resolution is equal to half the gantry rotation speed.  
A small allowance should also be made for the fan angle in calculating temporal 
resolution, but the major determinant, varying between scanners is the rotation 
speed.  Some CT scanners utilise partial scan reconstructions to increase quoted 
temporal resolution.  Using this technique data from adjacent cardiac cycles are used 
to reconstruct one axial data set.   For example by combining the data from two 
adjacent cycles the temporal resolution can be dropped to a quarter of the rotation 
speed (Figure 7).57  In vivo studies show that two-segment reconstruction can slightly 
improve diagnostic sensitivity in heart rates >65bpm.58  The problem with this 
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technique is that it assumes that the coronary artery always returns to exactly the 
same position in each cardiac cycle.  As this is not the case, although the temporal 
resolution is quoted lower, the resulting image contains potentially more error and 
artefact.  This technique must therefore be used with caution and is not a substitute 
for improving the true temporal resolution of a machine. 
 
 
 
 
 
Figure 7 Theoretical temporal resolution with single and multi-sector 
reconstructions 
 
The rotation speed of the gantry has been increased over the last few years to 250ms 
per rotation but as the speed increases further the logarithmic relationship between 
speed and centrifugal forces makes it increasingly hard to achieve faster rotations.  A 
novel approach to overcoming this hurdle and effectively halving the temporal 
resolution is to put two ct scanners inside the same gantry at right angles to each 
other (Figure 4).  This design halves the amount of time required to gather data from 
180 degrees around the heart, reducing the temporal resolution to 75ms, permitting 
accurate imaging at higher heat rates and less motion artefact.  
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1.5.b.iii ECG gating 
Depending on the coverage of the x-ray array, and to a lesser extent the pitch and 
rotation time, it takes around 6-12 seconds for a 64 slice CT scanner to cover the 
whole of the heart and so the coronary arteries need to be reconstructed from data 
obtained from multiple heart beats. With larger detector arrays the heart can be 
covered in 1 or two cardiac cycles. ECG gating enables us to use only the data from 
certain parts of each consecutive cardiac cycle to generate useful images and typically 
targets the acquisition or reconstruction of images to the period in the cardiac cycle 
when the heart is least mobile and thus least prone to imaging artefact (Figure 8).   
In prospective gating, the R-wave on the ECG is recognised, there is a time delay and 
then scanning starts, stopping after a certain period to resume at a similar time during 
the next cycle. Although this technique, when coupled with repeated axial acquisitions 
rather than a continuous spiral, has the potential to greatly reduce dose it is limited by 
the fact that a single ectopic beat or other arrhythmia may lead to the scanner starting 
at times when the heart is in a different position in the chest. In addition, if the time 
delay picked is not optimal, image quality will again suffer. As detector arrays with 
Figure 8 Effect of reconstruction at different points in cardiac cycle 
represented as % of rr interval from initial qrs 
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greater coverage become more commonplace in clinical practice prospective gating 
has become more frequently applied.  Less commonly implemented in modern 
scanners, though implemented in many of the initial 64 slice scanners is retrospective 
gating, when data are collected continuously throughout the cardiac cycle as the 
patient moves constantly through the scanner, and later reconstructed at an 
appropriate time interval (Figure 9). This can be quoted as a percentage of the RR 
interval (e.g. 65%) or as an absolute value (e.g. 700ms). The actual phase used can vary 
for each coronary artery and between patients. Several different phase 
reconstructions may be required to obtain optimal images of all vessels.  
 
 
 
Figure 9 Methods of defining retrospective gating reconstruction timing 
 
1.5.b.iv Performing a scan 
Here the procedure of undertaking a CTCA scan is described as it applies to the most 
commonly available 64 slice scanners. Patients do require some preparation prior to 
their non-invasive coronary angiogram. Firstly, there are a number of contra-
indications which are applicable to any contrast CT. In addition, there are several 
circumstances when cardiac CT may not be appropriate (Table 3).  Note that dual 
source scanners, due to the higher temporal resolution, can permit the scanning of 
patients with irregular rhythms and reduce the need for beta blocker administration. 
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Table 3: Exclusion criteria for CTCA 
Contraindications to Contrast Enhanced CT 
 Renal failure 
 Inability to lie flat 
 Contrast allergy 
 Caution in pregnancy 
Causes of Excessive Artefact in Cardiac Scans 
 Irregular heart beat (AF, frequent ectopics) 
 Inability to breathold 
 Tachycardia 
 (Pacing wires and metallic valves) 
 
 
An intravenous cannula is required for the contrast injection. To slow the heart beat 
and improve image quality a β-blocker (eg oral metoprolol 100mg) may need to be 
given an hour before the scan if the patient is not naturally bradycardic.  It is common 
to aim for a heart rate below 65 beats per minute. Patients intolerant of β-blockers can 
be given a calcium channel blocker.  The patient is placed in the CT scanner and 
attached to an ECG and contrast injector. Many centres also advocate the use of 
sublingual nitrate prior to scanning as this can improve coronary artery visualisation.59  
A scout X-ray is taken to ensure correct alignment of the patient and after some 
practice breath-holds the scan is performed. Depending on clinical question, a calcium 
score is sometimes carried out first and those patients with a high calcium score (>400 
Agatston units) may not be studied further because of reduced specificity. The start of 
the scan needs to be timed with the arrival of contrast in the ascending aorta. This can 
either be done automatically with the CT triggering once the Hounsfield unit of a 
region of interest in the aorta crosses a threshold due to the arrival of the contrast, or 
manually after measuring the contrast agent transit time in a separate step, using a 
‘test bolus’ of a small amount of contrast. The total volume of contrast given is of the 
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order of 50 – 100mls and the whole scanning process is complete after 10 to 15 
minutes.  Depending on the availability and robustness of implementation in your 
particular scanner; techniques that reduce the radiation dose such as ‘dose 
modulation’ should be used where possible.  Scans are usually performed in the 
craniocaudal direction, however when larger areas need to be covered in the presence 
of coronary artery bypass grafts, it is possible to scan in the opposite direction, giving 
priority to the native vessels so that the grafts are towards the end of the breath-hold. 
The large amount of data obtained need to be reconstructed (using the appropriate 
phase of the cardiac cycle as described above in the ecg gating section) and then 
analysed.  Different reconstruction algorithms or ‘kernels’ are used to convert the raw 
data from the spiral scan raw data into interpretable images.  Different kernels can be 
used in different situations with sharper but noisier kernels used to reduce blooming 
artefact in the presence of calcification or stents. 
The software used to assist the clinician in interpretation is almost as important as the 
scanner itself.  The raw, cross-sectional images are often reviewed first as these are 
often sufficient for diagnosis and also give information about the rest of the thorax 
(pericardium, mediastinum, aorta, lungs) which may harbour other unsuspected 
pathology.60-62  The coronary arteries themselves can be assessed through these raw 
axial images, but further reconstructions are made to aid analysis. 
The intensity of x-rays received by the detectors for an individual voxel (Hounsfield 
values) generated by the scanner are converted into greyscale to allow interpretation 
by the human eye with white areas representing high Hounsfield values and dark areas 
lower values. However the range of Hounsfield units generated from a CT scan is 
greater than the range of greys that the human eye can easily distinguish, thus 
‘windowing’ levels have to be set to map a relevant range of Hounsfield numbers to a 
grey scale.  There are two relevant parameters; the window width and the centre.  The 
centre defines the mid-point of the Hounsfield scale used and the window width 
determines the range of Hounsfield values used to determine the grey scale with all 
Hounsfield values above the upper limit displayed as white and below the lower limit 
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black (Figure 10.)  Different window settings have profound effect on the images 
displayed and different values are used to interrogate different tissues. 
 
 
Figure 10 Effect of using different window levels when viewing CT images 
as greyscale.  Top scale shows typical Hounsfield units for various 
materials.  The images below demonstrated the effect of applying the 
different windowing levels and centres on image appearance. 
 
The standard reconstructions used are multiplanar reformation (MPR) and maximum-
intensity projection (MIP) (Figure 11).  In MPR (Figure 11b) a straight or curved plane is 
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defined and only the data in this plane are displayed, this can be used to ‘stretch out’ a 
vessel and view it from many angles.  The MIP algorithm (Figure 11a) displays only the 
highest-attenuation voxels taken from a slab through the 3D data for each pixel in the 
resulting image.  Some software also enables the quantification of LV function and 
plaque composition. Volume rendering techniques produce visually pleasing images 
but these are generally only of clinical use in visualising bypass grafts or coronary 
anomalies. 
 
 
Figure 11 Comparison of MPR and MIP reconstructions.  The appearance 
of a stent in the left main coronary artery and left anterior descending 
artery is demonstrated with (A) MIP and (B) MPR reconstructions. 
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1.5.c Limitations with the technique 
1.5.c.i Radiation dose 
The main drawback with CTCA is the radiation dose. This was quoted as 10 – 15 mSv 
for a non-invasive angiogram in the scanner available for my research (around double 
the dose of a conventional angiogram).63  I collated data on radiaton dose in 30 
subjects at the beginning of our experience with CTCA demonstrating a mean dose of 
12mSv (standard deviation 3.74mSv).  It is difficult to correlate risk of medical radiation 
exposure but this probably equates to a lifetime risk of developing a malignancy of 1 in 
1200.64, 65  In contemporary practise widespread adoption of prospective gating which 
is more robust with large detector arrays or by lowering the X-ray power during less 
important parts of the cardiac cycle (eg systole) – this is termed “tube current 
modulation” or “dose modulation.” There is evidence that the radiation dose can be 
reduced to 5-6mSv whilst not impacting on diagnostic quality of the scans.66, 67  The 
additional radiation exposure should be considered in the context of the greater risks 
from the invasive nature of the conventional coronary angiogram68, 69 and is similar to 
other CT scans performed on a routine basis.  In the most recently available scanners 
employing larger detectors and using iterative reconstruction, considerably lower 
doses can be obtained,70 with some centres reporting routine sub millisievert doses 
71although in published studies there is still a large range in the doses reported from 
different centres even using identical scanners. 72 
1.5.c.ii Cardiac arrhythmias 
As stated earlier, patients with tachycardia or irregular heart beats (atrial fibrillation, 
extrasystoles) often provide non-diagnostic images and can not be accurately studied 
with this technique, although the higher temporal resolution of dual source CT makes 
assessment in more of these patients possible. 
1.5.c.iii Inability to perform intervention  
CTCA is most employed in patients with low likelihood of CAD due to the excellent 
negative predictive value that has been demonstrated.  In those found to have 
significant disease one of the major benefits of invasive angiography is the ability to 
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perform intervention in the same sitting.  Patients who have a non-invasive angiogram 
and then require PCI will have a potentially larger radiation dose with little clinical 
benefit. 
1.5.c.iv Assessment of flow  
Cardiac CT is not capable of assessing rate or quantity of flow across valves but can be 
used to measure valve orifice areas.73, 74 
1.5.c.v Interpretation   
Historically, cardiologists have taken control of cardiac imaging (catheterisation and 
ultrasound). However, radiologists receive specific training in CT and the vast majority 
of scanners are located in radiology departments.  Consideration must be given to the 
need for trained interpretation of the non-cardiac structures which may take the form 
of a secondary review by a radiologist if the CT coronary angiograms are primarily 
reported by cardiologists.  It is also important to consider what burden and benefits 
there are in identifying these incidental findings.  Local factors in the UK influence the 
provision of CTCA services with variations in input from radiology and cardiology 
depending on local circumstances. 
1.5.c.vi Training    
Despite the introduction of specific training criteria and the work of societies within 
the United Kingdom to stimulate and organise training programs there is currently 
limited access to cardiac CT expertise and many other countries have not yet created 
local training guidelines. Ideally these programs should be run as part of a joint service 
between radiology and cardiology and trainees from both disciplines should receive 
training in non-invasive cardiac imaging.75, 76 
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1.5.d Competing technologies 
1.5.d.i Magnetic resonance imaging    
MRI is capable of imaging the coronary arteries but the spatial resolution is currently 
lagging some way short of that capable with CTCA.  Ozgun 77 performed a study 
comparing MRA with 16 slice CTA and MRA was found to have markedly worse 
specificity (62%) and sensitivity (82%) than the now surpassed 16 slice CT technology. 
A review of 28 MR coronary angiography studies including 903 patients shows 83% 
segments assessable and gave a sensitivity of 72% and specificity of 87%.78  MR is more 
useful clinically in demonstrating cardiac function and viability and is also starting to 
play an important role in perfusion imaging. 
1.5.d.ii Radionuclide perfusion imaging   
Often used as a gateway to invasive coronary angiography, isotope perfusion scans 
give a similar radiation dose to CTCA. They provide information about coronary flow 
insufficiency which is fundamentally different to the anatomical information available 
from CTCA.  Perfusion imaging is better placed at demonstrating the significance of 
coronary lesions whereas CTCA gives information on coronary artery plaque and 
stenoses even before they become flow limiting. 
1.5.d.iii Stress echocardiography   
This technique has similar sensitivity and specificity to radionuclide perfusion imaging 
and is used extensively in the UK due to the lack of ionising radiation.  However it is 
fundamentally different to CTCA giving functional rather than the primarily anatomic 
data of CTCA.  Its main limiting feature is poor image quality from subjects with 
unhelpful body habitus, although the use of transpulmonary contrast agents makes it 
possible to achieve acceptable diagnostic images in the majority of patients. 
1.5.e The future 
CT technology is continuing to develop rapidly with several major areas of 
advancement. 
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1.5.e.i Dual-source CT 
Dual-source CT offers substantial improvements in temporal resolution that are 
paramount in cardiac imaging.  This is likely to see widespread uptake and further 
developments in multi-source CT are likely. 
1.5.e.ii Increased number of slices  
Scanners with larger arrays with more slices (eg 320-slice) allow a greater volume to be 
covered in one rotation of the scanner, thus reducing the breath hold and number of 
cardiac cycles over which a scan is performed.  If the whole heart can be imaged in one 
cardiac cycle, prospective cardiac gating could be used more reliably, and this could 
lead to lowering of radiation doses, however this has not yet been delivered by current 
prototypes.79  Whilst 256 and 320 slice scanners increase coverage, and reduce stitch 
artefact and decrease overall scan time, higher temporal resolution is still required to 
overcome motion artefact. All major manufacturers now have scanners above 64 slices 
with 128, 256 and 320 slices; the 256 slice scanner is reported to have a rotation speed 
of 250ms and thus a temporal resolution of 125ms, which represents an improvement 
over previous source scanners, but remains worse than that achievable with dual 
source scanners or invasive coronary angiography. 
1.5.e.iii Increased spatial resolution and reduced noise 
Improvements in detector technology that result in improved spatial resolution may 
allow the lumen of calcified or stented vessels to be better imaged, more sensitive 
detectors may improve image noise and allow for reduced radiation dose. 
1.5.e.iv Flat panel detectors 
Flat panel detectors offer very high spatial resolution, and can be considered an 
extreme example of increasing slice numbers thus increasing coverage and reducing 
detector unit width.  Unfortunately the scintillator material used in flat panels is 
slower to respond to x-ray stimulation than that used in CT scanners and thus 
prolonged afterglow reduces the ability to deliver sufficient temporal resolution for 
cardiac CT applications and this will probably require the development of new 
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materials for flat panel detectors.80, 81  They also have a lower contrast resolution. 
Whilst not applied to flat panel technology, one manufacturer, GE, have recently 
developed a new transparent polycrystalline scintillator material that makes a further 
leap in this direction. Although the new scintillator material has not delivered higher 
spatial resolution it is the speed of reaction of the crystal that is important.  This new 
scintillator material has a primary speed one hundred times faster than the gadolinium 
oxysulfide scintillator (GOS) that is used by other manufacturers and an afterglow that 
is four times quicker to decay than GOS scintillators.  GE have used this highly 
responsive scintillator to allow dual energy scans within one half rotation with one 
detector and x-ray source by employing rapid KV switching within a scan.82 There is 
thus hope that new scintillators can also be developed for flat panel detectors. 
1.5.e.v Dual energy 
Not to be confused with dual source, dual energy is the technique whereby a single 
area of interest is scanned using x-rays generated at different voltages (kV) and hence 
different powers.  As tissues interact differently with the different X-ray energies, the 
technique can help to improve tissue differentiation. In cardiac applications, it has the 
potential to 'remove' calcification, thus permitting a clearer view of the lumen.  The 
technique is most elegantly performed using a dual source scanner or rapid kV 
switching, especially for cardiac applications when the use of a single source scanner 
would otherwise result in too poor a temporal resolution. 
1.5.e.vi Iterative reconstruction 
Iterative reconstruction is a repeated algebraic process by which an image is 
reconstructed from the linear data received by the scanner.  It is in fact an old 
technique, but due to it’s large demands for computational power it was replaced with 
filtered back projection (FBP) as the technique most widely deployed in CT image 
reconstruction.  FBP as a technique produces quite noisy images and thus higher x-ray 
doses are required to overcome this.  As computational power has greatly decreased 
in size, power and cost, the iterative process is being revisited. It is not purely the 
computational power that has become available but also the development of 
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mathematical models that improve the efficiency of the process by incorporating 
additional steps and assumptions. Sophisticated mathematical models that 
incorporate a building block created from a filtered back projection that is then refined 
using the iterative process, combined with mathematical representations of scanner 
geometry, have been developed that produce considerable reductions in image noise 
and artefact.  These improvements allow imaging with lower x-ray doses and improve 
image quality, particularly in obese patients and in calcified vessels, or potentially in 
stents.83-86  Computational power has continually increased and it’s cost diminished 
over the last 50 years and it is likely that this trend will continue.  In this context, 
iterative reconstruction is likely to take a greater role in clinical imaging technologies, 
including but far from limited to Cardiac CT angiography. Indeed all the cardiac CT 
scanner manufacturers have released implementations of such a technique.87 
 
These and other technological developments will have significant impact on the 
accuracy and reliability of CT technology for assessing coronary artery disease and, if 
combined with the expected reduction in patient dose, the range of accepted clinical 
applications will expand.  
 
1.5.f Applications of cardiac CT  
1.5.f.i Calcium scoring        
The evaluation and quantification of coronary artery calcium was one of the first 
cardiac applications of CT technology.  Since the seminal work by Agatston,17 a large 
amount of data have been collected in a variety of populations that demonstrate that 
the calcium score is a predictor of future cardiac events. 88, 89  Calcium scores were 
originally assessed by electron beam CT but it has now been shown that they can be 
accurately obtained by the increasingly available multidetector CT scanners. Calcium 
scoring is a non-contrast scan that uses a very low radiation dose and calcium scores 
can be quickly and automatically calculated. Given the increasing ability of CT to assess 
non calcified plaque and assess luminal narrowing it is clear there is potential for 
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obtaining further prognostic information from CTCA, however at present this requires 
a higher dose of radiation and the injection of intravenous contrast media. Kwon90 
demonstrated that CTCA was a better predictor of risk in a group of low risk patients. 
1.5.f.ii Assessing native coronary artery disease 
 The technological advances that have occurred in cardiac CT have been directed 
towards non-invasive coronary angiography. The sensitivity and specificity of earlier 4-
slice scanners to identify stenosed coronary arteries was such that this modality was 
not clinically useful. There have been, however, many studies comparing both 16-
slice91-102 and 64-slice103-113 scanners with invasive quantitative coronary angiography.  
In terms of the studies with 64-slice scanners, most subjects have been male and 
nearly all have had stable, chronic angina although evidence is starting to appear from 
other groups such as acute chest pain.114  Table 4 summarises some of the published 
studies investigating 64 slice CT for native coronary artery disease.  
 
Table 4 64-Slice CT studies assessing native coronary arteries 
Study No. 
Patients 
Excluded 
segments 
Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
NPV 
(%) 
Leschka et al 103 67 <1.5mm 94 97 87 99 
Leber et al 104 59 0 79 97 72 98 
Raff et al 105 70 0 86 95 66 98 
Mollet et al 106 51 0 99 95 76 100 
Pugliese et al 107 35 0 99 96 78 99 
Malagutti et al 108 55 0 97 86 66 99 
Fine et al 109 66 <1.5mm 95 96 97 92 
Ropers et al 110 81 <1.5mm 93 97 56 100 
Plass et al 111 50 <1.5mm 93 97 91 98 
Ehara et al 112 69 0 90 94 89 95 
Schuijf et al 113 60 0 85 98 82 99 
 
It should be noted that all these studies, with the exception of the multi-centre study 
of older 16-slice MSCT by Garcia et al that showed markedly lower specificity102, are 
single centre studies.  The results above are generally based on a per segment or per 
Assessment of coronary artery disease by CT  Will Roberts 
 
56 
artery analysis of only the vessels that were of sufficient image quality on MSCT to be 
assessed and compare the ability to detect >50% stenoses.  A meta-analysis115, showed 
a sensitivity of 87% and specificity of 96% for 64-slice scanners.   
Meijboom116 assessed 360 patients referred for invasive coronary angiography.  In a 
segment-based analysis, the sensitivity was 88%, specificity was 90%, positive 
predictive value was low at 47% , and negative predictive value was 99%. 
Budoff117 also undertook a multicentre study of 64 slice CT in 230 individuals.  Using a 
vessel based assessment comparing stenosis ≥50% with invasive coronary angiography 
sensitivity was 84%, specificity was 90% and NPV was 99%, but PPV was only 51%. 
The multi-centre study investigating 64 slice CT in native coronary artery compared 
with invasive coronary angiography CORE 64118 only reported patient based results 
with similar results whether using quantitative CTA or visual lesion assessment.  The 
value in reporting per-patient results is of questionable value and probably 
overestimates accuracy. 
The sensitivity and specificity of 64-slice scanners is greater than that of the 16-slice 
scanners. In addition the studies investigating 64-slice scanners rarely excluded 
coronary artery segments on the basis of size, whereas this has been done frequently 
with the 16-slice scanners.   
Evidence from dual source CT and larger 256 and 320 slice scanners are starting to 
show smilar accuracy when compared with 64 slice CT.119-121 
1.5.f.iii Assessing grafts  
  Saphenous vein grafts are easier to image with CT, being generally larger than 
coronary arteries and less mobile. Invasive coronary angiography, on the other hand, 
can be technically more challenging in such patients, with larger contrast loads and 
radiation exposure.  Native coronary arteries in these patients often become heavily 
calcified making interpretation of stenoses difficult.  Studies assessing the accuracy of 
CT in this group of patients are summarised in Table 5.  Again, the sensitivity and 
specificity of 64-slice scanners is greater. Volume rendered images can also be useful 
when planning re-do bypass grafting.  
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Table 5 Studies investigating coronary graft assessment by CTCA 
Study 
 
Slices 
No. 
patients 
 
Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
NPV 
(%) 
Schlosser et al 122 16 48 96 95 81 99 
Burgstahle et al 123 16 13 100 96 89 100 
Anders et al 124 16 32 80 85 57 94 
Stauder et al 125 16 20 98 95 93 98 
Pache et al 126 64 31 98 89 90 98 
Malagutti et al 108 64 52 99 96 95 99 
Ropers et al 127 64 50 100 94 92 100 
 
1.5.f.iv Assesment of LV function 
As data are collected throughout the cardiac cycle, movie images of the heart 
throughout the cardiac cycle can be made demonstrating regional wall motion 
abnormalities.  Comparison of systolic and diastolic volumes allows accurate 
assessment of stroke volume and ejection fraction.128, 129  This technique cannot be 
used with prospectively gated scans were images are only obtained during part of the 
cardiac cycle. 
1.5.f.v Defining pulmonary vein anatomy 
CT is also becoming more widely used during electrophysiological procedures, in 
particular atrial fibrillation (AF) ablation.  A 3D CT image of the atria can be 
superimposed on the electrophysiology map improving the ability to localise 
pulmonary veins and reducing fluoroscopy times.130 
1.5.f.vi Evaluating morphology 
MSCT can also be used to identify the course of anomalous coronary arteries (Fig 13), 
which may be important where they take a so-called “malignant” course in between 
the aorta and pulmonary trunk,131 and to assess complex congenital heart disease. 
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1.5.f.vii Evaluating structural lesions 
Cardiac masses, thrombus, pericardial, pulmonary and aortic pathology are well 
delineated by cardiac CT. 
1.5.f.viii Plaque characterisation 
In contrast to conventional coronary angiography, CT has the potential to look at the 
coronary artery wall in addition to the lumen. Whilst not clinically useful currently, it 
may become possible to identify non-calcified plaque that is not flow-limiting but 
which is “unstable” and may lead to an acute coronary syndrome (Figure 12).  A 
technology that provides the potential to non-invasively assess the early stages of 
plaque formation and characterise its composition and prognosis has the potential to 
cause a huge shift in the practice of cardiology.  Meta analysis of studies comparing 
recognition of plaque type when compared with IVUS has demonstrated sensitivity of 
88-95% and specificity of 90-96%.132 
 
Figure 12 Plaque characterisation by CT.  Three different plaque types are 
illustrated showing the darker appearance of soft plaque, the bright 
appearance of calcified plaque and mixed plaque with features of both. 
 
1.5.f.ix Perfusion imaging 
Whilst the pharmacokinetics of CT contrast agents will allow first pass perfusion 
imaging133 and assessment of delayed enhancement (for scarred myocardium), MSCT 
is not widely used in this role – although there are on-going studies. The radiation 
doses involved remain a concern as this information can be obtained by cardiac 
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magnetic resonance imaging (CMR), which does not use ionising radiation.  However 
with the increasing implantation of pacing and resynchronisation devices generally 
rendering cardiac MRI unsafe, there may be a role in a small number of patients. 
1.5.f.x Assessment of coronary stents 
Coronary stents pose difficulties for imaging by CTCA due to their size and the density 
of the material from which they are constructed causing artefacts.  With 16 slice 
scanners, the results suggest the technique is not sufficiently reliable for clinical use.  
There is not yet sufficient clinical data with 64 slice scanners to see if the improved 
technology has led to improved reliability in this group.  This will be extensively 
explored in chapter 5.  
 
 
1.6 Circulating biomarkers in coronary artery 
disease  
Circulating biomarkers are substances involved in disease biology that are amenable to 
measurement and evaluation and provide information about the underlying disease 
process in terms of diagnosis, severity or prognosis.  A huge array of biomarkers of 
cardiovascular disease are at varying stages of assessment, a number of which have 
fulfilled their translational potential and found major clinical application (table 6).134, 
135  This is particularly true of troponins and natriuretic peptides which now play a 
central role in the diagnosis of myocardial infarction and heart failure. There is also 
evidence that these novel biomarkers may have a role for risk stratifying patients with 
stable coronary disease. Their diagnostic potential in patients with suspected angina 
attending chest pain clinics will be explored in more detail in chapter 6.   
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Table 6 Biomarkers in cardiovascular disease 
 Accelerated atherosclerosis- HBA1c, Blood glucose, lipid profile 
 Inflammation – HS CRP, myelpoeroxidase 
 Vascular damage –CrCL, microalbuminuria 
 Myocyte injury –CK, CK-MB, cardiac troponin I and T, GDF-15 
 Haemodynamic stress –BNP, NT-Pro-BNP, copeptin 
 
 
1.6.a Cardiac troponins 
The evaluation of myocardial infarction using biomarkers is now so embedded in our 
clinical practice that the definition of myocardial infarction includes elevation of 
biomarkers as one of its key tenets.136  However it was only with the development of 
assays for CK and CK-MB137 in the last 50 years  that this concept was first included in 
the generally accepted definition of myocardial infarction. 138 Since then the definition 
has been further elaborated and refined139 but the importance of cardiac biomarkers 
remains paramount. 
Initially CK-MB was the main cardiac biomarker used in the diagnosis of myocardial 
infarction but since the 1990s it has been shown that cardiac troponins I and T are 
sensitive and specific markers of myocardial injury140 and have now largely superseded 
the earlier use of the less specific biomarkers such as creatine kinase.141 
In contemporary clinical practice it is the cardiac troponin subunits Troponin I (TnI) and  
Troponin T (TnT) that are ubiquitously used in the setting of myocardial infarction.  
These troponin subunits are part of the thin filaments in cardiac and skeletal muscle 
and in combination with a third subunit, troponin C form part of the cardiac troponin 
regulatory proteins. 
 For muscle contraction to occur intracellular calcium ions are released from the 
sarcoplasmic reticulum and bind to Troponin C, resulting in a conformational change in 
the complex  with tropomyosin, withdrawing troponin I from the myosin binding site 
on actin, and allowing the myosin of the thick filaments to bind.  Conformational 
change of the myosin head unit, fuelled through the hydrolysis of ATP causes the thick 
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filament and thin filament to slide in relation to each other and muscle contraction 
occurs. 
The majority of troponin subunits are bound in sarcomeres, whereas the remainder 
are free in the cytoplasm.  For cTnI this free pool appears to represent 3-4% of cellular 
cTnI and 6-8% for cTNT.142, 143 
Troponin subunits I and T have cardiac specific isoforms, whereas troponin C has 
shared isoforms with skeletal muscle.  Cardiac troponins are released into the systemic 
circulation when cardiac myocytes are subject to injury and undergo necrosis.  Thus 
cardiac troponin I (cTnI) and cardiac troponin T (cTnT) have been logical targets as 
biomarkers for assessing damage to myocardial cells.   
Both cardiac cTnT and cTnI have been shown to be specific and sensitive markers for 
the diagnosis of myocardial infarction and levels also exhibit prognostic utility.144, 145  In 
the setting of myocardial infarction this is in keeping with the fact that the greater 
amount of myocardial infarction and thus myocyte necrosis, the greater the release of 
cardiac troponins.  As more of the myocardium is infarcted the degree of left 
ventricular dysfunction increases leading to heart failure and a larger substrate for the 
development of potentially fatal arrhythmias.146 
1.6.a.i Troponin elevation in absence of coronary occlusion 
It has however been noted that elevation in cardiac troponin levels is not purely found 
in the setting of myocardial infarction but may also occur in a range of other 
pathologies.144, 147 
  
Assessment of coronary artery disease by CT  Will Roberts 
 
62 
Table 7 Non - coronary causes of elevated troponin 
 Acute heart failure 
 Pulmonary embolism 
 Stroke 
 Acute aortic dissection 
 Tachyarrhythmias 
 Hypotension / Shock 
 Sepsis 
 ARDS 
 Perimyocarditis 
 Endocarditis 
 Tako-tsubo cardiomyopathy 
 Radiofrequency catheter ablation 
 Cardiac contusion 
 Strenuous exercise 
 Sympathomimetic drugs 
 Chemotherapy 
 
 
The mechanism for this elevation in troponin levels in the non myocardial infarction 
setting is debated.  In some disease states such as pulmonary embolism and 
myocarditis myocardial injury could still be occurring.  Although not due to coronary 
occlusion, this could lead to cell necrosis and troponin release.  However this theory 
does not fit well in situations such as stroke and sepsis, where it is harder to develop a 
model for myocardial necrosis.   
It is also now well documented that rises in cardiac troponins can occur in a large 
proportion (nearly 50%) of healthy individuals undergoing extreme exertion such as 
marathon running and this has been demonstrated in a variety of athletes including 
adolescents.  It has been noted that the release of troponin in this context has a 
different profile to that occurring in myocardial infarction, with a shorter decay period 
returning to baseline quicker.148  Thus one must consider the possibility of an alternate 
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mechanism of release for troponin outwith the setting of mycocyte necrosis. Katus 149 
also noted differing release kinetics between those patients suffering myocardial 
infarction but undergoing early reperfusion and those not.  Muller-Bardoff150 
demonstrated that patients with pulmonary embolism had a cTnT release that 
decreased faster than in patients with acute coronary syndrome, again suggesting 
there may be a different underlying mechanism. 
One possible explanation for the elevated levels of troponin I and T and delayed 
clearance in patients with renal impairment 151 is that there is always a small quantity 
of troponin in the circulation and that when this is allowed to accumulated due to 
reduced clearance, it becomes detectable with current assays.  If this is not the case a 
mechanism either of recurrent small myocardial infarction or some other loss of 
membrane integrity must be the cause of the raised levels of troponin identified in 
patients with end stage renal failure.152 
1.6.a.ii Mechanistic theories for troponin release in absence 
of coronary occlusion 
With that in mind we must consider the possibility that troponin release does not 
solely occur due to cell necrosis.  The two hypotheses that have developed to explain 
the observation of elevated troponin in the absence of overt myocardial infarction are 
the ‘minor irreversible damage’ theory and ‘cytosolic leak’ model. 
Minor irreversible damage is the theory that small levels of cardiac necrosis occur in all 
these disease states, sufficient to release detectable troponin, but insufficient to cause 
detectable levels of myocardial necrosis or its sequelae by means of imaging or clinical 
assessment.  The concept of cytosolic leak is that pathological, or indeed extremes of 
physiological states can lead to leakage of small levels of cardiac troponin into the 
circulation from cells which are not undergoing necrosis and thus there is no 
irreversible myocardial damage occurring. 
1.6.a.iii Troponin release and imaging evidence of infarction 
In the setting of small troponin rises in response to extreme exercise, various imaging 
and clinical assessments have generally shown no evidence of myocardial scar.153  
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Although one study by Niemala154 showed evidence of LV impairment in response to 
extreme exertion as assessed by echocardiography.  The concern however is that the 
amount of myocardial infarction may be too small to be detected by such means. 
Indeed it has been shown that in acute coronary syndromes or after PCI, despite 
significant troponin release, presumed due to myocardial necrosis this may not be 
detectable by clinical, echocardiographic, nuclear or magnetic resonance imaging 
techniques.155, 156  Thus it cannot be affirmed that the presumably small amount of 
necrosis in the minor irreversible damage theory would indeed be detectable by any 
current modalities having a comparatively low spatial resolution, and this alone is 
insufficient evidence to refute the minor irreversible damage theory. 
1.6.a.iv Release kinetics and mechanistic theories 
The comparison of the release kinetics of troponins in myocardial infarction is also 
inadequate evidence to support the cytosolic leak theory. In myocardial infarction 
there are many confounding factors that may alter the release profile of troponins. 
Microvascular obstruction is a well recognised phenomenon157 and this could 
contribute to the slower sustained release of troponin compared with non-infarct 
release.  The observation that the release of CK is much faster and quickly falls to 
baseline in myocardial infarction would tend to counter this argument, as CK is likely to 
be affected in a similar way to troponin by microvascular obstruction.  The relative size 
of the CK and troponin molecules does not easily explain the differing release profiles. 
CK 86000 daltons (half for each subunit) troponin I 28000, troponin T 41000  and 
troponin C 18000 daltons. 
The measured CK-MB is largely cytoplasmic, and not a measure of mitochondrial or 
sarcoplasmic CK whereas the majority of troponin I and T is bound in the sarcoplasm.  
If we were measuring purely the cytoplasmic troponin we may expect a similar release 
profile, however in cell necrosis both the cytoplasmic and sarcoplasmic troponins are 
released.  It has been suggested that the prolonged troponin release profile in 
myocardial infarction represents the release of the small proportion of troponin which 
is cytoplasmic followed by a slower release of the majority of the troponin that is 
found within the sarcomeres.  Thus this does support the concept that a faster release 
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and decay of troponin in non-infarct settings may reflect the release of only the 
cytosolic troponin due to membrane leak.  This would explain the similarity between 
the CK release profiles in myocardial infarction and the release profiles of troponin in 
non-infarct disease states. 
1.6.a.v Cell membrane disruption and troponin release 
Animal studies help to build support for the model of cytosolic leak by investigating 
the causes and consequence of cell membrane disruption or permeability.  Remppis158 
exposed isolated rat hearts to a calcium paradox to cause cell membrane damage.  The 
cells exhibited faster onset and return to baseline of troponin release compared to a 
no flow ischaemia model in a similar manner to the earlier described rapid rise and fall 
of troponin in endurance athletes.148 
Remppis induced cell membrane disruption using a chemical technique but 
demonstrated that this led to troponin release, most likely from the cytosolic pool, 
however evidence that mechanical stress and exercise can induce cell membrane 
permeability is also required to support the cytosolic release theory.  Clarke159 
demonstrated that cardiac myocytes could undergo survivable cell membrane 
wounding in response to mechanical stress and that this was exacerbated by β-
adrenergic stimulation of heart rate and force of contraction.  McNeil160 demonstrated 
exercise induced membrane wounds in rat skeletal muscle.   It is known that the heart 
adapts by undergoing hypertrophy of myocardium in certain situations of increased 
load such as hypertension and severe aortic stenosis. Myocytes undergoing this 
process exhibit an elevated rate of contractile protein synthesis. Stretching rat cardiac 
myocytes isolated on a deformable material161 results in rapid induction of genes and 
multiple messenger pathways. Fischer162 demonstrated transient cell membrane 
permeability in response to abrupt pressure loading of rat hearts.  
Thus we have seen that there is some evidence supporting the theory of cytosolic leak, 
that membrane permeability can be induced by mechanical stress and that membrane 
permeability leads to release of troponin with kinetics similar to that seen in disease 
states without coronary occlusion. 
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1.6.a.vi Troponin release in response to acute ischaemia 
Chocron demonstrated that myocardial ischaemia was associated with the release of 
cardiac troponin I in isolated rat hearts with no significant histologic difference 
between the group with shorter ischaemic time and controls, despite having raised 
troponin levels.163  A caution here that the sample size was small and the shortest 
ischaemic time was three hours. 
An elegant study by Suleiman demonstrated release of troponin I into the coronary 
sinus of patients undergoing off-pump CABG after only 3 minutes of controlled 
regional ischaemia.164   
Feng used a pig model whereby flow in the LAD was reduced by 36% and cTnI raised in 
reversible ischaemia compared with controls.165  Chen166 demonstrated that rats 
forced to swim had increased troponin T (and evidence of inflammation) in serum and 
myocardium compared with controls and had histological evidence of damaged 
myocardial fibres and inflammatory infiltrates rather than necrosis. 
Thus we have seen a plausible mechanism for the release of troponin in patients 
without coronary occlusion, and evidence that both mechanical and ischaemic factors 
can lead to cell membrane permeability and that transient ischaemia leads to troponin 
release.  
An interesting exception to the model of cytosolic leak in the reversible ischaemia 
model was noted by Tung in the case of subarachnoid haemorrhage where troponin 
elevation was associated with histologically demonstrated myocyte necrosis, probably 
neurally mediated.167 
The above works do support the hypothesis of a cytosolic membrane leak as a source 
of elevations in circulating troponins in reponse to ischaemia, however the evidence is 
considerably muddied by the variety of troponin assays used and the inherent errors 
and limits of detection.  It is necessary in the current era of higher sensitivity assays to 
repeat some of this work to enable a better understanding of the role and mechanism 
of elevated cardiac troponin levels in the non-infarct setting. 
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1.6.a.vii Troponin elevation in stable coronary artery disease 
Looking now to clinical studies of troponin in patients with stable ischaemia the 
evidence is less encouraging. Troponin measurements are well established in the 
diagnosis of acute coronary syndromes, however their role in the assessment of stable 
angina is less clear.  In stable coronary artery disease, multiple micro-infarcts, similar 
to the proposed minor irreversible damage theory could lead to troponin release, or 
via some mechanism leading to cytosolic release such as during periods of ischaemia 
as discussed above.  All these studies were performed with older, less sensitive assays 
than I will use later in Chapter 6. 
Angioscopy studies have demonstrated the presence of plaque rupture and 
thrombosis in stable angina patients.168  Mann169 demonstrated that 22% of 
histopatholgical specimens examined in patients with stable angina had evidence of 
thrombus formation.  Using optical coherence tomography 12% of patients with stable 
angina had disrupted plaques and 35% had thrombus formation.170  Mann171 
demonstrated from necropsy specimens that coronary arteries appear to undergo a 
phasic pattern of atherosclerotic plaque progression with continual rupture and 
healing, if these plaque ruptures lead to micro-infarction one would expect some 
release of troponin, that may be detectable in these patients. 
Carlson172 studied patients with evidence of ischaemia on dobutamine stress echo and 
showed that they had no difference in baseline troponin I or T levels and no rise in 
troponin from baseline after stress compared with those with no evidence of 
ischaemia.  Thayapran173 demonstrated no increased troponin I or T in any patients 
before or after exercise despite evidence of ischaemia on perfusion scan. 
Kokowicz174 did demonstrate a rise in troponin I levels after exercise in a small group of 
patients but this did not correlate with the number of stenotic lesions on invasive 
coronary angiography nor did it correlate with prognosis.  It was however noted more 
commonly in patients with impaired left ventricles or high systolic exertional blood 
pressures, perhaps a surrogate for LV wall stress. 
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Eggers found elevated troponin I levels in 22% of a population over 70 years old and 
this correlated with LV impairment and LV hypertrophy but not the presence of scar by 
MRI. 175 
In a sample of the Dallas population raised troponin T ≥0.01µg/L was found in only 
0.7% of the population aged 30-65 and demonstrated an association between elevated 
troponin and LVH, CKD and a composite heart failure index.176 
In a group of 70 year old men in Sweden with no clinical evidence of current or prior 
coronary artery disease, cTnI ≥0.04µg/L was associated with first cardiovascular event 
and mortality. 
It is difficult to combine the data from these various studies to get a clear 
understanding, as most of the biomarker elevations seen, particularly with the 
troponins, are at the lower end of the assays’ detectable limits, and as the assays are 
refined the limit of detection becomes lower and the accuracy of measurements at 
these lower limits becomes more reliable. 
Since my research was commenced there have now been even more sensitive assays 
developed that detect troponin I in nearly all healthy subjects.177  Thus the concept 
that any level of detectable troponin must represent myocardial necrosis cannot be 
correct.  With this knowledge and the evidence from the animal studies and human 
studies described above, the model of a continual slow turnover and elimination of 
troponin from the circulation is likely to represent physiological normality.  And it is 
plausible that disruption of this balance by processes such as the cytosolic leak theory 
can give rise to higher levels of troponin, and it is clearly necessary to examine the 
levels, profiles, mechanisms and consequences of the elevations found in these 
differing disease states. 
 
 
1.6.b Brain Natriuretic Peptide (BNP) 
The measurement of the neurohormone BNP has become an important diagnostic tool 
in the evaluation of heart failure. It was originally isolated from porcine brain and thus 
given the name brain natriuretic peptide, but it is present in greater concentrations in 
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myocardium in response to cardiac stress and is now generally called B-type natriuretic 
peptide or simply BNP.  In humans three natriuretic peptides are recognised; atrial 
natriuretic peptide (ANP), BNP and C-type natriuretic peptide (CNP) which is largely 
produced outside the heart.178  A fourth natriuretic peptide; dendroaspis natriuretic 
peptide (DNP), first isolated in green mamba venom may be a fourth endogenous 
natriuretic petide, though the evidence is as yet is inconclusive.179 
BNP is released in response to left ventricular wall stretch and volume overload. Its 
elevation in the plasma is a biochemical marker of high left ventricular end-diastolic 
pressure in patients with symptomatic left ventricular dysfunction.  BNP is also 
elevated in end stage renal failure and valvular heart disease.180  Along with the other 
cardiac natriuretic peptides, BNP plays a role in maintaining the compensatory 
mechanisms that are present in heart failure by promoting natriuresis, diuresis and 
vasodilation.  Although small quantities of BNP are stored in the atria, BNP is not 
stored in significant quantities in cardiac ventricular myocytes and its transcription is 
upregulated in response to cardiac stress as discussed above.181  When BNP is secreted 
it is cleaved from a pre-prohormone into the prohormone proBNP which is further 
cleaved into the active component BNP and the inactive fragment N-terminal proBNP 
(NT-proBNP).  BNP is cleared by binding with the inactive natriuretic peptide receptor -
C and neutral endopeptidase (NEP) and a small proportion (<5%) is cleared renally with 
a half life of approximately 20 minutes.182, 183  NT-proBNP is also cleared renally but at 
a slower rate with a half life thought to be 27-120mins.184  In healthy individuals there 
are very small levels of ANP and BNP produced in the atria. However in disease states, 
the ventricles produce large quantities of BNP, compared with a relatively modest 
change in ANP levels.185  It is this large difference between healthy and disease states 
that is a key factor in the clinical application of BNP as a useful biomarker. 
BNP binds to the cGMP coupled receptor natriuretic peptide receptor A (NRP-A) which 
is found in adrenal, lung, renal, adipose, ileal and aortic tissue.186  In human subjects 
infusion of synthetic BNP caused natriuresis and diuresis and suppressed plasma 
aldosterone.183  Mice with overexpression of BNP have hypotension and bone 
adbnormalities whereas BNP knockout mice developed multifocal cardiac fibrosis but 
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not hypertension. This has led to the suggestion that BNP may also exert a paracrine 
effect, potentially acting upon cardiac fibroblasts. 187, 188 
1.6.b.i BNP elevation in models of ischaemia 
Although the main stimulus for BNP is increased ventricular pressure and volume, it 
may also be secreted in response to myocardial ischaemia independent of ventricular 
pressure changes.189 In animal models Toth190 demonstrated that hypoxia increases 
circulating BNP in isolated rat myocardium, despite a decrease in LV pressure.   Similar 
results were obtained by D’Souza in ischaemic rat hearts.191  Hama ligated a coronary 
artery inducing infarction rather than ischaemia in rats and showed an increase in 
ventricular myocardial BNP and BNP mrNA.192  Goetze demonstrated increased BNP 
mRNA in ischaemic pig myocardium compared with non-ischaemic areas in the same 
hearts, further helping to exclude ventricular stretch as the stimulus, although the 
possibility of regional wall stress triggering BNP production remains. In the same paper 
it was also demonstrated that BNP mRNA was increased in oxygen deprived myocytes 
in culture medium.193   
Patients undergoing CABG or PCI but with normal LV function all had higher BNP and 
NT-proBNP than controls. Ventricular BNP mRNA expression in biopsies taken from 
hypoxic areas of myocardium in the CABG group correlated with plasma BNP and 
plasma NT-proBNP.194  Even transient ischaemia due to balloon inflation during 
coronary angioplasty can produce elevation of BNP.195 
 
1.6.b.ii BNP changes on exertion 
Given the evidence that BNP is released in response to ventricular stretch it is likely 
that it may rise in response to the haemodynamic load of exertion. Indeed all 
endurance athletes in a study by Neumayr had a measureable rise in NT-proBNP in 
response to extreme and prolonged exertion.196  Kohno measured the coronary sinus 
plasma levels of BNP in a group of hypertensive patients and noted increased BNP on 
ergometric exercise that was reduced by administration of an ACE inhibitor.197  The 
development of regional wall motion abnormalities during exercise or stress in 
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patients with coronary artery disease inducing regional ischaemia is the basis of the 
stress echo assessment of ischaemia and is a well established phenomenon.  The 
development of such regional variations in myocardial contraction may produce areas 
of increased wall stress within the ventricle that could trigger BNP release to a greater 
extent in such patients compared with patients with more global co-ordinated 
contraction. 
Studies assessing BNP changes in the setting of ischaemia are largely conflicting and 
will be examined below.  There are several studies demonstrating that the rise in BNP 
or NT-proBNP on exertion is greater in the presence of ischaemia.  Further studies 
suggest that the increase is largely associated with LV dysfunction, raised LV end 
diastolic pressure or areas of scar which may also be related to LV impairment.  A final 
group of studies suggest that it is the baseline BNP that is of significance and not the 
change on exercise.   
Marumoto demonstrated increased BNP levels on exercise in 35 individuals with 
angiographically proven coronary disease and stable angina compared with no 
elevation in a normal control subjects, whereas ANP rose in both groups.198  In the 
study by Chatha, NT-proBNP increased in patients with exercise ECG evidence of 
ischaemia but didn’t increase more than  those without.199 
Foote found that patients with known CAD, normal LV function, ischaemia on 
perfusion scanning and normal resting BNP and NT-proBNP had post exercise BNP 
higher than those patients with coronary disease but no evidence of ischaemia and 
healthy volunteers.200  However they were surprised to note that the baseline NT-
proBNP and BNP were also significantly different between the two groups. 
Although they did not look at the association between ischaemia and BNP Marumoto 
demonstrated that increased BNP on exercise in patients with proven prior myocardial 
infarction correlated with LV function and LVEDP.201  Similarly  Palumbo investigated 
patients with fixed, reversible or no perfusion defects on SPECT scans and noted that 
the highest levels of BNP was found in those with fixed defects, however those with  
reversible perfusion defects had higher levels than those without perfusion defects.202 
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Thus BNP does appear to rise in response to ischaemia but the degree to which the 
extent of change is directly related to ischaemia is unclear. 
1.6.b.iii Baseline BNP in patients with ischaemia 
The studies by Weber,203 Yeo204 and Asada205 suggest that it is the baseline BNP that is 
more useful as a predictor of ischaemia than the change in BNP on exertion.  Weber203 
found that NT-proBNP levels were raised in patients with CAD demonstrated on 
coronary angiography or with ischaemia and the ischaemia extent by SPECT correlated 
with NT-proBNP level.  However they documented no increase on exercise at 15 
minutes.  Yeo204 examined patients with coronary artery disease.  Those with 
ischaemia on SPECT had higher baseline BNP and NT-proBNP than non ischaemic or 
healthy volunteers, but also demonstrated a higher rise in ischaemic than non-
ischaemic group after exercise, even when fixed defects representing prior infarct 
were excluded from the comparison.  Asada,205 in a group of patients with known or 
suspected CAD found that pre- dobutamine stress echo (DSE) BNP levels predicted 
ischaemia but that the change between pre and post DSE was not significant.  Bibbins-
domingo189 assessed 355 patients with either clinical, angiographic or scintigraphy 
evidence of ischaemic heart disease or prior myocardial infarction.  It was found that 
baseline BNP level was associated with inducible ischaemia on exercise 
echocardiography. 
There is a clear difference in the level of exertion undertaken by the endurance cyclists 
in Neumayrs study196  and the intensity and duration of exercise in the other studies in 
clinical settings.  It may be that the release of BNP requires a longer sustained period 
of exertion that many of my subjects, particularly those with limiting angina will not be 
able to achieve.  A large part of the observed elevation of BNP particularly at rest could 
be related to ventricular pressure changes related to even small areas of LV 
impairment, however it is interesting to see that even when taking this into account 
there does seem to be a trend for patients with ischaemia demonstrating higher levels 
of BNP at rest. 
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1.6.b.iv BNP as a predictor of cardiovascular events 
BNP has important prognostic value in unstable coronary artery disease. In acute 
coronary syndromes, levels of BNP and N-terminal pro-brain natriuretic peptide (NT-
proBNP) strongly predict mortality and risk of future heart failure, independent of 
known risk factors.206  The usefulness of these cardiac peptides in identifying unstable  
patients with significant coronary stenoses extends to those with normal ECGs, 
echocardiograms and cardiac enzymes. 207  NT-proBNP predicted later LV dilatation 
post STEMI.207  NT-proBNP increased in unstable angina but not stable angina.208 
Emerging evidence suggests that BNP is related to prognosis even in patients with 
stable coronary disease. In the study of Omland et al. 186 patients with 
angiographically proven stable coronary disease were followed up for a period of 7.4 
years. Plasma BNP levels were independently related to long term survival.209 
Ndrepepa and Kragelund showed an association between degree of coronary artery 
disease and baseline NT-proBNP and BNP levels.  Ndrepepa 210 found that NT-proBNP 
predicted mortality in 1059 stable angina patients with angiographically demonstrated 
coronary stenoses but no detectable troponin rise who subsequently underwent 
percutaneous coronary intervention.  Kragelund211 demonstrated that in stable 
subjects with angiographically proven coronary disease, higher NT-proBNP levels were 
seen with greater degrees of coronary disease irrespective of LV ejection fraction by LV 
gram and LV end diastolic pressure (LVEDP) and NT-proBNP was a prognostic marker 
of all cause mortality. 
Bibbins-Domingo212 studied 987 patients with previous MI, angiographic stenoses or 
evidence of ischaemia.  Although they adjusted for LV function, the correlation 
between mortality and cardiovascular events was strongest in those with EF>50%.  NT-
proBNP did have weak association with future myocardial infarction but the greatest 
predictive value was for new onset heart failure. 
In a wider selection of the general population BNP levels seem to predict mortality and  
heart failure but are not a strong predictor of coronary artery events.  In Kistorp’s 
cohort of people aged 50-89 NT-proBNP when adjusted for LVEF was predictive of first 
major cardiovascular event (stroke or heart failure) and death, but there was no link 
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with CHD events such as myocardial infarction.213  Similar findings were obtained by 
Wang who measured BNP levels in the Framingham offspring study of unselected 
members of the community.  Here BNP was most strongly associated with heart failure 
and atrial fibrillation with no link to coronary artery disease.  However when they 
adjusted for LV function by echo the association between BNP and most outcomes was 
attenuated.214 
 
Thus raised BNP levels do appear to be predictive of mortality, stroke and heart failure 
but there is less evidence that it is predictive of coronary events such as myocardial 
infarction.  Baseline BNP levels do appear to predict ischaemia but the significance of 
the response to exercise or stress is unclear. 
 
1.7 Summary 
In this introductory chapter the pathogenesis of coronary artery disease by 
atherosclerosis has been outlined and the importance of its sequelae discussed. It has 
been seen that PCI and coronary artery stenting play an important role in the 
treatment of coronary artery disease and techniques for assessing restenosis within 
coronary stents have been discussed.  The technology underlying CT calcium scoring 
and CT coronary angiography has been explored in some depth and the evidence of its 
utility has been shown.  In the following chapters aspects of the CTCA technique will be 
explored and evidence for its efficacy in assessing native coronary artery disease and in 
Table 8 BNP and Ischaemia 
 Ischaemic tissue has increased BNP or BNP mRNA (1.6.b.i) 
 BNP increases in healthy subjects in response to extreme exertion (1.6.b.ii) 
 Weak evidence that rise in BNP on exertion correlates with ischaemia (1.6.b.ii) 
 Baseline BNP correlates with ischaemia (1.6.b.iii) 
 Baseline BNP is poor predictor of myocardial infarction (1.6.b.iv) 
 Baseline BNP predicts heart failure or surrogates (1.6.b.iv) 
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stent restenosis against the gold standard of intravascular ultrasound will be sought.  
The evidence for the role of the biomarkers cardiac cTnI, cTNT and BNP in the 
diagnosis and prognosis of coronary artery disease in the acute but also in the chronic 
setting in stable patients has been examined.  It has been shown that there is evidence 
from both animal, human and population studies suggesting evidence of release of 
both markers in chronic CAD and mechanistic models have been described. 
Chapter 2 will outline the cohort of patients recruited to the various parts of my 
research and highlight some important considerations in these groups. 
In Chapter 3 the effect of heart rate and rhythm will be explained and the medications 
available to reduce heart rate at the time of scan to improve image quality will be 
explored.  A systematic review of the literature on CTCA will be undertaken to assess 
the rate control regimes in use.  The rationale for the development of the rate control 
strategy employed in my centre will be discussed.  This regime will then be assessed to 
try to gain some insight into its utility in clinical practice. 
In Chapter 4 the ability of CTCA to assess native coronary artery disease will be 
explored, comparing the accuracy of the technique in this setting with that 
demonstrated in other studies. 
In Chapter 5 the accuracy of 64 slice CT coronary angiography for in stent restenosis 
will be examined, along with a discussion of the particular challenges faced in 
assessing coronary artery stents.  Establishing a more appropriate gold standard of 
IVUS for the assessment of in stent restenosis, comparision will be made between 
CTCA and invasive coronary. 
Chapter 6 demonstrates the potential utility of CTCA as an endpoint in the assessment 
of coronary artery disease.  I will explore the role of calcium scoring and CT coronary 
angiographically determined stenotic plaque and the biomarkers BNP and TnT, 
compared with exercise electrocardiogram testing in a cross-sectional study of 
patients attending a RACPC in North East London. 
Chapter 7 summarises the findings of this work and looks to the future of CTCA. 
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2. COHORTS 
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Three groups of patients were the subject of my research.   
 
Cohort 1, recruited from the outpatient service at the London Chest Hospital, is 
examined in Chapters 4 and 5. 
Cohort 2, recruited from the Newham University Hospital RACPC is examined in 
Chapter 6. 
Cohort 3 comprises 121 patients of whom 81 patients are from Cohort 1 and 40 
patients from the Hospital of St John and St Elizabeth radiology department.  This is 
the first group to be examined in the following chapter. 
 
 
2.1 Cohort 1 
The cohort examined in Chapters 4 and 5 represent a group of 80 patients all who 
had undergone previous coronary intervention and stent deployment.  They were 
recruited after referral for invasive angiography for investigation of recurrent 
angina. All consented to additional CTCA64 and a subgroup to intravascular 
ultrasound (IVUS) for gold-standard assessment of stent restenosis..  This group 
differs from the patients assessed in many of the studies outlined in chapter 1 
investigating the accuracy of CTCA which in the majority focused on patients with 
suspected coronary artery disease and represented a generally lower risk group.  In 
contrast, cohort 1 had known coronary artery disease and prior coronary stenting. 
My use of IVUS for accurate assessment of restenosis meant that only patients with 
patent stents could be included in the diagnostic evaluation of CTCA64 within the 
stent component of the study. Patients with occluded stents were, of necessity, not 
available for analysis yet represent the group most readily diagnosed by CTCA64. 
Inevitably, therefore my use of IVUS as a gold standard set the bar very high for 
CTCA64. 
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2.2 Cohort 2 
The cohort examined in chapter 6 comprised 229 patients recruited from a rapid 
access chest pain clinic in Newham in London.  This RACPC was one of the earlier 
RACPCs in the UK, established in 1996 and in previous studies has been 
demonstrated to have a large proportion of non-white patients.  This is reflected by 
data from the ONS in Figure 13 below which shows the high proportion of South 
Asians in the community.215 
 
 
Figure 13 Newham population breakdown by ethnicity in 2007215 
 
 
The table below is reproduced from unpublished work 216 and represents a larger 
cohort of patients investigated in earlier work from the same RACPC.  In patients 
with both angina and non cardiac chest pain there is a high percentage of South 
Asian patients. 
  
Assessment of coronary artery disease by CT  Will Roberts 
 
79 
 
Table 9 Ethnicity in previous cohort recruited from Newham RACPC216 
Diagnosis Angina(25%) NCCP (75%) 
   
Ethnicity   
White 55% 40% 
South Asian 38% 44% 
Black 8% 16% 
Risk factors   
HTN 51% 31% 
Diabetes 24% 11% 
Smoker 23% 23% 
 
 
The importance of racial group in this context is that epidemiological studies have 
identified high levels of diabetes and coronary artery disease in south Asian 
patients.217  Particularly pertinent to CTCA technology is the evidence that these 
patients have smaller coronary arteries.218, 219  Assessment of small structures is 
limited by the available spatial resolution of CT technology.  In CTCA the technology is 
operating close to its current limits of spatial resolution in assessing coronary arteries 
and thus a cohort with smaller vessels may be harder to assess. 
The area served by the RACPC is one of the poorest areas in London with high rates of 
deprivation and poverty and with lower life expectancy than the London average.215  In 
2007 Newham was ranked as 4th most deprived in the United Kingdom.220  Some of the 
limitations in the studies in chapter 6, to be discussed in more detail later, derived 
from the unwillingness of patients to re-attend for repeat blood tests or to travel for 
additional CT scans.  It may be that the relative poverty of this study group influenced 
their ability to take the time to attend scans during the working day. 
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2.3 Cohort 3 
In chapter 3 the importance of slow regular heart rates during CTCA will be examined 
and efficacy of a heart rate lowering regime in use in our institution will be explored. 
The final cohort examined in this chapter comprises a total of 121 patients.  94 of 
these patients were recruited as part of research studies and 27 were undergoing 
CTCA at the Hospital of St John and St Elizabeth for clinical indications. The 94 patients 
recruited as part of research studies represent early recruits to cohorts 1 and 2, 
recruited according to the criteria for the studies documented in chapters 4-6. Thus 
the proportion of cohort 3 with coronary artery disease was appreciably larger than 
expected in the routine clinical setting and this is made clear from the data in chapter 
3 with many of the subjects already treated with beta blockers at the time of CTCA.  
Patients with asthma were excluded from cohort 1 and this group is thus under-
represented in cohort 3. 
 
Table 10 Summary demographics and risk factors for Cohort 1-3 
 COHORT 1 
(n=80) 
COHORT 2 
(n=229) 
COHORT 3 
(n=121) 
Demographics    
Age (years) 
Mean ±SD, Median (IQR) 
63±10 53(11) 58(12) 
Women (n (%)) 13 (16%) 59 (26%) 23 (19%) 
Asian ethnicity (n (%))  134(59%)  
Risk factors    
Hypertension (n (%)) 56 (70%) 102 (45%) 80 (66%) 
Current smoker (n (%)) 49 (61%) 50 (22%) 57 (47%) 
Diabetes (n (%)) 14 (18%) 69 (30%) 26 (21%) 
Other factors    
Asthma 0 n/a 4(3%) 
Beta blocker use 63(79%) 19(8%) 69 (57%) 
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2.4 Summary 
In this chapter the study groups have been described for the various chapters.  The 
demographics and risk factors for each cohort is summarised in Table 10. 
Cohort 1, the group examined in Chapters 4 and 5, differ from many previous studies 
of CTCA as all had known coronary artery disease.  Cohort 2, examined in Chapter 6, is 
recruited from an area with high levels of poverty and deprivation and has a high 
proportion of South Asian patients.  Cohort 3, examined in chapter 3, has a low 
representation of asthmatics and a high proportion of people with known ischaemic 
heart disease. 
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3. HEART RATE AND RHYTHM 
DURING CT CORONARY 
ANGIOGRAPHY 
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3.1 Abstract 
Background 
The clinical application of cardiac computed tomography (CT) is increasing but heart 
rate control is often required to prevent motion artefact. 
Methods 
In the present study I describe a protocol for heart rate control in patients undergoing 
outpatient CT coronary angiography.  Among 121 consecutive patients, 75 (61.9%) 
with a resting heart rate >60 bpm required rate control medication.  My protocol 
called for oral metoprolol 100mg to be given 60 minutes before scanning, patients in 
whom beta-blockers were contraindicated receiving oral verapamil 240mg.  Additional 
5mg intravenous boluses (maximum for both drugs 15mg) were given if the heart rate 
remained >60 bpm prior to scanning. 
Results 
Of 71 patients treated with oral metoprolol 59 (83%) achieved a rate ≤65bpm and 46 
(65%) achieved a heart rate of ≤60bpm during the CTCA scan.  The 4 patients receiving 
verapamil all had a poor rate response with heart rates >70bpm at time of scanning.  
There were no adverse events due to rate control medication. Image quality was 
closely related to heart rate, severe motion artefact (Grade 3) occurring in only 0.9% of 
patients with a rate ≤60bpm compared with 50% of patients with a rate >70bpm. 
Conclusion 
The administration of oral metoprolol according to the protocol described in my study 
is a safe and effective way of reducing heart rate and improving scan quality in the 
majority of patients undergoing CT coronary angiography.  
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3.2 Introduction 
CT coronary angiography (CTCA) is a technique that has recently developed sufficiently 
to begin to be used for the visualisation of the coronary arteries avoiding the invasive 
technique of coronary angiography.  Imaging the coronary arteries poses many 
difficulties for CT technology as the coronary arteries are small, often calcified and 
move both with respiration and the cardiac cycle. In most patients it is possible to 
eliminate motion due to breathing by performing the scan during a breath hold. 
It is the movement of the heart that is most influenced by the heart rate and rhythm.  
Any imaging modality assessing the heart must have a fast temporal resolution in 
order to prevent blurring of the image, the temporal resolution being the time 
required to obtain a single image. Conventional invasive coronary angiography has a 
temporal resolution between 5 and 20milliseconds (ms) and is capable of reliably 
imaging the coronary arteries without any blurring from cardiac motion.  CT 
technology has gradually evolved from a temporal resolution of several minutes in 
early scanners to requiring less than 100ms to obtain an image with current dual 
source systems.  From the early days of CT technology, Alfidi221 postulated that a 
temporal resolution of less than 50ms was required to obtain detailed cardiac imaging.  
By measuring the velocity with which structures move, Ritchie222 calculated that scan 
time (temporal resolution) of less than 20ms was required to avoid artefacts.  As has 
been shown earlier, CT technology uses data from the attenuation of x-rays passing 
through an object from different angles.  In a still object the scanner may acquire these 
images without concern for temporal resolution, but in a moving object the scanner 
must acquire sufficient data to image the object in a short period of time to avoid 
artefacts from the object being in different places when data are acquired from 
different angles.  In single source scanners such as 64 slice CT scanners there is one x-
ray source and one x-ray detector that rotate in unison around the object being 
scanned, in this case a patient. The speed with which sufficient data can be acquired to 
reconstruct an image of the patients heart is thus directly related to the speed with 
which the x-ray source and detector rotate.  The gantry rotation time is the time it 
takes the scanner to complete one rotation around the patient. 
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In the absence of divergence of the x-ray beam a 360 degree scan would duplicate 
data acquisition of a still object when the source and detector are in opposite 
configurations.  In Figure 14 when the scanner is in position (a) the x-ray source is 
anterior to the patient and x-rays pass from anterior to posterior and are detected by 
the detector lying posterior to the patient.  If the gantry rotates 180 degrees to 
position (b), the x-ray source and detector are in opposite configurations and the x-
rays pass through the same part of the patient from posterior to anterior.  Essentially 
identical data are acquired, ie the same attenuation of the x-ray occurs as it passes 
along this path through the patient, irrespective of whether the x-rays pass from 
anterior to posterior or posterior to anterior. 
 
 
Figure 14 Tube and detector in opposite configurations 
 
Thus a full data set can be acquired from 180 degrees of rotation and the scanner 
temporal resolution is approximately half the gantry rotation speed. A small allowance 
needs to be made for the fan angle of the x-ray beam. 
Multi-segment reconstructions use data from more than one cardiac cycle to generate 
an image at a single level.93  Using these techniques, the relationship between 
temporal resolution and heart rate loses its simple linear behaviour and 223 becomes a 
function of the number of segments used and the rotation speed of the scanner.  As 
can be seen in Figure 15 taken from Greuter223 at lower heart rates multisegment 
reconstructions often provide little advantage over single segment reconstructions, 
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but as the heart rate increases the mathematical advantage becomes greater for 
multisegment reconstructions.  The point at which multisegment reconstructions 
become more beneficial is related to the rotation time of the scanner, with faster 
scanners favouring single segment reconstructions until higher heart rates than 
scanners with slower rotation times. 
 
 
Figure 15 Calculated temporal resolution as a function of heart rate of a 
reconstruction algorithm using N segments. The top graph represents a 
scanner with rotation time of 500ms and the bottom graph 420ms.  In 
addition, the temporal resolution of the Siemens Volume Zoom (VZ4) and 
the Siemens Somatom Sensation 16 (SS16) are shown.223 
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Halliburton224 examined the image quality comparing these techniques in 78 patients 
using a 4 slice scanner with a 500ms rotation time and a second group of 28 patients 
using a 12 slice scanner with a 420ms rotation time.  It was shown that the theoretical 
mathematical advantage of multisegment reconstruction did not translate into a 
measurable difference in image quality.  As the mechanical temporal resolution of 
scanners improves, the theoretical advantage of multisegment reconstructions will be 
further reduced and is likely to become less applied in clinical settings. 
In an attempt to image the heart when it is moving the least, CTCA scanners often try 
to use data from the period of the cardiac cycle when the heart is least mobile.  This 
period of time is during filling of the ventricle in mid diastole and is called diastasis.225  
There is also a shorter period of time at peak systole when the heart is fully contracted 
and momentarily stationary before it relaxes at the beginning of diastole.  It can be 
seen that the scan or the reconstruction of data from the scan must be linked to the 
cardiac cycle in order to generate images from these periods to reduce motion 
artefacts.  The simplest means to do this is to co-ordinate with the ECG which acts as a 
consistent indicator of the cardiac cycle.  Once the beginning and end of the cardiac 
cycle can be identified from the r wave on the ECG trace it is possible to select a time 
point relative to this that coincides with diastasis. There are two main methods of 
documenting this either as a percentage of the cardiac cycle (measured from the 
preceding r-wave) or as an absolute value in ms.  Absolute values can be taken from 
either the preceding r-wave and the convention is that this is recorded as a positive 
number (eg 600ms) or from the following r wave in which case a negative number of 
ms is used (e.g. -300ms) as illustrated earlier in figure 9.  Diastasis cannot be defined 
exactly by timing within the cardiac cycle as it is dependent on multiple other factors 
such as contractility and relaxation properties of the myocardium and the filling state 
of the patient.226   Diastasis does however occur at similar times within the cardiac 
cycle.  Hong,227 using a 4 slice scanner found that this was usually at 50% of the r-r 
interval for the RCA and later at 50-60% for left anterior descending artery (LAD) and 
60% for left circumflex arteries (LCx).  It is not possible to transfer these directly to 
other scanners given the difference in technology and reconstruction algorithms, 
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however the finding that the RCA is better imaged at an earlier time in the cardiac 
cycle should still apply.  In my institution it has been observed that the optimum 
cardiac phases are consistently later than those published by Hong and this may be 
due to differences in the way the reconstructions are extracted relative to the starting 
point. 
 
 
Figure 16 Image quality versus delay of ECG-gated reconstruction for 
individual and all coronary arteries.227 
 
An alternative method for identifying the phase in the cardiac cycle where there is 
least motion is the use of a kymogram as described by Kachelriess.228  This technique 
uses the raw data from an MDCT acquisition to calculate the centre of mass (COM) at a 
given level within a scan range.  Changes in this COM are tracked and the point of 
minimum and maximum variation in the COM can be identified and used as a marker 
for planning reconstructions in the same way as a the r waves on ECG.  Kachelriess 
compared the technique to ECG gated reconstructions from the same scans and 
showed close correlation. 
64 slice scanners have detectors between 3 and 4 cm in width and thus cannot cover 
the full volume of the heart within one rotation.  In order to image the whole of the 
coronary arterial tree, data from multiple rotations of the scanner must be combined.  
In order to complete multiple rotations within the diastasis of one cardiac cycle would 
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require vastly faster rotation times than is currently available and at such speeds, 
image noise levels are likely to be substantially increased.  A CT scanner gantry has a 
significant mass, and to be able to rotate the entire mechanism at this speed would 
encounter significant challenges due to the huge forces involved.  It is unlikely that 
such changes will occur in the near future if at all.  Thus with the limited coverage of 
64 slice scanners the image of the coronary artery tree must be compiled from 
rotations taken in more than one cardiac cycle.  With larger area detectors such as 
those on 320 slice scanners it is possible to image the heart in one or two rotations 
and thus this problem is overcome. 
Wang’s work exploring coronary artery motion by means of assessing invasive 
coronary angiograms with temporal resolution of 33ms229 shows that the right 
coronary artery (RCA) has the shortest rest period (66-200ms mean 120ms) and the 
largest velocities when mobile and moves the largest distance (Figure 17).  As heart 
rate increases it is diastasis that shortens most as the time required to complete the 
cardiac cycle must decrease and the amount of time required for ventricular 
contraction in systole is less variable.230 
 
Figure 17 Rest period for left and right coronary arteries at different heart 
rates229 
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Nieman231 investigated the relationship between heart rate and the number of 
assessable coronary segments on a 4 slice scanner with rotation time of 500ms.  It was 
shown that more segments were evaluable at lower heart rates.  The cohort of 78 
patients was split into three groups depending on heart rate and the sensitivity, 
specificity and positive and negative predictive values were calculated for each group.   
As can be seen in the table below, although the small numbers result in wide 
confidence intervals, the group with low heart rates (mean 55.8bpm, SD 4.1) had 
improved diagnostic accuracy compared to those in the faster group (mean 81.7bpm, 
SD 8.8). 
 
Table 11 Diagnostic accuracy of a 4 slice CT scanner for detecting ≥50% 
coronary artery stenoses at varying heart rates231 
 
 
Working with the same scanner, Hong rated scans with a five point scale for quality 
and artefact and found that patients with lower heart rates had higher image quality 
scores.227 
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Contemporary 64 slice scanners have faster rotation times of around 330-370ms and 
increased coverage compared to the 4 slice scanners used in the studies above. 
Leschka assessed the impact of heart rate on image quality using a 64 slice scanner 
with a gantry rotation time of 370ms.232  The study had a low mean heart rate during 
scanning of 63.3 beats per minute(bpm) ±13.1bpm and very few scans that were rated 
as having severe artefacts and no coronary artery was rated as uninterpretable.  No 
correlation was found between mean heart rate and image quality in LAD and RCA 
images, and only a weak correlation in the LCx images.  There was however a strong 
correlation between the variability of heart rate during scanning and image quality. 
Groen233 used a moving heart phantom to evaluate the effect of different heart rates 
on image quality using a 64 slice scanner with a rotation time of 330ms.  In this study 
stents were placed in the cardiac phantom and filled with air.  The average Hounsfield 
unit (HU) was measured on the images obtained from the air filled lumen of the stents, 
the supposition being that the more artefact the greater the HU value would appear to 
be within the stent, the true HU value of which should be very low in keeping with the 
air that fills the lumen.  The scan images were also visually graded for quality by two 
readers.  It was shown that there was an increasing HU value with increasing heart 
rate.  Quality scores also fell as heart rate increased, supporting the concept that low 
heart rates are key to reducing artefact in 64 slice CTCA. 
Heart rate is not the only parameter of the timing of cardiac motion that is of 
particular importance to CTCA.  Heart rhythm and the variability of the heart rate is of 
extreme importance.  In the era of 64 slice CT scanners nearly all research studies 
exclude patients with arrhythmias such as atrial fibrillation, although with the faster 
dual source scanners the susceptibility to arrhythmia is reduced and successful 
scanning in the presence of arrhythmia have been reported.  Atrial fibrillation results in 
a near random heart rhythm with variations in the cardiac cycle length and variations 
in the timing of periods of reduced cardiac motion.  As has been shown earlier, cardiac 
CT scanners can use ECGs to time the actual acquisition of a scan or modulation of x-
ray power.  Reconstruction algorithms use data from certain time points in the cardiac 
cycle in order to reduce artefact and if multisegment reconstructions are used data 
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from more than one cardiac cycle has to be used to construct an image at a given level.  
When the cardiac cycle length is erratic it becomes increasingly difficult to time when 
the heart is in the same phase of the cardiac cycle.  Atrial fibrillation usually results in 
the greatest beat to beat variability in heart rate, but even in patients in sinus rhythm, 
extrasystoles or sinus arrhythmia can be sufficient to reduce image quality.232 
CTCA is generally performed during a breath hold to reduce artefact originating from 
change in the position of the heart due to movement of the diaphragm and ribcage 
with breathing.  Unfortunately the process of breath holding itself can introduce 
variations in the heart rate due to normal physiological processes.227, 231 
The importance of a low heart rate during CTCA acquisition has been demonstrated 
above.  Most centres performing CTCA have developed their own protocols for the 
administration of medications to reduce the heart rate at the time of the scan.  Given 
that intravenous contrast administration is required to perform a scan, an intravenous 
cannula has to be inserted and therefore regimes with both oral and intravenous 
medications have been used. 
3.3 Regimes in use 
A systematic review of the literature for studies examining CTCA was performed.  
Publications were identified by searching medline via pubmed and reviewing citations 
of all identified studies and citations of reviews on the subject.  Any study that 
involved performing CTCA on human subjects in a non acute setting was included.  
Studies that did not state their heart rate strategy were excluded. For included studies 
details of the rate control regime used and the mean heart rate at time of scan where 
available where recorded.  The data are summarised in Table 12 below.  It can be seen 
that there are many different approaches to rate control in the context of CTCA.  All 
strategies employed administration of beta blockers and by far the commonest is oral 
metoprolol at a dose of 50-100mg. Other studies used oral atenolol and one study 
employed esmolol.  Most studies had a fixed dose strategy, but few had a variable 
dose strategy with higher doses given to subjects with higher heart rates.  Only one 
study administered medications before the day of the scan and most administered 
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medications between 45 mins and an hour prior to the scan being performed.  The 
protocol to follow when the subjects heart rate exceeded target after the initial 
medication was less well defined, but where stated, included administration of further 
intravenous doses of metoprolol up to 30mg. 
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Table 12 Rate reduction regimes in published studies 
Author Slices 
Rotation 
(ms) 
Arrhythmias 
Excluded 
Pre-Rx Target 
(bpm) 
Drug Route Dose (mg) 
Time 
pre-CT 
(mins) 
Post-Rx 
Target 
(bpm) 
Action if 
HR>Target 
Scan HR 
(mean±SD 
bpm) 
            
Nieman 16 
 
Yes 65 metoprolol oral 100 60 none none 56±6 
Ropers 16 
 
Yes 60 atenolol oral 50 60 
   
Martuscelli 16 
 
Yes All atenolol oral 50-100 OD 3/7 70 exclude 59±5 
Kuettner 16 
 
Yes 50 metoprolol oral 50-100 45 
  
64±10 
Mollet 16 420 Yes 65 metoprolol oral 100 60 
  
58±8 
Kuettner 16 375 Yes 65 metoprolol oral 50-100 45 
  
64±9 
Mollet 16 375 Yes 70 metoprolol oral 100 60 
  
57±1 
Achenbach 16 370 Yes 60 atenolol oral 100 60 60 
≤20mg iv 
metoprolol 
58±6 
Hoffman 16 420 Yes 75 metoprolol iv ≤20 0  
 
69±12 
Garcia 16 n/a Yes 65 metoprolol iv ≤15 0  
 
59±9 
Leber 64 330 Yes 70 metoprolol oral 50 60 
  
62±13 
Raff 64 330 Yes 65 atenolol oral 100 60 
   
    
50-65 atenolol oral 50 60 65 
≤30mg iv 
metoprolol 
65±10 
Mollet 64 330 Yes 70 metoprolol oral 100 45 
   
    
80 lorazepam oral 1 
   
58±7 
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Author Slices 
Rotation 
(ms) 
Arrhythmias 
Excluded 
Pre-Rx Target 
(bpm) 
Drug Route Dose (mg) 
Time 
pre-CT 
(mins) 
Post-Rx 
Target 
(bpm) 
Action if 
HR>Target 
Scan HR 
(mean±SD 
bpm) 
            
Pugliese 64 330 Yes 70 metoprolol oral 100 60 
  
58±6 
Malagutti 64 330 Yes 65 metoprolol oral ≤100 45 
 
proceed 60±7 
     
lorazepam oral 1 45 
   
Fine 64 330 n/a 
 
metoprolol oral / iv n/a 
   
n/a 
Ropers 64 330 Yes 60 atenolol oral 100 60 60 
≤20mg iv 
metoprolol 
60±9 
Schuijf 64 400 Yes 
 
n/a  
   
1 excluded 60±11 
Schlosser 16 420 Yes 70 esmolol iv n/a n/a 
 
exclude 64±5 
Burgstahler 16 375 n/a n/a metoprolol oral 50-100 30 
  
68±11 
Anders 16 420 Yes 60 atenolol oral 50 60 
  
63 
Stauder 16/64 
 
Yes 50 metoprolol oral 50-100 45 
  
67±9 
Pache 64 330 n/a 65 metoprolol oral 50-100 n/a 
 
proceed 63±7 
Ropers 64 330 Yes 60 atenolol oral 100 60 60 
≤20mg iv 
metoprolol 
59±9 
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3.4 Rate reducing drugs; pharmacodynamics and 
pharmacokinetics 
The choice of drug to use to reduce the heart rate in patients undergoing CTCA must 
consider the following issues:  Efficacy in reducing heart rate, safety, route of 
administration, speed of onset, half life and duration of action, availability and 
familiarity, local facilities and logistics.  When considering such medications the range 
of rate reducing medications that are potentially available to the physician is large.  As 
most cardiac CT with 64 slice scanners is restricted to patients in sinus rhythm the ideal 
agent would be active on the sinus node to reduce heart rate whilst preserving sinus 
rhythm.  Drugs working on other parts of the conduction system are not likely to be 
beneficial in this setting, as the introduction of heart block is potentially dangerous 
and may lead to irregularity of rhythm. 
Potential drugs that work in this manner are beta blockers, calcium channel blockers 
and recently ivabradine. 
Beta Blockers are a group of drugs that are antagonists for β-adrenoreceptors found in 
many tissues in the body.  There are two main types of β-adrenoreceptors, β1 and β2 
with β1 found predominantly in the heart where they are responsible for the positive 
chronotropic and inotropic effects of catecholamines.  Beta blockers, being antagonists 
to these receptors have a negative chronotropic and inotropic effect on the heart by 
blocking the sympathetic ‘tone’ that is generally present at a resting state.  Different 
drugs have differing selectivity for β1 and β2 adrenoreceptors, and thus have varying 
degrees of non-cardiac activity.  The most important side effect of beta blockers is due 
to their action on β2-adrenoreceptors in the lungs that can cause bronchoconstriction 
and is particularly important in asthmatic patients.234  The table below outlines some 
of the important features of beta blockers used in UK practice compiled from UK 
MHRA SPCs and FDA monographs and other reviews on this topic.235  It should be 
noted that metoprolol succinate is not available in UK and has different 
pharmacodynamic properties to metoprolol tartrate. 
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It can be seen that metoprolol and atenolol have the nearest qualities to our ideal 
agent for an orally administered drug.  Being relatively selective to β1 adrenoceptors 
reduces likelihood of side effects such as bronchoconstriction.  They have fast onsets 
compared with other beta blockers and relatively short half-lives, potentially 
improving safety.  Metoprolol has slight advantage over atenolol with faster onset of 
action and its shorter duration increases safety.  This is reflected in its extensive 
utilisation in centres undertaking CTCA.  Esmolol is of interest given rapidity of action 
and short duration making it safe but lack of familiarity and the need for a continuous 
infusion may deter some centres from using it.  It should be noted that although the 
speed of onset of action is fast for intravenous esmolol, metoprolol and atenolol, 
titration over a period of time rapidly increases the time to reach target heart rate, as 
it is necessary to wait till the maximum efficacy of any bolus is reached before 
administering a further bolus, and during this time patients must be carefully 
monitored. 
Calcium channel blockers are another possible group of medications that could be 
applied in this context.  Calcium channel blockers disrupt movement of calcium 
through L-type calcium channels in the cell membrane.  Blockade of voltage gated 
calcium channels in cardiac myocytes and smooth muscle in blood vessels, leads to 
decreased intracellular calcium levels.  Intracellular calcium is required for contraction 
and thus calcium channel blockers reduce contractility of cardiac muscle and cause 
vasodilation of blood vessels, together this results in a fall in blood pressure.  In cardiac 
sinotrial nodal and atrioventricular nodal tissue, L-type calcium channels play an 
important role in pacemaker currents that regulate heart rate.  Blocking L-type calcium 
channels reduces the speed with which calcium can enter the nodal cells and thus 
slowing the time taken for the cell to depolarise and reach an action potential 
threshold.  This prolonged time to depolarisation relates to a decreased sinus node 
rate, and also reduces conduction through the atrioventricular node.  There are three 
classes of calcium channel blocking agents; dihydropyridines have a predominant 
effect on smooth muscle and less effect on cardiac calcium channels, whereas non-
dihydropyridines of the phenylalkylamine (verapamil) and benzothiazepine (diltiazem) 
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classes have more cardiac effect and vascular effects.  Of the two non-
dihydropyridines, verapamil has the greater cardiac effect, whilst diltiazem has both 
cardiac depressant and vasodilator actions.  Verapamil, therefore is more likely to be 
useful in the setting of CTCA, reducing the likelihood of unwanted hypotension whilst 
maximising rate limiting potential.236-238 
Verapamil can be administered in oral or intravenous forms.  After oral administration, 
peak plasma concentrations are attained within 1-2 hours and the half life is 5-12 
hours with conventional release preparations.239  After intravenous injection maximum 
effect on heart rate is at 10-15 minutes and effects last 1-6 hours. 
Ivabradine is a new and interesting drug that acts on the If channel in the sinoatrial 
node to reduce heart rate in sinus rhythm.  It has no effect on blood pressure or 
cardiac output and is thus a potentially ideal candidate for use in the setting of 
CTCA.240  Majewski241 demonstrated significant reduction in heart rate with an oral 5 
day regime of ivabradine when compared with placebo.  Pichler242 compared a single 
dose of ivabradine 15mg with metoprolol 50mg and found similar reductions in heart 
rate but less reduction in blood pressure in the ivabradine group. There has also been 
development and assessment of an intravenous form of ivabradine by the 
manufacturer but efficacy data are not available.  
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Table 13 Characteristics of rate reducing agents 
Generic Name 
Route of 
administration 
Dose Selectivity Onset Duration of action 
Propranolol Oral / IV 1-10mg IV 
40mg-160mg PO 
β1 / β2 5mins IV 
2hrs PO 
2-3hrs IV 
3hrs PO 
Atenolol Oral / IV 2.5-20mg IV 
25-100mg PO 
β1 5min IV 
1-4hrs PO 
12hrs IV 
24hrs PO 
Metoprolol 
tartrate 
Oral / IV 5-15mg IV 
50-100mg PO 
β1 10mins IV 
1hr PO 
5-8hrs  
Bisoprolol Oral 1.25-10mg PO β1 1-4hrs 24hrs 
Carvedilol Oral 3.125-25mg PO β1 / β2 1.5-7hrs 12hrs 
Esmolol IV 500mcg/kg/min for 1 min loading 
50-200mcg/kg/min infusion 
β1 1min 5-10mins 
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Whilst it is clear that there is widespread use of a number of medications for rate 
reduction prior to performing CTCA there is very limited evidence of efficacy in this 
specific setting.  In the only study of this, Shim243 assessed the efficacy of a regime 
using oral propranolol at a dose of 20mg one hour prior to scanning which could be 
repeated if subjects’ heart rates had not fallen below the target heart rate of 65bpm.  
It was shown that there was a significant difference in mean heart rate in subjects not 
receiving the propranolol regime (mean HR 80.3 S.D. ±18.6 bpm) and those who did 
receive propranolol (mean HR 54.0 S.D±6.7 bpm).  The two groups studied compared 
were likely to have significant confounding differences as one group were volunteers 
and the other had known ischaemic heart disease and thus likely to be on rate 
reducing medication as part of their regime.  Propranolol would also not seem to be 
the most logical choice for use in this setting given its relatively slow onset and lack of 
selectivity. 
In my study the standardised regime for heart rate lowering that had previously been 
developed by myself and routinely employed in our institution was examined in a 
cohort of 121 outpatients attending our radiology department.  Given the data 
discussed above, and particularly the data in Table 13 the regime used oral metoprolol 
as the preferred agent supplemented with intravenous metoprolol and oral and 
intravenous verapamil in those patients with specific contraindications to beta 
blockers. 
 
3.5 Methods 
Ethics. Heart rate reduction using beta-blockers or verapamil is a clinical requirement 
for patients undergoing diagnostic CT coronary angiography (CTCA).  I was advised that 
ethical approval was not, therefore, needed for this study. 
 
 All patients undergoing CT coronary angiography (CTCA) were managed using the rate 
control regime documented below.  Blood pressure and heart rate were measured 
before the scan and use of rate slowing medication (beta-blockers, verapamil) was 
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documented.  The mean heart rate during the part of the scan used to reconstruct 
images of the coronary arteries was recorded.  All patients in this study were scanned 
irrespective of heart rate, but in clinical situations consideration should be given for 
cancelling the scan and considering alternative means of assessment or postponement 
until further techniques (discussed later) to ensure adequate heart rate control can be 
utilised. 
3.5.a Patient demographics 
Patients included those undergoing CTCA for clinical indications (n=24) and as part of 
research studies (n=97).  Due to the inclusion and exclusion criteria for the research 
studies,  my cohort includes a larger proportion of patients with known coronary 
artery disease and a smaller proportion with asthma than would be expected in the 
general outpatient radiology service.   
 
3.5.b Rate lowering regime 
Patients were asked to attend the radiology department one hour prior to the 
scheduled scan time.  All patients were in sinus rhythm.  The blood pressure and heart 
rate were checked using an automatic sphygmomanometer.   A short medical 
questionnaire was completed to cover the standard contrast safety screening and the 
contraindications to rate control medications. 
The target heart rate was defined as 60bpm and patients above this threshold were 
treated with either a beta-blocker (metoprolol) or a calcium channel blocker 
(verapamil) if the systolic blood pressure was ≥110mmHg.  Metoprolol was used 
preferentially with verapamil in patients with contraindications to beta blockers. 
Contraindications specific to beta blockers were asthma that required the use of 
regular inhaled bronchodilators.  Contraindications that applied also to verapamil were 
drug allergy, any degree of atrioventricular heart block or severe aortic stenosis.  
Patients requiring heart rate control were treated according to the protocol 
summarised in Figure 18.  They were given 100mg oral metoprolol (n=75) except those 
in whom beta blockers were contraindicated who received 240mg of oral verapamil 
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(n=4).  After one hour patients were prepared for CTCA and connected to the 
integrated electrocardiogram monitor on the CT scanner.  If the target heart rate of 
≤60bpm had not been achieved additional metoprolol or verapamil was administered 
as 5mg slow intravenous boluses (maximum for both drugs 15mg) at 5 minute intervals 
under continuous electrocardiographic monitoring.  Patients received 1mg glyceryl 
trinitrate sublingually and thereafter all patients were scanned irrespective of heart 
rate.  Patients were allowed to leave the department one hour after the last oral dose 
or 30 minutes after last intravenous dose of rate control medication.   
3.5.c Scan parameters and final heart rate 
Scans were performed using a Siemens Somatom Sensation 64 multi slice CT scanner 
with rotation time of 330ms and 64x0.6mm collimation.  All patients initially 
underwent a topogram and a low dose sequential calcium scoring sequence.  A test 
bolus scan was performed to ascertain circulation time for triggering of the main CTCA 
scan.  The test bolus scan involved the injection of 20ml of contrast (Iomeron 400) at 
5ml/sec followed by 20ml of Normal Saline at 5ml/sec.  The final CTCA scan required 
the injection of 80ml of contrast (Iomeron 400) at 5ml/sec and 40ml of Normal Saline 
at 5ml/sec.   
The final rate was documented automatically by the CT scanner which calculates the 
mean heart rate during the approximately 12 second acquisition of the CTCA scan.  
Electrocardiograms were visually checked to exclude miscalculation of heart rate due 
to extrasystoles or artefact.   
 
3.5.d Quality scoring 
All scans were reviewed and graded for motion artefact with the scoring system in 
Table 14 below. 
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Table 14 Quality scoring levels 
Grade Criterion 
1 No significant motion artefact 
2 Minor motion artefact affecting evaluation in 1 
segment 
3 Severe motion artefact affecting 2 or more 
segments 
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PATIENT SUITABLE AND PREPARED  FOR CTCA 
 
HR>60bpm  BP >110mmHg 
 
PATIENT SUITABLE FOR RATE CONTROL 
ORAL METOPROLOL 
100mg ONE HOUR 
PRIOR TO STUDY 
NO 
CONTRAINDICATIONS 
TO BETA-BLOCKERS 
 
IV METOPROLOL    
5-15mg TITRATED 
TO RATE 
  
HR >60bpm 
HR≤70bpm AND REGULAR 
 
ADMINISTER GTN 
AND THEN SCAN 
ORAL VERAPAMIL  
240mg ONE HOUR 
PRIOR TO STUDY 
IV VERAPAMIL        
5-15mg TITRATED 
TO RATE 
 
BETA-BLOCKERS 
CONTRAINDICATED 
BUT NOT VERAPAMIL 
 
HR >60bpm 
HR>70bpm OR IRREGULAR 
CONSIDER REBOOKING  
Figure 18 Suggested rate reducing regime for clinical use 
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3.6 Results 
Heart rate data were recorded from 121 patients undergoing CTCA, 46 of whom 
required no further rate control medication. Of the 75 patients (62%) who required 
rate control medication 71 received metoprolol and 4 received verapamil due to co-
existent asthma.  Figure 2 shows the flow of patients through the rate control 
protocol. 
Patients with a resting heart rate >60bpm and requiring rate control were less likely to 
have known CAD and be taking beta blockers than patients not requiring rate control 
(chi square p<0.001), but there were no other differences between the groups (Table 
15).  Of the 77 patients previously on a calcium channel blocker or beta blocker, 34 
(44%) required additional rate control medication.  
 
Table 15 Patient characteristics by requirement for rate control therapy 
 Patients requiring 
rate control  n=75 
Patients not requiring 
rate control  n=46 
Beta blocker 29 (39%) 40 (87%) 
Calcium channel blocker 12 (16%) 8 (17%) 
Ca-channel and beta blocker 7 (9%) 5 (11%) 
Diabetic 17 (23%) 9 (20%) 
Smoking history 
(current or >20 pack years previously) 
34 (45%) 23 (50%) 
Hypertension 48 (64%) 32 (70%) 
Hyperlipidaemia 64 (85%) 38 (83%) 
Known coronary artery disease 44 (59%) 38 (83%) 
Blood pressure (mmHg) 138/83 (±17.6/±10.2) 133/77 (±22.2/±12.3) 
Initial heart rate (bpm) 75 (±9.7) 56 (±4.5) 
 
Of the 71 patients receiving rate control with oral metoprolol 59 (83%) achieved a rate 
≤65bpm and 46 (65%) achieved a heart rate of ≤60bpm during the CTCA scan.  The 
mean heart rate in this group was 59±7.7bpm with a rate reduction of 17±9.7bpm.  In 
the 12 patients requiring additional IV metoprolol only 3 had a heart rate ≤65bpm at 
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time of scanning.  The 4 patients receiving verapamil had poor responses to rate 
control medication with heart rates >70bpm at time of scanning.  
There were no adverse effects in any patients related to beta blocker or calcium 
channel administration with no reports of pre-syncope in any patients.  Two patients 
experienced minor contrast extravasation which settled with cold compression.  One 
patient found to have severe aortic stenosis on the scan was already taking a beta 
blocker and had not required additional rate limiting medication. 
Table 16 shows the relation between heart rate during CTCA scanning and motion 
artefact.  Among the 77 patients with a heart rate ≤60bpm, 76 (99%) had little or no 
motion artefact (Grade 1 or 2) but in the 16 patients with a heart rate >70bpm severe 
motion artefact (Grade 3) was present in 50% of patients.  The proportion of patients 
with severe motion artefact (Grade 3) increased with heart rate.   
 
Table 16 Heart rate at scan time compared with quality score 
Rate at scan time 
(bpm) 
Grade 3 Grade 2 Grade 1 
≤60      (n=77) 1 7 69 
61-70   (n=28) 5 6 17 
>70      (n=16)    8 6 2 
 
There is a clear relationship between heart rate and quality score with worse quality 
scores in patients with higher heart rates (Chi square p value <0.001).  
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121 Patients undergoing CTCA 
 
ORAL METOPROLOL 
n=71 
ORAL VERAPAMIL 
n=4 
 
IV VERAPAMIL 
n=4 
HR >60bpm 
n=4 
HR >60bpm 
n=12 
HR ≤60bpm 
n=59 
 
IV METOPROLOL 
n=12 
HR >60bpm 
n=75 
HR ≤60bpm 
n=46 
Scanned 
Scanned 
Scanned Scanned 
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3.7 Discussion 
An effective heart rate control protocol for use during CTCA scanning in the outpatient 
setting has been demonstrated.  My data confirm the importance of heart rate control 
for reducing motion artefact and improving image quality.  Given the numbers in my 
study it is difficult to draw conclusions on safety but there were no significant adverse 
events in this cohort.  The study is limited by not being randomised against placebo 
group for comparison. 
Oral beta-blockers were effective in the majority of patients and are the drugs of 
choice for rate control, verapamil being largely ineffective in the present study. There 
is a clear need for alternative rate lowering drugs in patients in whom beta-blockers 
are contra-indicated, and the potential role of ivabradine merits further study.244. 
Intravenous administration of metoprolol provided little additional rate reduction in 
the minority of patients in whom oral treatment was ineffective. 
The question of how to deal with patients who do not respond to the full regime of 
oral followed by intravenous beta-blockers remains unanswered but a clinical decision 
needs to be made about the likelihood of obtaining a diagnostic scan set against the 
risk of unnecessary radiation exposure. My preferred strategy in these patients is to re-
book the CTCA scan at a later date when an anxiolytic such as diazepam is given in 
addition to the metoprolol.   In the review of rate control strategies undertaken 
earlier, it was noted that oral lorazepam was used at one centre as an adjunct to 
scanning in some patients. An alternative strategy is to gradually up-titrate the dose of 
beta-blockers over several weeks prior to attendance for the scan. A third strategy, is 
to administer higher doses of IV metoprolol (up to 30mg) but the safety and efficacy of 
all these strategies is unknown and further research is needed given the rapidly 
increasing clinical application of cardiac CT.  
Pannu245 retrospectively reviewed the medications received by 123 patients given rate 
control medication prior to undergoing CTCA.  It is hard to draw many conclusions 
from this data because of the apparently varied approaches taken, but it appears that 
a lower dose of oral metoprolol of 50mg was used in the majority of patients and 
Assessment of coronary artery disease by CT  Will Roberts 
 
109 
 
those that went on to have IV metoprolol had all only received 50mg of oral 
metoprolol.  
In the study by de Graaf,246 a regime using 50-100mg of oral metoprolol (and in 4% of 
patients an additional 1mg oral lorazepam) was assessed.  In patients in whom beta 
blockers were contra-indicated the image quality was worse as no alternative rate 
lowering regime was employed.  Of those patients receiving the ‘optimal’ oral 
metoprolol strategy (50-100mg metoprolol dependant on initial heart rate) 27% did 
not achieve the target heart rate of <65bpm. 
Maffei247 retrospectively analysed 560 patients who underwent CTCA and grouped 
them to various startegies of oral metoprolol, intravenous atenolol or diltiazem or 
benzodiazepines.  Higher doses of metoprolol appear to have been used (100-200mg) 
than described elsewhere and 62% of patients received lorazepam.  The groups 
receving oral metoprolol or IV atenolol with or without sublingual nitrates had 
significant reduction in heart rate but there remained nearly 20% of patients in the 
treated groups who failed to reach a heart rate under 65bpm. 
The regime used by Shapiro248 was a pure intravenous metoprolol strategy whereby 
repeated boluses of 5mg metoprolol where administered.  It is not entirely clear how 
quickly the dose was titrated as the paper states that heart rate ‘was reassessed every 
2 min until a HR of <65 bpm was achieved or a maximum dose of metoprolol 20 mg 
was administered.’  Given the pharmacokinetics discussed earlier such titration 
regimes should wait at least 10 minutes between boluses before repeating.  Only 35% 
of those given intravenous metoprolol achieved target heart rate of <65bpm.  The 
mean dose of metoprolol was 12±10 mg.  When this is compared to the oral doses 
given in mine and other studies and the approximately 50% bioavailability of oral 
metoprolol is taken into account it can be seen that this reduction in efficacy could be 
related to comparative underdosing. 
Degertekin249 examined a protocol combining the use of oral atenolol and intravenous 
esmolol boluses of 1-2mg/kg doses dependant on heart rate.  The strategy appeared 
to reduce heart rate with only transient bradycardia or hypotension in the majority of 
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patients, however 126 out of the 500 included patients had heart rates above the 
target of 65bpm after completing the protocol. 
Since undertaking this study, ivabradine has increased in clinical use for angina 
pectoris and heart failure due to the publication of two significant papers 
demonstrating  a reduction in coronary events in angina patients and hospitalisation in 
heart failure patients.250, 251  Guarrici undertook a randomised trial assessing the use of 
5 days of oral ivabradine before undergoing CTCA.252  It was shown that there was a 
significant reduction in heart rate in the ivabradine group, however this was not 
compared against a beta blocker but either with or without concomitant 
administration of oral and intravenous atenolol. 
At the European Society of cardiology 2010, the results of a randomised trial of a single 
intravenous bolus of either 10 or 15mg ivabradine, dependent on heart rate, were 
presented.253  This was undertaken in patients in whom beta blockers were 
contraindicated and target heart rate ≤65bpm was reached in 55% of the treatment 
arm versus 23% in the placebo arm.  This certainly has some promise, however 
intravenous ivabradine is not yet widely available, is not licensed in the United 
Kingdom and is ineffective in atrial fibrillation. 
It can be seen that there still remains heterogeneity in the use of heart rate reduction 
protocols for performing CTCA.  Taken in the context of other studies, the oral beta 
blocker regime I describe appears to be efficacious and easy to administer, however 
there are still a large number of patients that fail to reach target heart rates with beta 
blockers and furthermore there are a significant number of patients who cannot 
receive beta blockers due to contraindications.  With the advent of yet faster scanners 
the need for rigorous rate control may diminish but meanwhile more work is needed 
to determine appropriate regimens for those patients who fail to respond to the oral 
and IV beta-blocker regime described in this study. 
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4. CT FOR ASSESSING CORONARY 
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4.1 Abstract 
BACKGROUND 
Computed Tomography Coronary Angiography (CTCA) is a technique for imaging 
coronary arteries with increasing indications in clinical cardiology.  It has a high 
negative predictive value and thus is commonly applied for the exclusion of significant 
coronary disease in low risk populations.   
AIMS 
To examine the diagnostic accuracy of 64 slice CTCA in patients with known coronary 
artery disease (CAD). 
METHODS 
The diagnostic value of CTCA in unstented arterial segments of patients with suspected 
angina and known coronary artery disease was evaluated by comparison with invasive 
coronary angiography. 
RESULTS  
80 patients underwent CTCA and invasive coronary angiography.  724 coronary arterial 
segments were available for analysis. The sensitivity and specificity of CTCA for 
significant (≥ 50%) luminal stenosis was, respectively, 83.3% (95% CI 67.1-92.5%) and 
96.7% (95% CI 95.1-97.9%) with a positive predictive value of only 63.5% (95% CI 50.4-
75.3%) and a negative predictive value of 98.8% (95% CI 97.7 - 99.5%). 
CONCLUSION 
CTCA64 is of limited value for assessment of disease severity in high risk patients and 
its low positive predictive value indicates that it cannot substitute for invasive 
coronary angiography. Its value for ruling out coronary artery disease in low risk 
populations, however, is not challenged by my findings. 
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Introduction 
In chapter 1 I examined the technology of CT coronary angiography (CTCA) and looked 
at the evidence for the accuracy of CT technology.  It was seen that as the technology 
has evolved, particularly with the development of 64 slice scanners the accuracy of the 
technique has continually increased.  There remain some difficulties with the 
technique, particularly artefact related to motion and calcification.  Data from the 
early adopter centres shows universally excellent negative predictive values and, 
based on this, the technology is enjoying enthusiastic clinical uptake, particularly for 
rule out of coronary artery disease in low risk populations.254  However, studies in 
which higher risk groups have been included have reported more variable diagnostic 
value116, 117, 255 and there is the need for further work in such groups to define 
potential clinical applications.  In this chapter I explore the diagnostic value of CTCA for 
evaluating significantly diseased arterial segments in patients with known coronary 
artery disease and in the next chapter I will go on to evaluate CTCA for determining the 
severity of stent restenosis. Taken together these chapters will provide a platform for 
the clinical evaluation of CTCA in patients with previous coronary stenting and 
recurrent chest pain in whom information is needed about stent patency and the 
progression of native disease. 
 
4.2 Methods 
4.2.a Ethics 
Ethical Approval for this study was given by East London and the City Research Ethics 
Committee, Study Ref: 05/q0605/183 on 26th June 2006. 
 
4.2.b Population 
All patients attending for invasive coronary angiography or percutaneous coronary 
intervention with prior coronary stent implantation were screened for inclusion in the 
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study. Exclusion criteria were the presence of unstable symptoms, renal failure, 
arrhythmias, asthma, age <40, allergy to intravenous contrast media and women of 
child bearing age.  All patients agreeing to participate underwent CTCA within two 
weeks prior to their scheduled invasive coronary angiography.  
 
4.2.c Imaging 
CTCA was performed using a Siemens Somatom Sensation 64 Slice CT scanner.  
Patients with a heart rate >60 bpm received oral or intravenous metoprolol before the 
scan, with the aim of scanning at 60 bpm. 1mg of GTN was administered sublingually 
immediately prior to scanning. Scan parameters vary with patient characteristics but 
were in the order of: 0.6 mm detector collimation, rotation time 330ms; tube voltage 
120 kV; 900 mAs. All scans were performed using retrospective gating without beam 
modulation.  Optimal reconstruction time point at (e.g.) 600ms of cardiac cycle was 
chosen with the use of preview series. For evaluation of coronary arteries two data 
sets were reconstructed;  the first using the B46f algorithm, slice width 0.6mm and 
increment 0.2mm and the second with the B35f algorithm, 0.75mm slice width and 
0.4mm increment. 
 
Two radiologists, blinded to the results of the invasive angiography reviewed the CTCA 
images independently using Siemens Circulation software to generate axial images, 
oblique multiplanar reformatted images and curved multiplanar reformatted images.  
A segmental scoring developed by the American Heart Association (see Figure 19) was 
applied and a total of 724 segments were predefined and graded as significantly 
diseased (≥50% luminal narrowing) or unobstructed (<50% luminal narrowing). Vessels 
that could not be classified, due for example to excessive artefact, were classified as 
non-assessable and excluded.  Disagreement about lesion severity was resolved by 
consensus.  
Assessment of coronary artery disease by CT  Will Roberts 
 
115 
 
 
Figure 19 AHA Coronary tree classification system 
 
 
Invasive cardiac catheterisation (CAX) was performed using standard protocols with a 
minimum of 6 views of the left coronary system and 2 of the right. The invasive 
coronary angiograms were reported independently by two cardiologists blinded to 
results of CTCA or IVUS. The same segmental scoring system (see Figure 19) was used 
and again disagreement was resolved by consensus. 
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4.2.d Statistical methods 
For the baseline characteristics continuous variables were presented as mean with 
standard deviation.  To compare the diagnostic performance of CAX and CTCA 
sensitivity, specificity, positive predictive value (PPV) and negative predictive value 
(NPV) were calculated with binomial confidence intervals from a 2x2 table, assuming 
CAX showed the true disease status.  Previously stented segments were excluded from 
analysis. Tables show true positives (stenoses correctly identified as stenoses), false 
negatives (unrecognised stenoses), false positives (normal but identified as stenosed) 
and true negatives (correctly identified as normal). Sensitivity of CAX/CTCA is the 
proportion of stenoses correctly identified, whereas specificity is the proportion of 
non-stenosed arteries correctly identified. PPV and NPV are the proportions of 
correctly identified test positives and test negatives. Stata 8 (version 8.2, StataCorp, 
College Station, Tex) was used for all analyses in this study. 
 
 
4.3 Results 
4.3.a Patients  
There were 80 patients with 724 vessel segments available for analysis. Stented 
segments were not analysed in the present study. 
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Table 17 Patient baseline characteristics 
Patients All patients (n=80) 
N (%) or Mean ±SD 
 
Age 63 ±10 
Female sex  13 (16%) 
Previous MI 36 (45%) 
Previous CABG 9 (11%) 
Diabetes 14 (18%) 
Smoking history 49 (61%) 
Hypertension 56 (70%) 
Hypercholesterolemia 69 (86%) 
BMI * 28 ±4.1 
Drugs  
 CAB 16 (20%) 
 BB 63 (79%) 
 ACE  68 (85%) 
 Aspirin 79 (99%) 
 Statins 75 (94%) 
 Clopidrogel 54 (68%) 
 
 
Of 724 native coronary arterial segments, 681 (94.1%) were unobstructed (<50% 
luminal narrowing), while the remainder (n=43) had significant disease with ≥50% 
luminal narrowing. CTCA correctly identified 99% of all normal or minimally diseased 
segments, with a specificity of 96.7% (95% confidence interval 95.1 – 97.9%) and a 
negative predictive value of 98.8% (95% confidence interval 97.7 - 99.5%). The 
diagnostic sensitivity of CTCA for significant luminal stenosis was 83.3% (95% 
confidence interval (67.1-92.5%) and positive predictive value of 63.5% (95% 
confidence interval 50.4-75.3%). 
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Table 18 Diagnostic value of CT coronary angiography for native vessel stenosis (≥50% luminal narrowing) in 724 vessel segments in 80 patients 
compared with invasive coronary angiography. 
 
  
*true abnormal diagnosis defined as stenosis >=50% lumen loss or >=50% luminal narrowing of native vessel according to coronary angiography 
 
 
 
CT Angiography vs Coronary Angiography for Native Vessel Assessment 
                 CT 
 
Angio 
Severe disease 
(≥50% luminal 
narrowing) 
Widely patent 
(<50% luminal 
narrowing) 
Sensitivity % 
(95% CI) 
Specificity % 
(95% CI) 
PPV % 
(95% CI) 
NPV % 
(95% CI) 
Severe disease 
(n=43 segments) 40 (93%) 3 (7%) 83.3 
(67.1 – 92.5) 
96.7 
(95.1 – 97.9) 
63.5 
(50.4 – 75.3) 
98.8 
(97.7 - 99.5) Widely patent 
(n=681 segments) 
8 (1%) 673 (99%) 
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4.4 Discussion 
In the present study I have shown that 64 slice CTCA in patients with recurrent 
symptoms after coronary stenting has a rather low sensitivity for significant disease in 
unstented segments of the coronary arteries but, as in low risk populations, it provides 
reliable rule out of disease in unobstructed segments. Clinically, however, the 
questions to be answered in these patients with recurrent symptoms after stenting are 
1) is progressive disease present in the native circulation or 2) is there restenosis 
within the stent? My study shows that the first of these questions cannot reliably be 
answered by CTCA64 and the fact that unobstructed segments are correctly identified 
in >95% of cases does not alter the fact that the clinical role of CTCA64 in these high 
risk patients is very limited.  
 
It is important to emphasise that mine was a different group of patients from those in 
which the diagnostic value of CTCA has previously been evaluated. I included only 
patients with known coronary artery disease who had undergone prior coronary 
intervention. This contrasts with the lower risk patients included in many of the earlier 
published studies and differs from the clinical application for which CTCA is most often 
used; that is in the exclusion of coronary disease in patients with low probability of 
coronary disease. 
 
There have been three multicentre studies looking at 64 slice CTCA for assessment of 
native coronaries compared with invasive coronary angiography (Table 19).  These are 
particularly relevant to my study because all were performed in patients with a high 
(50-100%) prevalence of coronary artery disease and all showed diagnostic accuracy 
that falls short of clinical requirements. Importantly, the positive predictive values for 
significant (≥50%) coronary artery disease in two of these studies was less than 60% 
and almost identical to the value I report in this chapter. In the third study by Miller255 
the positive predictive value of CTCA64 was 82% which, although somewhat higher, is 
scarcely sufficient for diagnostic purposes.  Taken together with the work I report in 
Assessment of coronary artery disease by CT  Will Roberts 
 
120 
 
this thesis, it is clear that in high risk patients, CTCA64 is of limited value for 
assessment of disease severity and cannot substitute for invasive coronary 
angiography. Its value for ruling out coronary artery disease in low risk populations, 
however, is not challenged by my findings. 
 
 
Table 19 Multicentre studies of 64 slice CTCA 
 Sesnitivity Specificity PPV NPV 
Budoff 2008117 84 (74-91) 90 (88-92) 51 (43-59) 99 (98-99) 
Miller 2008255 75 (69-81) 93 (90-94) 82 (77-86) 89 (86-92) 
Meijboom 
2008116 
95 (92-97) 77 (74-80) 59 (55-63) 98 (96-99) 
 
 
4.4.a Strengths and Limitations 
The key strength of this study is that it enrolled a well-defined high risk group of 
patients, all of whom were known to have previously treated coronary artery disease.  
A key weakness is that I did not record data in such a way that the interobserver 
variability could be reported which would have been a useful parameter in considering 
the utility of the technique in clinical practice. Nevertheless, the similarity of my 
findings to those reported in larger multicentre studies indicates that reporting quality 
was unlikely to have been substantially different. 
4.4.b Conclusion 
This study shows that CTCA with a 64 slice CT scanner has a rather low positive 
predictive value for quantifying the severity of coronary artery disease in high risk 
populations. All my patients had prior coronary stenting and in the next chapter the 
value of CTCA for assessing stent restenosis will be reported.   
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5. CT FOR ASSESSING CORONARY 
ARTERY STENTS 
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5.1 Abstract 
OBJECTIVES 
To compare the assessment of coronary stents by computed tomography coronary 
angiography CTCA, invasive coronary angiography and intravascular ultrasound. 
BACKGROUND 
Angiographic assessment of coronary stents is difficult because the arterial lumen is 
variably obscured by metallic struts. Studies using CTCA have reported limited 
diagnostic value for stent restenosis but the comparator has been invasive coronary 
angiography. 
METHODS 
We used intravascular ultrasound (IVUS) to define restenosis within stented segments 
of coronary arteries and compared the findings with 64 slice CTCA and invasive 
coronary angiography. Treating every stent as an observation (overlapping stents 
counted as one) and adjusting for independent observations between patients there 
were 80 patients with 125 stented segments available for analysis. Forty-eight patients 
had additional IVUS examination of 69 stented segments. 
RESULTS 
Using IVUS as the gold-standard for stent restenosis (minimal lumen diameter <50% 
proximal and distal reference diameters) CTCA and invasive coronary angiography had 
comparable diagnostic specificities for binary stent restenosis: 82.7% (95% confidence 
intervals(CI) 69.7-91.84%) and 78.9% (95% CI 65.3-88.9%), respectively. Sensitivities 
were lower, particularly the sensitivity of CTCA which was only 11.8% (95% CI 1.5-
36.4%) compared with 58.8% (95% CI 32.9-81.6%) for invasive coronary angiography.  
However, when the diagnostic value of CTCA was tested against the invasive 
angiographic gold standard specificity increased to 90.1% (95% CI 81.5-95.6%) but 
sensitivity remained low at 29.6% (95% CI 16.8-45.2%).  
CONCLUSION 
Angiographic evaluation of coronary stents, whether by CTCA or invasive angiography, 
commonly yields false negative diagnosis of binary restenosis. Future evaluation of 
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new technologies should use IVUS or other imaging comparators with a more robust 
diagnostic performance.  
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5.2 Introduction 
Coronary stents are frequently deployed in the treatment of coronary artery disease.  
Despite advances in technology with increasing use of drug eluting stents, a significant 
number of patients will develop restenosis in coronary stents.  There is also a 
significant number of patients returning with chest pain post stent implantation who 
are later shown to have no evidence of in stent restenosis. 
In Chapter 1 the current techniques for assessing in stent restenosis were examined, 
the mainstay of which is invasive coronary angiography (CAX) supplemented by 
intravascular ultrasound (IVUS).  With the increasing volume of stent procedures now 
being undertaken, angiography for suspected restenosis represents a substantial part 
of an interventional laboratory’s workload.  In our own centre about 30% of all 
diagnostic procedures are in patients who had previously undergone coronary 
stenting.  Computed tomography coronary angiography (CTCA) has the advantage of 
being a non-invasive technique that allows visualisation of the coronary arteries.  In 
Chapter 4 I assessed the accuracy of CTCA compared with CAX in native coronaries and 
showed that its positive predictive value is low at 63.5%, as has also been found in 
other studies. Nevertheless, in symptomatic patients who have undergone coronary 
stenting, the value of CTCA for assessing restenosis is also relevant, even though stents 
pose a unique challenge for CT technology.  This is due to a combination of the factors 
that affect assessment of all coronary arteries (motion artefact and limits in spatial 
resolution) and also the particular artefacts due to the dense stent material and their 
small size. 
As early as 1994256 electron beam computed tomography (EBCT) was used to identify 
the location of early Palmaz-Schatz stents in the coronary arteries.  As has been 
discussed earlier EBCT is a technique that sends a steered beam of electrons at the 
area of interest achieving a high temporal resolution but a low spatial resolution, such 
that it cannot visualise accurately the lumen within a stent. An alternative approach, 
therefore, has to be used to assess flow of contrast to the coronary artery beyond 
stented segments.   
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Three studies used a similar methodology to evaluate stent patency in the following 
manner.  Initially a static non-contrast scan was used to locate the stents and then an 
area of interest was selected distal to the stent within the artery and repeat scans 
were performed at this level during the injection of peripheral intravenous contrast 
medium.  From these images a cine of contrast filling distal to the stent and a time 
density curve of contrast enhancement distal to the stent can be obtained. 
Schmermund257 reported a small series of patients who underwent EBCT after 
coronary stent placement and reported that there was some scope for assessing for 
stent occlusions by EBCT by examining contrast flow beyond the stent but that it was 
not possible to comment on other degrees of restenosis within the stent. 
Pump258 attempted to assess 321 stents in 202 patients; artefacts and technical 
problems excluded 4% of vessels. 96% of stented vessels could be assessed by visual 
cine loop assessment but only 53% of vessels could be assessed by time density curve. 
Only 23 of the assessed stented segments were significantly stenosed on invasive 
coronary angiographic assessment. The results were compared with invasive coronary 
angiography and a sensitivity of 78%, specificity of 98% with a positive predictive value 
of 82% and negative predictive value of 97% were reported. 
In 2003 Knollam259 undertook EBCT on 117 patients in the above manner and these 
results were then compared to invasive coronary angiography.  No correlation was 
found between the visual assessment and invasive coronary angiographic findings.  
There was a correlation between the time to peak contrast density beyond the stent 
but the optimal threshold yielded a sensitivity of 72% and specificity of 60%. Knollman 
also unsuccessfully attempted assessment by visual evaluation of stent lumen patency. 
EBCT gradually fell out of clinical use as MSCT became more widespread and attention 
turned to the new MSCT scanners as a potential means of assessing coronary stents.  
Nieman260 investigated a number of stents in vitro, in a model that excluded cardiac 
motion using 4x1mm and 2x0.5mm collimator arrangements.  It was shown that the 
high density of the stent material made them appear much larger than they were and 
a combination of beam hardening and partial voluming artefacts resulted in a higher 
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average CT density within the stent lumen and only a small area of the lumen 
remained free of artefact.   
Beam hardening artefacts are caused by the loss of lower energy photons from the X-
ray beam as it passes through an object, resulting in an increase in mean energy.  This 
can result in streak artefacts or cupping where an object of uniform density appears 
less dense in its centre. Partial voluming artefacts occur when dense objects such as 
coronary stents that are off centre protrude partially into the x-ray beam.  Due to 
divergence of the x-ray beam the beam has a different width when the off centre 
object is scanned from different directions as the tube rotates. From some angles the 
beam will be wide enough to include the object and from other angles the beam will 
be narrower and thus not include the object. The inconsistencies between the views 
can cause shading artefacts to appear.261 
Numerous post-processing algorithms have been developed by CT manufacturers to 
counter some of these problems.  One particular technique that was employed in my 
centre to optimise stent visualisation was the use of a sharper reconstruction 
algorithm for stent assessment, which although it can increase noise levels within 
images, reduces the blooming artefact caused by both stents and calcification.  The 
increased image noise often means higher X-ray output (mAs) is used to overcome this 
and thus results in potentially higher patient radiation doses. 
Kruger262 used a scanner with 4 x 1mm collimation and a rotation time of 500ms to 
investigate 32 stents in the native coronary arteries of 20 patients, excluding patients 
with CABG and arrhythmias.  It was not possible to visualise any of the lumen within 
the stents, but they did comment on a lack of contrast beyond two stents that 
matched with occluded stents demonstrated by invasive coronary angiography. 
Cademartiri 263 assessed 47 stents in 42 patients using Siemens Sensation 16 slice 
scanner.  This scanner has a rotation time of 420ms and collimation was 16x0.75mm 
slices. Only patients with one stent in the native coronary tree, under the age of 70, in 
sinus rhythm with a heart rate less than 65 bpm were included. The stents were 
assessed for the presence of stenosis ≥50% and this was compared with 
contemporaneous invasive coronary angiography assessment.  It was demonstrated 
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that MSCT had a sensitivity of 50% (95% CI 19-81%), specificity of 100% and positive 
predictive value of 100% and negative predictive value of 88% (95% CI 73-98%). 
Cademartiri published a second study264 of 76 stents in 51 patients performed in the 
same manner on the same scanner with results compared to invasive coronary 
angiography.  Sensitivity was 83.3% (95% C.I. 35.9 – 99.6%), specificity 98.5% (95% C.I. 
92.1-100%), positive predictive value 83.3% (95% C.I. 35.9-99.6%) and negative 
predictive value 98.5% (95% C.I. 92.1 to 100%). 
A further study using 16 slice MDCT265 assessed 42 stents in 31 patients, all in sinus 
rhythm using a scanner with 16x0.75mm collimation and 420ms rotation time. It was 
shown that smaller stents had greater degrees of artefact and 7 stents were excluded 
from analysis because of poor image quality. Separate results were reported for two 
readers of CT and comparing all the included stents with invasive coronary 
angiography the sensitivity of MDCT for evaluating stent patency was 83% (reader 1) 
and 100% (reader 2), specificity was 90% (reader 1) and 93% (reader 2), positive 
predictive value was 63% (reader 1) and 75% (reader 2), and negative predictive value 
was 96% (reader1) and 100% (reader 2). 
The left main coronary artery is often the largest area in the coronary tree as it 
bifurcates and gives rise to the left anterior and left circumflex arteries that supply a 
large area of myocardium.  Thus, when stenting of the left main coronary artery is 
undertaken it is likely that larger stents will be used. Given that some of the artefacts 
in coronary stent CTCA are exacerbated by the small size of the stents it is possible that 
CTCA is more reliable in these larger stents.  Given the importance of the left main 
coronary artery and the severe consequence of occlusion of this vessel, there has been 
a suggestion that all left main coronary artery stents undergo repeat angiography at an 
interval of 1-6 months post stent implant although lately this is falling out of 
practice.266  There would therefore be an even greater desire to find a less invasive 
means to assess these stents. Gilard267 investigated 16 slice MDCT in 29 patients from 
this subgroup with a mean stent diameter of 3.9mm. The scanner used had 
16x0.75mm collimation and a rotation time of 420ms and patients with arrhythmias 
were excluded. CTCA result was compared with invasive coronary angiography for 
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stenoses >50%.  Two stents could not be analysed due to excessive calcification in the 
left main stem, but all other stents were correctly graded giving a sensitivity of 100%, a 
specificity of 92% and positive predictive value of 100% and negative predictive value 
of 92%.  This would support the supposition that stents in the left main stem can be 
more reliably assessed by CTCA.  
Gaspar268 investigated 111 stents in 65 patients using a 40 slice scanner with 40 x 
0.625 mm collimation and gantry rotation speed of 420ms.  Using both >50% 
restenosis and >60% restenosis cut-offs and comparing with invasive coronary 
angiography, poor sensitivity and specificity were found, although a negative 
predictive value of 97.4% (95% CI 93.8–100%) was found when using a >60% restenosis 
definition. 
Evidence from phantom studies269-271 have shown that 64 slice scanners are likely to 
better visualise stents with less artificial narrowing of the lumen due to artefact. 
Rist272 studied a small number of patients using a 64 slice scanner with 64 x 0.6 mm 
collimation and rotation time of 330ms.  In this promising pilot study compared with 
invasive coronary angiography consensus readings for in stent re-stenosis gave a 
sensitivity of 75%, specificity of 92%, positive predictive value of 67% and negative 
predictive value of 94%. 
In the in vivo studies described above, invasive coronary angiography was used as the 
gold standard to which CTCA was compared.  However, as has been explored in 
Chapter 1, invasive angiography is a flawed gold standard due to its planar nature and 
inability to visualise coronary plaque in relation to stent struts, and a more accurate 
gold standard for this purpose is intravascular ultrasonography (IVUS). 
Intravascular ultrasonography has a spatial resolution far greater than that of 
conventional invasive angiography. Furthermore, invasive angiography which provides 
two-dimensional representations of the coronary arteries cannot fully reveal the 
nature of three-dimensional plaque and the angiographic view can be obscured by 
overlapping vessels.  IVUS can be used to provide detailed visualisation of stents, stent 
apposition to vessel wall and the presence of neo intimal hyperplasia.  IVUS is now 
often used as the gold standard for assessing in stent restenosis and hyperplasia, 
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particularly when comparing different coronary stents.  In stent restenosis is often 
seen as very short segments of stenosis (<1mm)48 which can be missed by 
conventional angiography.  The IVUS probe within the vessel is more likely to detect 
the area of most narrowing.  Angiography only allows a measurement in variations of 
luminal diameter of stented and adjacent non-stented areas and provides only an 
indirect measure of in-stent neointimal hyperplasia and cannot account for positive 
remodelling.49 
In this study CTCA and conventional invasive angiography are evaluated against the 
gold standard IVUS assessment for stents.  
 
5.3 Methods 
5.3.a Ethics 
Ethical Approval for this study was given by East London and the City Research Ethics 
Committee, Study Ref: 05/q0605/183 on 26th June 2006. 
5.3.b Population 
All patients attending for invasive coronary angiography or percutaneous coronary 
intervention with prior coronary stent implantation were screened for inclusion in the 
study. Exclusion criteria were the presence of unstable symptoms, renal failure, 
arrhythmias, asthma, age <40, allergy to intravenous contrast media and women of 
child bearing age.  All patients agreeing to participate underwent CTCA within two 
weeks prior to their scheduled invasive angiography.  A subgroup of patients was also 
assessed using intravascular ultrasound to determine the minimum luminal area and 
percentage stenosis of stents except where the lumen was too small to pass the IVUS 
probe. 
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5.3.c Imaging 
CTCA was performed using a Siemens Somatom Sensation 64 Slice CT scanner.  
Patients with a heart rate >60 bpm received oral or intravenous metoprolol before the 
scan, with the aim of scanning at 60 bpm. 1mg of GTN was administered sublingually 
immediately prior to scanning. Scan parameters vary with patient characteristics but 
were in the order of: 0.6 mm detector collimation, rotation time 330ms; tube voltage 
120 kV; 900 mAs.  All scans were performed using retrospective gating without beam 
modulation.  Optimal reconstruction time point at (e.g.) 600ms of cardiac cycle was 
chosen with the use of preview series. For evaluation of stents two data sets were 
reconstructed;  the first using the B46f algorithm, slice width 0.6mm and increment 
0.2mm and the second with the B35f algorithm, 0.75mm slice width and 0.4mm 
increment. 
Images were reviewed using axial images, oblique multiplanar reformatted images and 
curved multiplanar reformatted images using the Siemens Circulation software.  Two 
radiologists, blinded to the results of the invasive angiography or IVUS independently 
reviewed the images and, in cases of disagreement, a consensus result was recorded.  
The degree of in-stent restenosis was defined in a binary manner as being <50% 
stenosis or stenosis ≥50% including complete occlusions.  Stents that were unable to 
be classified, due for example to excessive artefact, were classified as non-assessable 
and excluded. 
Cardiac catheterisation was performed using standard protocols with a minimum of 6 
views of the left coronary system and 2 of the right. Angiograms were analyzed 
independently by two cardiologists blinded to the results of CTCA or IVUS.  In cases of 
disagreement a consensus result was recorded. Again, a binary classification was used 
for stent restenosis 
 
Intravascular ultrasound was performed on any accessible stents using a Volcano In-
Vision Gold system with a 20Mhz Eagle Eye Gold IVUS probe and a R200 automated 
pullback device at 0.5mm/s and data saved in DICOM format for analysis. These 
data were analysed by a cardiologist blinded to the results of the CTCA or invasive 
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angiography.  Percentage stenosis was calculated using proximal and distal 
reference areas compared to the minimal lumen area.  Where the distal reference 
area was larger than the proximal, the vessel was assumed not to taper and the 
distal reference was used to calculate stenosis severity.  When the distal reference 
area was smaller than the proximal area the vessel was assumed to taper in a linear 
fashion and the predicted vessel area was calculated at the point of maximal 
stenosis. These data were then recorded in a binary fashion in a similar manner to 
the data from CT and CAX. 
 
5.3.d Statistical methods 
For the baseline characteristics continuous variables were presented as mean with 
standard deviation.  To compare the diagnostic performance of CAX and CTCA with 
IVUS sensitivity, specificity, positive predictive value (PPV) and negative predictive 
value (NPV) were calculated with binomial confidence intervals from a 2x2 table, 
assuming IVUS showed the true disease status.  Tables show true positives 
(stenoses correctly identified as stenoses), false negatives (unrecognised stenoses), 
false positives (normal but identified as stenosed) and true negatives (correctly 
identified as normal). Sensitivity of CAX/CTCA is the proportion of stenoses correctly 
identified, whereas specificity is the proportion of normal stents correctly identified. 
PPV and NPV are the proportions of correctly identified test positives and test 
negatives. Stata 8 (version 8.2, StataCorp, College Station, Tex) was used for all 
analyses in this study. 
 
5.4 Results 
There were 80 patients with 125 stented segments available for analysis. Forty-eight 
patients had additional IVUS examination of 69 stented segments.  These 69 stented 
segments included 111 stents and the characteristics of these stents are detailed in 
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Table 21. I compared the results between IVUS, CTCA and invasive angiography in 
these 69 segments.  
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Table 20 Patient baseline characteristics 
 
 
  
Patients Patients with IVUS (n=48) 
N (%) or Mean ±SD 
All patients (n=80) 
N (%) or Mean ±SD 
 
Age 62 ±10 63 ±10 
Female sex   9 (19%) 13 (16%) 
Previous MI 24 (50%) 36 (45%) 
Previous CABG 5 (10%) 9 (11%) 
Diabetes 7 (15%) 14 (18%) 
Smoking history 31 (65%) 49 (61%) 
Hypertension 31 (65%) 56 (70%) 
Hypercholesterolemia 40 (83%) 69 (86%) 
BMI 27 ±3.8 28 ±4.1 
Drugs   
 Ca channel blocker 9 (19%) 16 (20%) 
 BB 36 (75%) 63 (79%) 
 ACE  40 (83%) 68 (85%) 
 Aspirin 48 (100%) 79 (99%) 
 Statins 45 (94%) 75 (94%) 
 Clopidrogel 33 (69%) 54 (68%) 
Stents   
 LMS 10 (14%) 12 (7%) 
 LAD 11 (11%) 61 (37%) 
 Circumflex  18 (18%) 24 (14%) 
 RCA  32 (32%) 54 (32%) 
 Others: Intermediate 
artery 
1 (1%) 3 (2%) 
 Diameter (mm) 3 ±0.5 3 ±0.5 
 Length (mm ) 18 ±6.1 18  ±6.1 
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Table 21 Stent characteristics 
 Stents with characteristic (n=111) 
n (%) or Mean ±SD 
 
  
Implant Location  
Right coronary artery 38 (34%) 
Left main stem 11 (10%) 
Left anterior descending 40 (36%) 
Left Circumflex 20 (18%) 
Intermediate 2 (2%) 
  
Stent Type  
Taxus 19 (17%) 
Liberte 16  (14%) 
Cypher 17 (15%) 
Velocity 2 (2%) 
Driver 12 (11%) 
Endeavour 3 (3%) 
Crossflex 4 (4%) 
Zeta 4 (4%) 
Sonic 3 (3%) 
Other/Unknown 31 (28%) 
  
Time from implant 27 months ± 27months 
  
Stent Size  
Diameter (mm) 3 ±0.5 
Length (mm ) 18 ±6.1 
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5.4.a IVUS comparator 
The diagnostic performance of CTCA and Invasive coronary angiography for stent 
restenosis compared with the IVUS gold standard is summarised in Table 22. IVUS 
examination of the 69 stented segments showed that 52 were normal or minimally re-
stenosed, while the remainder (n=17) had severe restenosis with ≥50% luminal 
narrowing. The CTCA examination correctly identified 43 (83%) of the normal or 
minimally re-stenosed stented segments but only 2 (12%) of the segments with ≥50% 
restenosis. Invasive coronary angiography in the same patients correctly identified 41 
(79%) of the normal or minimally re-stenosed stented segments and 10 (59%) of the 
segments with ≥50% restenosis. Comparison of diagnostic value showed that the 
specificities of CTCA (82.7% (95% confidence intervals 69.7-91.84%)) and invasive 
coronary angiography (78.9% (95% confidence intervals 65.3-88.9%)) for binary stent 
restenosis were comparable. Sensitivities were lower, particularly the sensitivity of 
CTCA which was only 11.8% (95% confidence intervals 1.5-36.4%) compared with 
58.8% (95% confidence intervals 32.9-81.6%) for invasive coronary angiography.  
Inclusion of the 2 patients with complete stent occlusions by invasive coronary 
angiography, both of which were correctly identified by CTCA, increased the diagnostic 
sensitivities to 21% for CTCA and 63% for invasive angiography, respectively. 
 
5.4.b Invasive coronary angiography comparator 
Diagnostic performance of CTCA for stent restenosis using invasive coronary 
angiography as gold standard is summarised in Table 23.  Invasive coronary 
angiography identified 104 of the 125 stents as normal or minimally re-stenosed and 
21 stents as re-stenosed with ≥50% luminal narrowing, including 2 with complete 
occlusion. The diagnostic value of CTCA using invasive angiography as the comparator 
showed that specificity was 90.1% (95% confidence intervals 81.5-95.6%) but 
sensitivity was only 29.6% (95% confidence intervals 16.8-45.2%). 
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Table 22 IVUS gold standard: diagnostic value of CT and invasive coronary angiography for stent restenosis (IVUS: ≥50% 
luminal narrowing) measuring 69 stents in 48 patients. True abnormal diagnosis defined as restenosis >=50% lumen loss 
according to IVUS. 
 
 
CT Angiography vs IVUS for Stent Assessment 
                    CT 
 
IVUS 
Restenosis 
(≥50% lumen 
loss) 
No restenosis 
(<50% lumen 
loss) 
Sensitivity % 
(95% CI) 
Specificity % 
(95% CI) 
PPV % 
(95% CI) 
NPV % 
(95% CI) 
Restenosis (n=17 
stents) 
2 (12%) 15 (88%) 
11.8 
(1.5 – 36.4) 
82.7 
(69.7 – 91.8) 
18.2 
(9.1 - 61.4) 
74.1 
(61.9 – 84.7) No restenosis 
(n=52 stents) 
9 (17%) 43 (83%) 
 
 
 
Invasive Coronary Angiography vs IVUS for Stent Assessment 
                  Angio 
 
IVUS 
Restenosis 
(≥50% lumen 
loss) 
No restenosis 
(<50% lumen 
loss) 
Sensitivity % 
(95% CI) 
Specificity % 
(95% CI) 
PPV % 
(95% CI) 
NPV % 
(95% CI) 
Restenosis (n=17 
stents) 
10 (59%) 7 (41%) 
58.8 
(32.9 – 81.6) 
78.9 
(65.3 – 88.9) 
47.6 
(25.7 – 70.2) 
85.4 
(72.2 – 93.9) No restenosis 
(n=52 stents) 
11 (21%) 41 (79%) 
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Table 23 Diagnostic value of CT coronary angiography for in-stent restenosis and native vessel stenosis (≥50% luminal 
narrowing) measuring 125 stents in 80 patients when invasive coronary angiography taken as gold standard.  True abnormal 
diagnosis defined as restenosis >=50% lumen loss or >=50% luminal narrowing of native vessel according to coronary 
angiography. 
 
 
 CT Coronary Angiography vs Invasive Coronary Angiography for Stent Assessment 
                 CT 
 
Angio 
 
Restenosis 
(≥50% lumen 
loss) 
No restenosis 
(<50% lumen 
loss) 
Sensitivity % 
(95% CI) 
Specificity % 
(95% CI) 
PPV % 
(95% CI) 
NPV % 
(95% CI) 
Restenosis  
(n=21 stents) 
13 (62%) 8 (38%) 
29.6 
(16.8 – 45.2) 
90.1 
(81.5 – 95.6) 
61.9 
(38.4 - 81.9) 
70.2 
(60.4 – 78.8) 
No restenosis  
(n=104 stents) 
31 (30%) 73 (70%) 
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5.5 Discussion 
 
5.5.a What is already known 
Previous studies have shown that the diagnostic performance of CTCA with 64 slice 
scanners for stent assessment is inadequate, many cases of significant restenosis being 
missed due to low diagnostic sensitivity.273-275 
Negative predictive value appears higher and the use of CTCA for rule out of restenosis 
has been suggested by some investigators276 similar to its growing role for rule out of 
native coronary artery disease in patients with a low probability of disease. The 
majority of these studies, however, have used invasive coronary angiography as the 
comparator which may not itself provide reliable diagnostic information about luminal 
obstructions within coronary stents. 
 
5.5.b Comparison with other studies 
Since commencing this study there have been further studies published investigating 
the role of 64 slice CTCA in native coronary arteries and in stented arteries. 
Rixe273 used a 64 slice scanner with 64x0.6mm collimation and rotation time of 330ms 
to assess in stent restenosis compared with invasive angiography.  Only 58% of all 
stents were classed as evaluable by MDCT and excluding non-evaluable stents the 
sensitivity was 86% (95% CI 42-99%), specificity 98% (95% CI 88-100%), positive 
predictive value 86% (95%CI 42-99%) and negative predictive value 98% (95%CI 88-
100%). 
Van Mieghem277 used IVUS as the gold standard in a study using 64 slice CT.  Over 83% 
of the stents in their study were left main coronary artery stents and there were only 
11 stents with sufficient restenosis to compare IVUS and CTCA for in stent restenosis 
and there was only a moderate correlation between CTCA and IVUS for diameter and 
area restenosis. 
Assessment of coronary artery disease by CT  Will Roberts 
 
139 
 
Ehara274 used a 64 slice scanner with 64 x 0.6mm collimation and rotation time of 
330ms to assess 125 stented lesions in 81 patients compared with invasive coronary 
angiography.  When including unassessable segments, sensitivity was 92% (95% CI 81-
100%), specificity was 81% (95% CI 74-89%), positive predictive value was 54% (95% CI 
39-69%), and negative predictive value was 98% (95% CI 95-100%). 
Cademartiri275 again used invasive coronary angiography as a gold standard and two 
different 64 slice scanners were used with 64x0.6mm collimation and rotation time of 
330ms and 64x0.5mm collimation and 400ms rotation time.  Stents <2.5mm diameter 
were excluded and 7.3% of stents were excluded due to artefact. It was shown that 
sensitivity, specificity, and positive and negative predictive value to detect significant 
in-stent restenosis were 95.0% (95% CI 85-100%), 93.0% (95% CI 90-97%), 63.3% (95% 
CI 46-81%), and 99.3% (95% CI 98-100%).  The superior results in this study cannot be 
attributed to the improved spatial resolution of the 64x0.5mm scanner as only 32 
patients were scanned on this scanner compared with 150 on the 64x0.6mm scanner. 
 
5.5.c What this study adds 
It is not clear whether the under-performance of CTCA compared with invasive 
coronary angiography for stent assessment is the result only of technical inferiority in 
visualising the stent lumen or whether it is an artefact of an imperfect comparator. 
This study suggests that invasive coronary angiography is indeed an imperfect 
comparator for assessing the patency of coronary stents by showing that when CTCA is 
compared with intravascular ultrasound (IVUS) its performance remains sub-optimal 
for diagnostic purposes but is only little worse than the performance of invasive 
coronary angiography. The difficulties of stent assessment by invasive coronary 
angiography have been previously reported35-40 but my study shows how these can 
undermine the value of invasive coronary angiography as a comparator for evaluating 
emerging technologies. In contrast, IVUS provides direct visualisation of the internal 
stent lumen allowing more precise assessment of intimal hyperplasia and restenosis 
against which to judge the diagnostic value of CTCA. The pick-up rate for stent 
restenosis by CTCA and invasive angiography was low in comparison with previous 
Assessment of coronary artery disease by CT  Will Roberts 
 
140 
 
studies, but this no doubt reflects the fact that stent occlusions - reliably detected by 
angiography - were excluded because IVUS examination was impossible. This study 
also includes a more clinically realistic unrestricted cohort including older stent designs 
with larger strut thickness with over 55% of identified stents having a strut thickness 
greater than 100µm.  These thicker stent struts are more prone to blooming artefact 
by CT and are thus likely to be less reliably assessed by CTCA and this could contribute 
to the lower sensitivities and specificities compared with other studies. 278  
Nevertheless, my conclusions concerning stent assessment by CTCA are likely to be 
robust because the analysis comparing it with the conventional invasive angiographic 
gold-standard, confirmed a diagnostic performance similar to that reported by 
previous investigators.116, 117, 279 
 
5.5.d Strengths and limitations 
An important strength of this study was the near contemporaneous assessments of 
stent patency by 3 separate technologies in 48 patients. The study covered a more 
realistic clinical range of patients with a variety of stent types and stenting techniques 
implanted over a wide timescale prior to assessment.  The study was limited by having 
to exclude patients with the most severe stenoses and complete stent occlusions from 
IVUS analysis since the probe cannot be passed in these cases. It is certain that the 
diagnostic value of CTCA64 would have been greater had such patients been included 
since coronary obstructions are reliably identified by CTCA64.  It would have been 
useful to assess individual readers assessment for each modality allowing calculation of 
interobserver variability which is an important parameter when considering the 
reproducibility and applicability of a diagnostic modality. There continue to be further 
advances in CT technology, with increase in coverage and temporal resolution likely to 
reduce artefact, however there has, as yet been no major improvement in spatial 
resolution which will be necessary to allow more accurate assessment of stents and in 
stent restenosis.280-282 The use of iterative reconstruction is likely to see improvements 
in stent assessibility even with the same scanner technology due to reduction in noise 
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and reduced blooming artefact and stent evalution will need to continually be re-
evaluated as the technological capabilities continue to improve. 
 
5.5.e Conclusions  
CTCA64 cannot provide the diagnostic performance required clinically for assessing 
stent restenosis. Thus in patients with recurrent angina after coronary stenting neither 
the progression of native disease nor the severity of stent restenosis can be reliably 
assessed using CTCA64. The recommendation based on the work I have presented in 
the last two chapters, therefore, is that these patients are assessed by invasive 
coronary angiography with additional ischaemia testing or IVUS evaluation of the stent 
lumen as necessary.     
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6. CTCA AS AN ENDPOINT FOR 
EVALUATION OF BIOMARKERS IN 
STABLE CORONARY ARTERY DISEASE 
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6.1 Abstract 
BACKGROUND 
Computed Tomography Coronary Angiography (CTCA) is a technique for imaging 
coronary arteries with increasing indications in clinical cardiology with potential utility 
as an endpoint in clinical research. 
AIMS 
To demonstrate utility of CTCA as an endpoint in assessment of novel biomarkers. 
METHODS 
The utility of CTCA for evaluating the diagnostic value of B-type natriuretic peptide 
(BNP) and high sensitivity cardiac troponin I (hs-TnI) was evaluated by blood sampling 
in patients with suspected angina before and after exercise. 
RESULTS  
In 93 patients with suspected angina CTCA provided a useful endpoint for assessing the 
diagnostic value of novel circulating biomarkers.  BNP levels were higher in the 13 
patients shown to have significant (≥50% stenosis) coronary artery disease compared 
with patients who had unobstructed coronary arteries (18.08pg/ml (IQR 22) vs 
9.14pg/ml (IQR 12.62), p=0.024) and increased significantly with exercise, particularly 
in the group with anatomic coronary artery disease (2.73 ± 5.69 pg/ml vs 1.27±3.29 
pg/ml, p=0.16). Conversely I found no association between hs-TnI and the presence of 
CAD. 
CONCLUSION  
CTCA is a useful non-invasive method for diagnosis of coronary artery disease, with a 
high sensitivity for rule-out in low risk populations.  CTCA also finds application as an 
endpoint for diagnostic evaluation of novel biomarkers and confirmed an association 
between BNP and stable coronary artery disease. 
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6.2 Introduction 
 
As discussed in chapter 1 CTCA has a useful role for diagnosis of coronary artery 
disease, particularly in populations with a low prevalence of disease in whom it 
provides a reliable rule-out. It is less useful for determining the severity of disease in 
higher risk populations as I showed in chapter 4, but even in these patients it can 
provide a reliable indication of whether the coronary arteries are normal. Its ability to 
confirm the absence of coronary artery disease noninvasively makes it an attractive 
test endpoint for novel diagnostic markers. 
 
In Chapter 1 I discussed the well established role of the biomarkers cardiac troponin 
and B-type natriuretic peptide for the diagnosis of acute coronary syndromes and 
heart failure.  However, both biomarkers may also be elevated in stable ischaemia but 
this has received little attention from researchers.  Indeed, the most recent NICE 
guideline CG95283 did not even consider the diagnostic potential of novel biomarkers in 
patients with suspected angina.  The development of high sensitivity troponin assays 
which lower the detection threshold by a factor of at least six heightens the diagnostic 
potential of this biomarker in stable coronary disease.  However, neither troponins nor 
BNP have been systematically evaluated for the diagnosis of coronary artery disease in 
patients attending RACPCs with suspected angina. 
 
In the present study, therefore, I have used CTCA as an endpoint for evaluating the 
diagnostic value of BNP and hsTnI in patients with recent onset chest pain attending a 
RACPC. 
 
It was my aim within the setting of the RACPC to assess the utility of the biomarkers 
cTnI and BNP and both calcium scoring and CTCA for predicting cardiac outcomes in 
the cohort of patients presenting with stable chest pain of recent onset. The aim was 
to assess these new techniques in addition to existing clinical assessment and exercise 
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ECG.  The protocol, ethical approval and funding were obtained to allow recruitment of 
patients from this clinic.  All assessments were to be done on site except for the CT 
coronary angiogram which was to be performed at a separate centre due to the 
scarcity of the technology at the time, and the generous donation of the facilities for 
this purpose. The other centre was 12 miles from the recruiting centre, the other side 
of central London. During recruitment it became clear that the patients were reluctant 
to travel across London for the CTCA and a large proportion of patients were failing to 
attend for their scans.  This may be partly due to the additional need for time off work 
in a relatively poor population and the knowledge that the scan would not alter the 
patients treatment. Thus my initial plan to recruit for a cohort study looking at 
outcome measures failed to recruit sufficient numbers to be able to provide significant 
results and thus I present a cross sectional analysis of the data obtained from these 
patients.  A similar issue was found when attempting to assess cTnI levels 24 hours 
post exercise test with only a very small number of patients returning for repeat blood 
sampling. 
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6.3 Methods 
6.3.a Ethics 
Ethical Approval for this study was given by East London and the City Research Ethics 
Committee, Study Ref: 06/Q0605/94 on 24th Nov 2006. 
6.3.b Inclusion criteria  
All patients with undifferentiated chest pain and a high (>80%) or intermediate (20-
80%) probability of coronary artery disease based on age, gender and typicality of 
symptoms.284 Typicality of symptoms is defined by site (retrosternal, arms, throat), 
precipitating factors (exercise, cold, emotion), and relieving factors (rest, GTN), chest 
discomfort with all 3 defining features being classed TYPICAL, any 2 out of 3 ATYPICAL, 
and only 1 out of 3 NON-SPECIFIC. 
6.3.c Exclusion criteria  
Women of child−bearing potential, age <40, inability to consent, severe anaemia (Hb 
<11.0 g/dl), previous history of coronary heart disease (revascularisation, ACS) 
conditions precluding exercise tolerance test or its interpretation (inability to exercise, 
left bundle branch block, repolarisation abnormalities, paced rhythm, digoxin therapy 
etc).  Conditions precluding CT coronary angiography (persistent atrial fibrillation, 
known renal failure with creatinine >160 mmol/l, inability to breathold ≥10secs, and 
previous allergic reaction to intravenous contrast). 
 
6.3.d Patient recruitment and protocol 
All patients attending the RACPC were logged onto a clinical database that included 
demography, risk factors, examination findings, ECG findings, clinical diagnosis and 
treatment.  Probability of coronary artery disease was generated automatically using 
Diamond and Forrester estimates,284 and those patients with high or intermediate 
probability were invited to participate in the study, having given written and informed 
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consent. All patients had routine investigation as follows:12 lead ECG, blood sampling 
(blood count, renal function). 
 
6.3.e Blood sampling 
 Blood samples were collected after 30min supine rest and 15 minutes after treadmill 
stress testing into a pre chilled EDTA bottle stored at -80 degrees C for less than 3 
months for analysis of biomarker concentration (see below). 
 
6.3.f Treadmill stress testing 
All patients underwent symptom-limited treadmill stress testing using the Bruce 
protocol.  The tests were interpreted by a cardiologist as either positive, negative or 
inconclusive based on ST segment changes. 
 
6.3.g Multi-slice CT scan 
This was performed within three weeks of recruitment. Patients received oral or IV 
metoprolol or verapamil before the scan, with the aim of scanning at (or about) a heart 
rate of 60 bpm. All patients were scanned on a 64 slice MSCT scanner. Scan 
parameters were in the order of: 0.75mm collimations; rotation time 0.33s; tube 
voltage 100 kV; 680 mAs. All scans were performed using retrospective gating with 
beam modulation with aim of reducing radiation dose.  Reconstructed slice width 
1mm. Reconstruction time point at (e.g.) 425ms of cardiac cycle (varies according to 
individual patient). 1-5mm axial and double-oblique MIP and MPR image 
reconstructions.  A test dose of 20 mls. of non-ionic contrast medium to enable timing 
of the scan with passage of the main contrast volume (e.g. Omnipaque 350, Amersham 
Health) injected IV at 4ml/s. This was followed by an IV injection of 40mls of normal 
saline as a ‘chaser’. Calcium scores were obtained using the conventional Agatston 
scoring procedure. Multi-slice CT coronary angiograms using axial, double maximum 
intensity projections (MIPs) and multiplanar reconstructions were generated and the 
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presence of significant coronary disease was classified according to the presence of 
one or more stenosis ≥50% in the major epicardial vessels. 
 
6.3.h Biomarker assays 
 
Both biomarkers assessed in this study were analysed using commercially available 
assays. 
6.3.h.i BNP assay 
BNP was assessed using Bayer (now Siemens) Advia Centaur BNP assay which is an 
automated two site sandwich immunoassay utilising direct chemiluminescent 
technology. The assay uses two monoclonal antibodies supplied by Shionogi & Co.  The 
first reagent is an acridinium ester labelled monoclonal mouse anti-human BNP F(ab’)2 
fragment specific to the ring structure of BNP and the second a biotinylated 
monoclonal mouse anti-human antibody specific to the C-terminal of BNP and is 
coupled to streptavidin magnetic particles. 
The minimum detectable concentration is 2pg/ml, at 20% coefficient of variance 
functional sensitivity was 2.5pg/ml.285, 286 
6.3.h.ii High Sensitivity cTnI assay (hsTnI) 
Cardiac troponin I levels were measured using the highly sensitive Bayer (now 
Siemens) chemiluminescent Advia Centaur TnIUltra method.  This method uses 2 
monoclonal capture antibodies and a tracer polyclonal goat antibody labelled with 
acridinium ester.  Manufacturers data gives lower limit of detection  of 0.006 μg/L and 
the 99th percentile reference value of 0.040 μg/L. Assay total imprecision was 
reported by Siemens to be 10% at 0.03 μg/L.287  Similar values were obtained by 
independent analysis.288 
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6.3.i Statistical methods 
Anonymised data were extracted from Excel into SPSS v 17 and analyses were 
performed by myself. 
Data are presented as mean (±standard deviation), however the data pertaining to 
measures of the biomarkers hs-TnI and BNP were found to be heavily skewed and not 
normally distributed and could not be normalised through transformation and thus are 
presented as median (interquartile range). 
For comparison of normally distributed data the independent t test was used. 
For comparing the change in hs-TnI and BNP pre and post exercise the Wilcoxon signed 
ranks t-test was used.  To compare the levels of BNP and hs-TnI in various groups the 
Mann-Whitney U test was applied. Troponin levels below the lower limit of detection 
of the assay were transformed to a value of 0.001 μg/L. Some continuous variables 
were transformed into categorical data such as calcium score 0 or greater than 0, hs-
TnI ≤0.006 μg/L or >0.006 μg/L and data were then compared using the Chi squared 
test.  
 
 
6.4 Results 
6.4.a Cohort characteristics 
I recruited 229 patients into the study, 126 patients successfully underwent CT scans, 
of these 93 had both calcium scores and CTCA.   I defined two groups based on the 
presence of significant coronary artery disease as determined by CTCA. 
 
Table 24 Demographic and clinical characteristics of cohort (n=229), 
characteristics represented as n (%). 
Age  53  (11)   
Male  170  (74%)   
Racial group White 67  (29%) Asian 134  (59%)   Black 28  (12%) 
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DM  69  (30%)   
Hypertension  102  (45%)   
Current Smoker  50  (22%)   
CCF 1  (0.4%)   
 
There was a majority of South Asian patients consistent with the local population 
distribution within the catchment area of Newham University Hospital.  This no doubt 
contributed to the high prevalence of diabetes within the cohort, although the 
prevalence of other risk factors was more consistent with the RACPC populations 
reported elsewhere. 
First I will explore the differences between patients with and without CAD as 
determined by CTCA paying particular interest to the biomarkers hs-TnI and BNP. I will 
then explore the response of BNP and hs-TnI to exercise in the whole cohort and 
subgroups. 
6.4.b Anatomic Coronary Artery Disease by CTCA 
Table 25 summarises the characteristics of those patients with and without CAD as 
determined by CTCA.  Of the 93 patients for whom calcium score and CTCA were 
available; 13 had significant coronary artery disease evidenced by one or more luminal 
stenoses of ≥50% as determined by CTCA. 
Patients with CAD were older and had a significantly higher pre-test probability of 
disease based on Diamond and Forrester criteria.  I identified no other significant 
differences in baseline characteristics between the two groups. 
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Table 25 Demographic and clinical characteristics in presence or absence 
of CAD on CTCA. Represented as n (%) or median (IQR). 
   Significant Angiographic CAD (≥50%) P 
  Yes (n=13) No (n=80) 
 
Age - median (IQR)  56(10) 51 (9.75) <0.05 
 
Asian Ethnicity -  n(%)  8 (61.5) 45 (56.3) 0.87 
 
Women -  n(%)  3 (23.1) 10 (27.5) 0.74 
 
Diabetes-  n(%)  5 (38.4) 25 (31.2) 0.82 
 
Current Smoker-  n(%)  3 (23.1) 22 (27.5) 0.74  
 
Pre-test Prob- median (IQR) 58 (37.6) 54(26.5) 0.02 
 
Creatinine – median (IQR)  96(26) 94(18) 0.37 
 
 
6.4.c Biomarkers measured after 30 minutes supine rest: 
associations with anatomic CAD. 
90 patients had data for biomarkers available.  The distribution of biomarkers was 
significantly skewed and attempts to transform the data did not render a normalised 
distribution and thus non-parametric testing was used to test the significance of 
differences between the groups. 
hs-TnI after 30 minutes supine rest was detectable in 65% of all patients and in 37% of 
patients with both a negative exercise test and no anatomic CAD.  Nevertheless hs-TnI 
tended to be higher in patients with coronary artery  disease (median 0.120μg/L IQR 
0.10) than without (median 0.007μg/L IQR 0.11) but the difference was not significant. 
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To examine the difference between patients with troponin values at the extreme lower 
end of detection and all others I stratified baseline hs-TnI below the lower limit of 
detection for the hs-TnI assay (0.006 μg/L) as negative creating two groups; those with 
positive hs-TnI and those with negative hs-TnI.  Comparing these groups there was no 
significant difference in proportions with evidence of anatomic CAD by CTCA (Chi 
squared p=0.160)  
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Table 26 Biomarkers at rest: associations with anatomic CAD, coronary calcium score and positive exercise test (ETT). 
 CAD p Calcium Score 
(Agatston Units) 
p ETT p 
 
Yes No  0 >0  Pos neg  
hs-TnI (μg/L) 
median(IQR) 
0.120(0.10) 0.007(0.11) 0.07 0.007(0.01) 0.009(0.014) 0.07 0.010(0.005) 0.007(0.13)  
Trop +ve (n) 11 50 0.16 39 41 0.33 24 107 0.21 
Trop –ve (n) 2 27 0.16 20 14 0.33 7 55 0.21 
BNP (pg/ml) 
Median(IQR) 
18.51(25) 9.2(13) 0.02 9.26(13) 12.87(17) 0.08 13.43 9.26  
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BNP measured after 30 minutes supine rest was significantly higher in patients with 
significant coronary disease as determined by CTCA than those without 
(18.08pg/ml(IQR 22) vs 9.14pg/ml (IQR 12.62), p=0.024) 
 
 
 
Figure 20 Boxplot of BNP levels at rest in presence or absence of 
significant CAD by CTCA. 
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6.4.d Biomarkers after 30 minutes supine rest: 
associations with coronary calcification 
The calcium score was considerably higher in patients with significant CAD by CTCA, 
but there was no significant difference in hs-TnI or BNP concentrations between 
patients with and without coronary calcification, as defined by a calcium score of zero 
(Table 26). Moreover I found no correlation between ca score or BNP (r=0.14 p=0.14) 
and only a weak correlation between troponin I (r=0.26 p=0.05)  and calcium score. 
 
 
 
Figure 21 Boxplot of calcium scores in patients with and without 
significant CAD by CTCA 
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6.4.e Exertional ischaemia by exercise ECG 
Table 27 summarises the characteristics of those patients with and without an 
abnormal exercise ECG.  Of the 113 patients, those with a positive test had a higher 
pre-test probability of CAD compared with those with negative or inconclusive tests. 
 
 
Table 27 Demographics, baseline biomarkers and ischaemia by ETT. 
Displayed as n(%) mean ±SD and median(IQR) 
 
   ETT Ischaemia  p 
  Inconclusive Negative Positive  
 
Age median (IQR)  54 (12) 51(12) 55(15) 0.17 
 
Asian Ethnicity  11 (55.0%) 41 (60.3%) 13 (52.0%) 0.148 
 
Women  8 (40.0%) 15 (22.1%) 5 (20.0%) 0.199 
 
Diabetes  8 (40.0%) 20 (29.4%) 9 (36.0%) 0.161 
 
Current Smoker  4 (20.0%) 20 (29.4%)  2 (8.0%) 0.51  
 
Pre-test Probability 58.9±19.7 47.7±18.8 69.2±23.6 <0.0001 
 
Creatinine  90(22) 90(18) 92(28) 0.63 
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6.4.f Biomarkers after 30 minutes supine rest: 
associations with an abnormal exercise ECG. 
Table 26 shows there was no significant difference between baseline hs-TnI levels in 
patients with positive and negative exercise ECGs, and stratification into hs-TnI positive 
and hs-TnI negative, defined by a hs-TnI  ≤0.006> μg/L, showed no significant 
difference in proportions with and without a positive exercise ECG (p=0.214).  However 
BNP was significantly higher in patients with a positive exercise ECG compared with 
patients with a negative exercise ECG (13.43pg/ml (IQR 31) vs 9.26pg/ml (IQR 14), 
p=0.008). 
 
6.4.g Biomarker responses to exercise 
Table 28 shows changes in troponin I and BNP levels measured before and 15 minutes 
after exercise stress testing. 
 
Table 28 Change in biomarker levels with exercise in 90 subjects. 
 Pre  ETT Post ETT p 
hs-TnI (μg/L) 
median (IQR) 
n=90 
0.008 (0.011) 0.008 (0.012) 0.354 
BNP (pg/ml) 
median (IQR) 
n=90 
10.6 (16) 12.5 (19.8) <0.0001 
 
 
BNP concentrations increased significantly but exercise had no significant effect on hs-
TnI.  The increase in BNP concentration tended to be greater in patients with anatomic 
CAD and in patients with a positive exercise ECG (Table 29) but the differences were 
not significant. Changes in hs-TnI were always small and unaffected by the presence of 
anatomic CAD or a positive exercise ECG.  
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Table 29 Comparison of degree of biomarker change with CAD or 
ischaemia 
 
 
6.5 Discussion 
In this chapter I explored the characteristics of a cohort of patients attending a RACPC 
in north east London and examined the differences in biomarkers at baseline and 
following exercise, comparing subgroups with and without evidence of ischaemia and 
anatomic coronary artery disease.  I found that in patients with suspected angina, 
CTCA provides a useful endpoint for assessing the diagnostic value of circulating 
biomarkers. BNP levels were higher among patients shown to have coronary artery 
disease although the differences were small and unlikely of diagnostic value.  cTnI 
levels assessed with a high sensitivity assay showed no difference between those with 
and without coronary artery disease.  
Although numbers recruited for this research were small, the findings strongly suggest 
that hs-TnI has no diagnostic value in patients with undifferentiated chest pain 
attending chest pain clinics. Thus neither resting serum concentrations nor 
concentrations measured after exercise distinguished between patients with and 
without anatomic CAD by CTCA. The apparent conflict with studies in healthy cohorts 
that have reported troponin elevations after exercise can be resolved by noting that 
exercise in those studies was considerably more strenuous and prolonged and the 
 CAD No CAD p ETT positive ETT negative p 
∆hs-TnI (μg/L) 
Median (IQR) 
n=90 
0.001(0.01) 0.00(0.01) 0.89 0.002(0.01) 0.00(0.01) 0.24 
∆BNP (pg/ml) 
Median (IQR) 
n=90 
2.73(5.69) 1.27(3.29) 0.16 2.48(4.77) 1.24(3.16) 0.49 
Assessment of coronary artery disease by CT   Will Roberts 
 
159 
 
elevation of troponin occurred considerably later than the 15 minute window in my 
study. Of some interest was the finding that a significant proportion of the cohort had 
detectable elevations of hs-TnI often with no evidence of CAD or ischaemia on exercise 
stress testing. The data provide no indication of a mechanism, although it is consistent 
with the theory of cytosolic leak outlined in chapter 1. 
BNP looked potentially more useful as a diagnostic marker than hs-TnI in this group of 
patients. It was not only higher in patients with anatomic CAD but also increased 
significantly on exercise, the increase tending to be greater in patients with anatomic 
coronary disease and patients with exertional ischaemia during stress testing.  
However, changes were generally quite small and whether BNP can provide any 
incremental diagnostic value over and above that provided by clinical factors needs 
testing in larger cohorts.  It had been my intention to measure both the TNI and BNP 
levels again at 24 hours post exercise but very few patients returned for blood 
sampling.  It remains unknown, therefore, whether late post-exercise BNP or hs-TnI 
measurement might improve diagnostic value, although the poor re-attendance rate in 
my study suggests that clinical value of late testing would be limited. 
 
6.5.a Comparison with other studies 
In chapter 1 I looked at the evidence for troponin and BNP elevation in patients with 
both stable and unstable coronary disease.  
 There are several prior studies demonstrating an association between BNP, ischaemia 
and prognosis, however none of these studies use CTCA as a means to assess the 
presence of CAD. The present study provides further evidence for the association 
between raised BNP levels and CAD. 
 Two other studies have used assays of similar sensitivity to that in the current study to 
investigate the role of troponin elevation, however they assessed cTnT and not hs-TnI, 
and no similar study has been published assessing hs-TnI in this circumstance. 
In a substudy of the PEACE trial, Omland289 demonstrated detectable levels of troponin 
T in 97.7% of patients in a cohort of 3679 patients with stable coronary disease with 
levels above the 99th percentile value of healthy subjects in 11.1%.  Even low levels of 
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troponin showed correlation with cardiovascular death and heart failure.  Myocardial 
infarction was only found to be weakly correlated in an unadjusted model, and this 
became statistically insignificant after adjustment for other factors. This is a 
significantly higher proportion of patients found to have troponin elevation than I 
found in the present study when examining hs-TnI, although the levels are not directly 
comparable, but it also provides evidence of the prognostic value of cTnT in the stable 
setting. 
Ndrepepa290 demonstrated that small baseline troponin T elevations, previously 
undetectable by the earlier generation of assays, predicted mortality and 
cardiovascular mortality but not nonfatal myocardial infarction in 808 patients with 
stable angina even though nearly all patients subsequently underwent 
revascularisiation with either percutaneous coronary intervention or coronary artery 
bypass grafting.  This cohort had a large percentage of patients with previous CABG or 
myocardial infarction and although the referral route is not clearly described, it 
appears that this is a selected group of patients, unlike the cohort assessed in the 
current study. 
The lack of a significant difference between the groups for hs-TnI levels may indicate 
an important difference in the underlying mechanism between cTnI and cTnT release 
in this setting and has implications for the further development of this concept.  cTnT 
and cTnI have different release kinetics and different quantities in the free cytosolic 
pool and the two biomarkers need to be considered separately. 
 
6.5.b Limitations 
The main limitations here were the small numbers in the study and the lack of follow 
up data due in part to poor recruitment and the distance between the assessment 
sites with reluctance of patients to re-attend for CTCA. A further limitation was the 
lack of assessment of LV function to help further define the significance of the BNP 
levels and whether this was confounded by visually measurable differences in LV 
function. The short time period from exercise to evaluation of post exercise hs-TnI is 
likely to have reduced the ability to assess the elevation of hs-TnI as the release 
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kinetics suggest that a later sample might be more informative. This had initially been 
planned, but the unwillingness of the majority of study participants to return for a 
repeat test prevented this. 
 
 
6.6 Chapter summary 
In this chapter I demonstrated the usefulness of CTCA as an endpoint when assessing 
novel diagnostic biomarkers for patients with suspected CAD.  The data as presented 
above show that a significant number of patients presenting with stable chest pain 
have elevated levels of cardiac troponin I when measured with a highly sensitive assay 
although no differences were observed between patients with and without anatomic 
coronary artery disease. Baseline BNP levels, however, were higher in patients with 
coronary artery disease or myocardial ischaemia and showed a small rise after Bruce 
protocol testing.  However, the differences were not marked and its diagnostic value 
for coronary artery disease in patients with suspected angina is unlikely to be clinically 
helpful. 
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7. SUMMARY 
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In this work the application of CT technology to the assessment of coronary artery 
disease has been explored.  CT technology has been described and a detailed 
assessment made of the key limiting factors and the advances that have been made to 
overcome them allowing CTCA to evolve into a useful clinical tool.   
 
In Chapter 3 an in depth examination of the continuing need to maintain a slow and 
regular heart beat at time of scan was outlined.  Existing studies demonstrating the 
benefit of lower heart rates were outlined and my own data confirming the association 
between lower heart rate and image quality was presented.  The potential candidates 
for rate lowering pharmacotherapy where explored and the rationale for my regime 
explained with the relatively short onset time of oral metoprolol.   Other existing 
strategies were documented and my protocol for heart rate lowering in CTCA was 
presented with my evidence demonstrating a mean reduction in heart rate in patients 
following this regime of 17bpm.  Although no statistical significance could be 
demonstrated in this relatively small group, there was a suggestion that the 
administration of further intravenous metoprolol to non responders of oral therapy 
made little difference, presenting the need for this to be further explored and 
alternatives assessed.  Only 4 patients received verapamil with universally 
disappointing results and, although no claims can be made on the basis of these 
patients, it would be wise to consider alternative strategies at the same time as further 
assessing verapamil efficacy.  One of the potential drugs that could be used in this way 
is ivabradine, that slows the heart rate only in sinus rhythm through action on the If 
channel. 
 
 
Prior to 64 slice CTCA technology it has been shown that CTCA was not sufficiently 
accurate for routine clinical use and was not able to assess for in stent restenosis.  The 
technical improvements in coverage, temporal and spatial resolution that came with 
development of the 64 slice CT scanners marked a significant milestone in CTCA 
technology heralding in more widespread clinical application of CTCA.  CTCA was 
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shown to have good accuracy for assessing native coronary arteries with an excellent 
negative predictive value.  Multi centre trials demonstrated consistently good results 
for the negative predictive value of the technology but low positive predictive values, 
which were somewhat less than from the original single centre studies. 
Chapter 4 explored the accuracy of CTCA in a cohort of patients all with previously 
treated coronary artery disease.  Similar levels of accuracy were found to those in 
multi centre trials of CTCA using 64 slice technology, but somewhat lower than those 
in early adopter centres, who largely investigated lower risk groups. As has been the 
case through many trials of CTCA I demonstrated a very good negative predictive 
value, even in this higher risk group of 98.8%, with a considerably lower positive 
predictive value.  This demonstrates that even in patients with previously treated 
coronary artery disease unstented vessels can be shown to be free of significant 
stenoses with considerable confidence. However, the positive predictive value of 
CTCA64 for coronary artery disease is too low for diagnostic purposes and its clinical 
use is best reserved for rule out in patients with a low probability of disease. 
In Chapter 5 I described the difficulties of coronary artery stent assessment both with 
conventional invasive coronary angiography (CAX) and CTCA.  The limits of CTCA spatial 
resolution and the susceptibility to blooming artefact renders stent assessment harder 
than native vessel assessment.  Much of the previous studies of the accuracy had 
compared these two flawed standards with each other.  In the study presented I 
compared CTCA and CAX with intravascular ultrasound (IVUS) and found that both had 
difficulty correctly identifying significant in stent restenosis compared with IVUS as a 
gold standard.  My results in CTCA were somewhat worse than those in other studies 
outlined, however my cohort included a significant number of large strut stents of 
older designs and this may have contributed to this difference.  CTCA as performed in 
this study cannot be advocated for the assessment of stented arteries.   Developments 
in the field of CT technology have been fast and whilst some reduction in motion and 
stitch artefact has been reduced with the implementation of larger detectors with 
increased coverage, there has not been a significant increase in the spatial resolution 
of the technology.  The implementation of iterative reconstruction technology reduces 
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noise in the images and may provide an advantage to the assessment of stents which 
when combined with the other marginal improvements may lead to an increased 
accuracy in this setting. 
 
In Chapter 6 I investigated the utility of CTCA as an endpoint for evaluation of novel 
biomarkers in the setting of rapid access chest pain clinics.  The cohort investigated 
had a significant number of patients with South Asian ethnic origin from a poor area of 
London.  I measured baseline and post exercise hs-TnI and BNP levels in a cohort of 
patients with suspected angina, comparing subgroups with and without CTCA evidence 
of coronary disease.  I found no difference in baseline hs-TnI levels between the groups 
but BNP showed significant elevation in patients with coronary disease on CTCA. 
However, the difference was small and clinical utility is doubtful.  
Response of biomarkers to exercise was also investigated and while hs-TnI was 
unchanged, a significant rise in BNP was identified, and this was more marked in 
patients with than without CAD.  Whether BNP will find a role in diagnosis of CAD in 
patients with suspected angina will need further studies in larger groups in order to 
determine its incremental value over and above clinical factors and simple non-
invasive tests.  
 
7.1 Limitations 
In assessing the heart rate reduction regime the absence of a control group reduces 
the value of the study.  A larger study with a randomised placebo group would be 
preferable.  Reluctance to perform a technique involving administration of intravenous 
contrast agent and the use of ionising radiation made the concept of potentially 
performing non-diagnostic studies on patients unacceptable within our institution.  
Whilst the evidence for the efficacy of the rate lowering algorithm had not been 
proven it had become accepted practice and similar procedures had been adopted 
elsewhere, supported by the evidence of efficacy of the drugs out of the context of 
CTCA. An observation of change to heart rate and a measure of the proportion of 
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patients reaching target heart rate at scan time was felt to be the most useful 
approach in this context. 
When assessing CTCA in coronary arteries and stents, evaluating the inter observer 
variability would have been useful to improve the validity and applicability of the 
studies. It would have been useful to increase the number of patients evaluated 
through IVUS to provide narrower confidence intervals and a more accurate result, 
however I was limited by resources and the number of patients in whom IVUS could be 
passed beyond severe lesions. 
In assessing CTCA and biomarkers in the RACPC it would have been ideal to obtain 
follow up data for mortality, MACE and revascularisation in a larger cohort which was 
not possible within my resources.  This would have provided further insight into the 
utility of CTCA for predicting outcome however is not likely to have altered the findings 
related to baseline biomarkers in relation to the presence of CAD.  With a larger cohort 
it may also have been possible to start to examine the role of non stenotic coronary 
plaque on cardiovascular events. 
 
7.2 Future Research 
Further evaluation of rate reducing regimes is likely to remain useful in the coming 
years as the CT temporal resolution increases have generally been marginal with the 
exception of the development of dual source scanners which are not widespread.  
Research should be undertaken in a multi centre setting evaluating the efficacy of a 
rate control regime and other potential drugs such as ivabradine warrant further 
assessment. 
As CT technology has developed at great speed in recent years, scanners with larger 
detector coverage and higher rotation speeds have become increasingly available with 
improved reconstruction techniques leading to a reduction in image artefact.  Thus far 
there has been only marginal improvement in spatial resolution compared to the 
scanner used in my research and this is a key factor in improving the ability of CT 
technology to accurately assess coronary artery disease in high risk groups and is 
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particularly important for the assessment of stent restenosis.  Research to assess the 
cumulative effect of the continual small advances made is useful and is ongoing but a 
key milestone is likely to be seen when a significant change in spatial resolution can be 
achieved. 
BNP showed some potential within the stable CAD patients assessed in chapter 6 and 
this warrants investigation with follow up in a larger group of patients to determine 
the incremental value of BNP in addition to existing risk scoring algorithms. 
CTCA has the potential to become a modality that can non invasively assess non 
stenotic coronary plaque, this presents the possibility to identify coronary artery 
disease at a much earlier stage in development.  This would require very large 
numbers of patients to be studied over a long period due to the small number of 
events expected and would only be useful if an additional intervention could be made 
that would alter the prognosis in those identified at risk of cardiovascular events. 
 
7.3 Conclusion 
In this thesis I have provided an analysis of CTCA technology with particular emphasis 
on 64 slice scanners.  I have presented a heart rate lowering strategy with evidence of 
efficacy and provided further evidence of the link between heart rate and image 
quality. CTCA64 has been demonstrated to have good negative predictive value in the 
non-diseased arterial segments of patients with known CAD but its positive predictive 
accuracy for significant luminal obstruction is low limiting its clinical application. I have 
also shown that CTCA64 cannot reliably identify in-stent restenosis, although its 
performance is little worse than invasive angiography when compared with an IVUS 
gold standard.  There is however huge promise in the technology with continual 
developments and rapid progress which are likely to further enhance its application for 
coronary imaging.  Meanwhile CTCA has important research potential for providing an 
anatomic endpoint in studies of novel biomarkers. In this thesis, I have shown that, 
despite the important clinical application of cTnI and BNP for diagnosis of myocardial 
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infarction and heart failure, these biomarkers are unlikely to have a useful role for 
diagnosing CAD in patients with suspected angina attending chest pain clinics. 
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